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The maintenance of zinc homeostasis at the whole body and cellular levels is 
critical in optimising the biological functions of zinc. There is growing evidence 
suggesting interactions between zinc homeostasis, pathophysiology and clinical 
management of chronic diseases, including the role of exercise. The primary 
objective of this thesis was to explore the determinants and impact of zinc status 
under conditions of health, exercise and chronic disease, in particular Type 2 
diabetes mellitus (DM) and cardiovascular diseases (CVD).  
 
To evaluate the evidence of relationships between zinc status and risk of Type 2 
DM and CVD, we undertook a systematic review of prospective cohort studies. The 
overall findings revealed a trend towards protective effects of higher dietary zinc 
levels on Type 2 DM risk in previously healthy populations. Higher serum zinc 
concentrations were related also to lower risk of CVD, particularly in those with 
pre-existing Type 2 DM. Currently, limited robust evidence is available to provide 
clinical advice regarding dietary zinc levels for the prevention of chronic diseases; 
further investigations into the mechanisms of zinc’s action on the pathogenesis of 
chronic diseases and additional evidence from observational studies are required.  
 
Exercise training is an established management and prevention strategy for Type 2 
DM and CVD. To assess the influence of exercise on zinc homeostasis, systematic 
reviews and meta-analyses were conducted for the quantification of changes in 
zinc biomarkers after an aerobic exercise bout. Acute fluctuations in systemic zinc 
levels were observed, specifically an increase in serum zinc concentration 
immediately after exercise (change from baseline: 0.45 ± 0.12 µmol/L, P < 0.001; 
mean ± SE), subsequently followed by a decrease of serum zinc during exercise 
recovery (change from baseline: -1.31 ± 0.22 µmol/L, P < 0.001). Secondary 
analyses revealed greater fluctuations of post-exercise serum zinc levels for 
untrained individuals or participants with lower baseline zinc status. Dietary 
advice to increase total zinc intake, at least to meet the recommended dietary zinc 
intake level, may be considered for at-risk populations in clinical practice.  
 
The examination of zinc status in humans is hindered by the inherent limitations 
of the currently available zinc biomarkers. In a time course, randomised controlled 
trial, we examined the use of novel markers, specifically zinc transporters and 




of the MT-2A gene was observed following 2 days of zinc supplementation (40 ± 
18% increase from baseline, P = 0.011); significant relationships were noted 
between MT-2A gene and the expression of zinc transporters, suggestive of 
coordination within the cellular zinc transport system.  
 
The synergy between cellular zinc homeostasis and cellular functions was 
demonstrated in the reported relationships between inflammatory cytokines and 
cellular zinc transport network for individuals with Type 2 DM. Trends towards 
upregulation of cytokine gene expressions, specifically TNF-α, were observed 
following 12 weeks of zinc supplementation. The expression of IL-1β gene was 
predicted by zinc transporters that are responsible for the transport of zinc ions in 
intracellular zinc signalling and the secretory pathway. The interaction between 
zinc availability and immune function shown in the reported study extends the 
understanding of the chronically activated innate immune system that is 
intrinsically linked to the pathology of Type 2 DM.  
 
The differences in cellular zinc homeostasis within Type 2 DM are highlighted in 
the reported expression and interrelationships of zinc transporters and MT genes. 
Gene expression levels of most zinc transporters and MT were significantly lower 
in individuals with Type 2 DM, compared to control (P < 0.01). Multivariate 
statistical approaches were used to identify groupings within 10 zinc transporters 
and MT gene expressions. The groupings of zinc transporters and MT between 
healthy and Type 2 DM were largely similar, with the exception of the placement 
of ZnT1 and ZIP7. These transporters have potential implications for intracellular 
zinc levels and related functions, such as insulin signalling. Zinc transporters and 
MT were predictive of plasma zinc concentration in healthy participants, but not 
in those with Type 2 DM. This study in cellular zinc transport system supports the 
proposed disturbance in whole body zinc homeostasis associated with Type 2 DM 
pathophysiology.  
 
In this thesis, the presented critical and quantitative evaluation of the literature 
revealed relationships between zinc status, chronic disease risk and exercise, 
providing evidence for future clinical guidelines and research direction. The 
experimental studies explored the coordination within cellular zinc transport 
system, in addition to elucidating the potential mechanisms of interactions 
between external stimuli, zinc transport and cellular functions. Collectively, the 
results extend the current understanding of zinc homeostasis, at the whole body 
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This doctoral thesis has been completed by preparing a series of four peer-
reviewed academic papers, in addition to two papers (Chapters 2 and 7) that are 
submitted for publication. Consequently, there may be a small amount of 
repetition between chapters, particularly in the introductions of Chapters 2-7. 
Table P1 outlines the four papers and provides details on the authors, the 
contribution of the candidate to the papers, journals for publication, and current 
status at the time of printing of this thesis. The content within each published 
paper is in effect the same as that found in Chapters 3-6.  
 
Table P1 Thesis chapters, paper titles, authorship and contribution of candidate 
of academic publications produced for this thesis.  



















































































































Other types of publications arising from this thesis are listed in Table P2.  
 
Table P2 List of other publications arising from this thesis. 













































































































































































The increasing prevalence of obesity-related chronic diseases, such as Type 2 diabetes 
mellitus (DM) and cardiovascular diseases (CVD), is recognised as a significant public 
health concern. In 2014, the global prevalence of diagnosed DM was estimated to be 
9%, with accelerating rates observed in low- and middle-income countries (LMIC) [1]. 
Type 2 DM is characterised by the poor maintenance of blood glucose levels, which 
leads to macro- and micro-vascular complications such as CVD, retinopathy and 
nephropathy [2]. The causal relationship between Type 2 DM, mortality and 
morbidity is well established, with a significant contribution from the higher rates of 
CVD observed in patients with Type 2 DM [3].  One of the major risk factors for CVD 
is the presentation of Type 2 DM, specifically as a result of macrovascular changes 
induced by hyperglycaemia and dyslipidemia. With 32% of all deaths attributable to 
CVD in 2012, this group of diseases remains the leading cause of death worldwide [4].  
 
Multiple factors are involved in the development of obesity-related chronic diseases. 
The role of nutrition for the management of chronic metabolic diseases is supported 
by emerging evidence of interactions among dietary intake, risk of CVD and Type 2 
DM and the gut microbiome [5]. Depletion or altered composition of gut microbiome 
and bacterial-derived metabolites have been identified in patients with CVD and Type 
2 DM [6], however the role that diet plays, in particular zinc intake, on the 
composition of the microbiome and pathogenesis of chronic diseases remains unclear.  
 
Poor maintenance of glucose homeostasis in Type 2 DM is the result of insulin 
resistance and the subsequent inability of the body to produce sufficient insulin. 
Insulin resistance, the initial contributor in the pathogenesis of Type 2 DM [7], refers 
to the reduction in the physiological responses induced by insulin. In relation to 
glycaemic control, the primary actions of insulin are to suppress hepatic glucose 
production and increase glucose uptake from peripheral tissue, of which the skeletal 
muscle system is the predominate contributor. The development of insulin resistance 
results in increased levels of insulin required for optimal glycaemic control. Although 
the exact molecular mechanism remains unclear, the primary established treatment 
strategies for insulin resistance and Type 2 DM is through lifestyle modifications, such 
as increasing physical activity and medical nutrition therapy [2].  
 
Modifiable risk factors, such as physical activity and diet, are the main targets of 




complications [1]. In the clinical setting, exercise prescription and dietary 
management are the primary first-line treatment strategies for the management and 
prevention of Type 2 DM [8]. Participation in physical activity has been shown to 
improve blood glucose control in those with Type 2 DM and prevent or delay the onset 
of disease in high-risk individuals [9]. The beneficial effects of physical activity are 
attributed to improvements in insulin sensitivity, fat oxidation and storage in muscle 
and changes in body composition. In addition to the benefits induced by physical 
activity, exercise can effect changes in nutrient status with implications on the 
favourable exercise-mediated adaptations [10]. For example, higher demand for 
dietary protein is observed after resistance exercise for the full activation of training-
induced skeletal muscle adaptations. The interaction between exercise and 
micronutrients, such as zinc, is currently unknown.  
 
While dietary advice for the treatment and prevention of Type 2 DM primarily focuses 
on macronutrient composition in the diet, there is increasing evidence showing that 
deficiencies in micronutrients, such as zinc, is implicated in the pathogenesis and 
management of disease [11]. In particular, the conventional dietary advice to increase 
dietary fibre intake in the management of Type 2 DM may reduce dietary zinc 
bioavailability [12]. Taken together with potentially higher demand for zinc as a result 
of exercise prescription, individuals with Type 2 DM may be at a higher risk of zinc 
deficiency. Zinc deficiency has been suggested to impact multiple body systems due to 
the extensive involvement of zinc in numerous physiological functions of the body. 
Based on estimations from World Health Organisation (WHO)/ Food and Agriculture 
Organisation (FAO) national food balance data, up to 17% of the world’s population 
may be at risk of inadequate dietary zinc intake [13], contributing to a substantial 
proportion of disease burden worldwide, primarily through diarrhoeal disease causing 
deaths in children from LMIC [14,15]. There is convincing evidence that improved zinc 
intake in at-risk populations, through dietary or supplementation sources, can 
improved clinical outcomes, such as duration of diarrhoea [16].  
 
The interest in the metabolism and function of zinc in humans was amplified by the 
identification of human zinc deficiency in the 1960s [17]. Since then, zinc has been 
implicated in numerous metabolic functions, including energy metabolism, immunity 
and antioxidant activity. Almost 10% of all proteins found in the human body have 
been predicted to bind zinc in vivo [18]. The extensive involvement of zinc in biology 
can be categorised into structural, catalytic and regulatory roles. The importance of 




fingers’. ‘Zinc fingers’ are protein motifs characterised by a zinc ion coordinated with a 
combination of cysteine and histidine residues which maintain structural integrity of 
the protein (Figure 1.1) [19]. In addition, ‘zinc fingers’ also have the ability to serve as 
sensors of cellular zinc ions. An example of an intracellular zinc sensor in humans is 
metal-responsive transcription factor-1 (MTF-1). This transcription factor represents 
the primary regulatory control of cellular zinc homeostasis at the transcription level  
[20]. Although proteins containing ‘zinc fingers’ were initially recognised for their 
interactions with nucleic acids with implications on genomic stability [21], recent 
evidence suggests that proteins with the ‘zinc finger’ motifs also play a crucial role in 
other biological functions, for instance, in mediating protein-protein interactions [22].  
 
 
Figure 1.1 Structure of a zinc finger motif derived from nuclear magnetic resonance 
study [19]. The silver sphere, representing a single zinc ion, is coordinated with nearby 
cysteine and histidine residues thereby maintaining structural integrity of the protein.  
 
In humans, zinc serves a catalytic role in over 50 metalloenzymes, spanning across all 
six classes [23]. Carbonic anhydrase (CA) was the first zinc metalloenzyme to be 
discovered; other zinc enzymes include carboxypeptidase, alkaline phosphatases 
(ALP), transferases, ligases, lyases, isomerases, DNA/RNA polymerase, reverse 
transcriptase and superoxide dismutase (SOD) [24]. Recent findings also suggest that 
zinc can modulate the activities of proteins that typically are not identified as zinc 
proteins. For example, transient fluctuations in cytoplasmic zinc concentration can 




responsible for effecting post-translational modifications on proteins that are 
important for cellular processes [25]. Many proteins that can be modulated by zinc are 
mediators of cellular signalling pathways, supporting the role of zinc ions as second 
messengers within the cell, akin to calcium. An example of the major signalling 
pathways in which zinc participates includes the redox signalling pathway [26] where 
zinc, despite being a redox inert metal, provides an overall antioxidant effect.  
 
To maintain optimal function of zinc in the body, the current Australian and New 
Zealand guideline recommends a dietary zinc intake of 14 mg/d for adult men and 8 
mg/d for adult women, with additional requirements during pregnancy or lactation 
[27] . Overt zinc deficiency often manifests with clinical signs, such as impaired 
immunity and growth retardation. In LMIC, zinc deficiency in young children 
contributes to the rates of morbidity and mortality arising from persistent diarrhoea 
and pneumonia [14]. Other manifestations of overt zinc deficiency include diverse 
forms of skin lesions, impaired wound healing, hypogeusia, behavioural disturbances 
and night blindness [24]. In contrast, marginal zinc deficiency presents with a 
spectrum of ambiguous signs and symptoms. The consequences of suboptimal zinc 
status are suggested to impact many chronic diseases, including Type 2 DM [28] and 
CVD [29]. The insidious effects of marginal zinc deficiency are reflective of the 
numerous physiological roles in which zinc is involved and also the lack of current 
understanding in the interaction between zinc status and chronic diseases.  
 
The following sections will describe the current knowledge on the determinants of 
whole body and cellular zinc homeostasis and their relations to chronic diseases, with 
regard to pathophysiology and interactions with current management, such as diet 





Of the dietary zinc that is absorbed through the gastrointestinal tract, the majority is 
delivered through the small intestine, primarily at the levels of distal duodenum or 
proximal jejunum. The modes of zinc absorption in the gut involve both saturable and 
passive mechanisms. Current evidence suggests that the saturable pathway is 
responsible for zinc absorption of up to 7-9 mg of daily ingested zinc [30] and requires 
the expression of specific zinc transporters and divalent metal transporters. At dietary 




diffusion becomes the prominent mean of zinc absorption [31]. The fractional 
absorption of zinc appears to be dependent on total dietary zinc intake, rather than the 
host’s intrinsic zinc status [32].  
 
In addition to the level of dietary zinc intake, a major factor in the determination of 
zinc absorption within the gut is the bioavailability of zinc amongst the chyme formed 
from digestion. Factors that influence zinc bioavailability and their effects on 
fractional zinc absorption were reviewed recently [33]. The absorption of zinc can be 
hindered through direct competition with other nutrients or by the presence of anti-
nutrients, such as phytate [12], which form insoluble zinc complexes within the lumen 
(Figure 1.2). In vitro studies suggest that calcium and magnesium can form 
precipitates of phytate, enabling high affinity binding of zinc within insoluble 
complexes and thereby decreasing the availability of zinc for absorption. Moreover, 
high iron to zinc ratio in the diet, typically achieved by iron supplementation, has been 
shown to decrease zinc bioavailability significantly and ultimately impact on zinc 
status [34]. In contrast, zinc absorption may be enhanced by the formation of 
coordination complexes between zinc and small molecular weight ligands.  
Specifically, the amino acids histidine and cysteine can form stable complexes with 
zinc in the lumen, which improves the efficiency of zinc absorption [35]. The major 
food sources of histidine and cysteine originate from animal products, which also 
present as good sources of dietary zinc intake. The introduction of animal protein into 
plant-based meals can significantly improve the bioavailability and absorption of zinc 
[36]. Increase in zinc content from animal protein source can improve fractional zinc 
absorption in phytate containing meals, thereby dampening the inhibitory effect of 
phytate on zinc absorption [37]. Figure 1.3 summarises zinc homeostasis in the 







Figure 1.2 Chemical structure of phytate at pH 6-7 [38]. Zinc ions can bind to the 
phosphate groups, forming precipitate of zinc and phytate, thus inhibiting intestinal 





Figure 1.3 Factors affecting bioavailability and absorption of zinc within the 
gastrointestinal tract [39]. !, promotes;   , inhibits.  Zinc absorption in the 
lumen is determined by exogenous factors such as phytate, protein, iron and small 
molecular weight ligands, such as citrate and histidine. Endogenous zinc secretion 
also contributes to the luminal zinc concentration. Compensatory mechanisms in zinc 






In order to estimate zinc bioavailability in the diet, the WHO identified 3 categories of 
zinc bioavailability according to the food source of zinc, phytic acid:zinc (PA:Zn) 
molar ratio and total calcium intake [40]. A high fractional zinc absorption of 50% 
dietary zinc is estimated for a highly refined diet with PA:Zn molar ratio of less than 5. 
In contrast, an unrefined diet, which corresponds with a PA:Zn molar ratio of greater 
than 15, reduces estimated zinc absorption by 70%. However, most of the studies 
identified from the WHO report derived fractional zinc absorption from single meals, 
which may not be representative of the total diet. Figure 1.4 shows zinc content and 
PA:Zn molar ratios in common foods. In 2004, International Zinc Nutrition 
Consultative Group (IZiNCG) developed two categories for estimating dietary zinc 
absorption in the context of the total diet [41]. Mixed diets and refined vegetarian 
diets, with PA:Zn molar ratio of 4-18, were grouped into a single category, with 
fractional zinc absorption predicted to be 26% in men and 34% in women. The second 
category, of lower zinc bioavailability, consists of unrefined, cereal-based diets with 
PA:Zn molar ratio greater than 18. However, the small number of studies identified in 
the latter category limits the interpretation of the cut-offs. 
 
 
Figure 1.4 Zinc content (mg/100 g edible portion) and phytic acid:zinc (PA:Zn) 
molar ratios of selected foods. PA:Zn molar ratios of 5, 10 and 15 are shown to 
represent high, moderate and low zinc bioavailability foods, respectively. While foods 
with higher PA:Zn molar ratio has been predicted to provide a lower percentage of 
bioavailable zinc in the gut, higher total zinc content in these foods may compensate 
for the reduced efficiency of zinc absorption, resulting in a greater amount of total zinc 
absorbed. Data adapted from [42]. 
"
The excretion of zinc in humans is primarily through faecal zinc originating from 




the turnover of mucosal cells. Regulation of faecal excretion is crucial in the 
maintenance of whole body zinc homeostasis [43]. In zinc depletion and 
supplementation studies, the amount of faecal zinc excreted is inversely correlated to 
dietary zinc intake, through changes in fractional zinc absorption and endogenous zinc 
secretion. Under marginal habitual dietary zinc intakes (< 8 mg/d Zn), a reduction in 
endogenous zinc excretion appears to be the initial point of homeostatic adjustment 
[44]. It is unclear whether the mechanism of action is through increased efficiency in 
the reabsorption of luminal zinc or a decrease in endogenous zinc secretion. In 
comparison to faecal zinc losses, urinary zinc represents a negligible route of excretion 
and remains largely unchanged with small fluctuations in dietary zinc intakes, but 
responds to increased zinc exposure [45]. However, urinary zinc losses may become 
significant in conditions that increase urine production, such as uncontrolled DM 
[28], or induce catabolism, for example severe burns, trauma/surgery.  
Tissue&distribution&&
 
Zinc is found in all body organs and tissues, approximating to 1.2-2.3 g of zinc in a 
human adult (Figure 1.5) [24,46]. Zinc primarily exists intracellularly, with close to 
95% of total body zinc found within different body tissues [47]. The remainder of zinc 
resides in extracellular fluid, such as plasma or serum zinc which represents 0.1% of 
total zinc within the body. While the highest concentrations of zinc are observed in the 
choroid of the eye and the prostate gland, the majority of zinc within the body is found 
in the musculoskeletal system [24]. Zinc concentration within red blood cells (RBC) is 
a number of magnitudes higher than the concentration of blood plasma. The majority 
of RBC zinc is associated with CA, with some zinc ions found incorporated in the cell 
membrane [31].  
 
After absorption in the intestinal tract, zinc is bound to albumin and delivered to the 
systemic circulation via the hepatic portal system [49]. Approximately 30-40% of 
absorbed zinc in the portal blood exchanges with the liver, where zinc can be 
sequestered by hepatic metallothionein (MT). The liver represents a pool of readily 
exchangeable zinc in the body. The presence of hormones and inflammation can 
initiate the redistribution of zinc within the body, leading to changes in hepatic zinc 







Figure 1.5 Diagram showing the distribution of zinc in the body. Dietary zinc is 
absorbed from the small intestinal and distributed to peripheral tissues. Zinc can be 
secreted through the kidney, pancreas and skin. Reproduced from [48]. 
 
The plasma/serum zinc concentration is maintained within 10-18 µmol/L with diurnal 
variations across the day [41]. Albumin binds to ~75% of zinc found in plasma due to 
its abundance in blood and high affinity to zinc. Recent observations suggest that the 
binding and release of zinc from albumin may be modulated by fatty acids in the 
circulation [50]. The remaining zinc ions found in plasma are bound to α-2 
macroglobulin (~25%) or with low molecular weight complexes (~1%), such as 
cysteine and histidine. The uptake of zinc into peripheral tissue appears to be 
dependent on the properties of zinc carriers. From the systemic circulation, zinc is 
transported into interstitial fluid through the endothelium via one of two transport 
systems [51]. Zinc-albumin complex is transported mainly via a saturable pathway by 
receptor-mediated transcytotic vesicles. The alternative endothelial transport system 
is a non-saturable pathway where zinc, complexed with albumin or histidine, is 




transcytosis. Under conditions of sufficient zinc status, plasma zinc is predicted to 
turn over ~150 times; turnover of zinc increases by one third when challenged with 
very low dietary zinc intake (< 5 µmol/d) [52]. Zinc isotopic studies have identified a 
rapidly exchangeable zinc pool, which includes the total zinc content in plasma, in 
addition to a portion located within the liver [53]. This kinetically defined metabolic 
zinc pool reflects habitual dietary zinc intake and may be useful in predicting total 
absorbed zinc in the gastrointestinal tract [43].  
 
The musculoskeletal system contains 90% of total zinc in the body, of which two-
thirds reside in skeletal muscles (Figure 1.5) [47]. The majority of zinc in muscles is 
found within protein complexes, where zinc provides structural stability and promotes 
enzymatic activities of metalloenzymes such as lactate dehydrogenase (LDH), SOD 
and CA. At rest, the turnover of zinc within muscles and bone has been suggested to be 
slower than the liver and other metabolically active tissues [53]. During exercise, 
muscular contractions can disrupt cellular structures [54] which leads to the release of 
proteins and ions, such as zinc, from myocytes. In recovery from exercise, the initial 
stages of muscle repair occur with monocytes and leukocytes infiltrating muscle cells, 
initiating cytokine production and stimulating the subsequent inflammatory response 
[55]. Inflammatory cytokines have been shown to regulate the expression of cellular 
zinc transporters in a number of tissues and thereby alter whole body zinc 
homeostasis [56]. The interaction between exercise-related process and zinc status is 




Systemic zinc concentration, analysed in serum or plasma, is currently the 
recommended biomarker when assessing zinc status within a population [57,58]. In a 
recent systematic review and meta-analysis which examined the relationship between 
zinc intake and plasma zinc concentration in healthy populations, a doubling of zinc 
intake corresponded with a 6% increase in plasma or serum zinc concentration 
(Figure 1.6) [59]. However, it is well-known that systemic zinc concentration can be 
confounded by factors other than zinc status, which limits its usefulness as a 
diagnostic biomarker in individuals. Age, diurnal variations and interaction between 
zinc and other nutrients or drugs, including oral contraceptive agents, are examples of 
factors known to impact serum zinc concentration in healthy populations [36]. 
Fluctuations in hormones, such as insulin and leptin as a result of fasting or the post-




and metabolic stress, due to exercise, infection and chronic diseases, are conditions 
which cause redistribution of zinc in the body, all typically causing a decrease in 
plasma zinc concentration [60].  
 
 
Figure 1.6 Relationship between zinc intake (mg/d) and serum/plasma zinc 
concentration (µmol/L), estimated by meta-analyses of randomised controlled trials. 
Reproduced from [59]. 
 
Zinc concentrations in various blood components, such as RBC, mononuclear cells, 
polymorphonuclear cells and platelets were determined to be poor indicators of zinc 
status in meta-analyses of zinc supplementation and depletion studies [57]. Moreover, 
there is limited evidence to support the use of other biological tissues, such as saliva 
and nail, in the assessment of zinc status in humans. In contrast, data from zinc 
supplementation studies suggests that urinary zinc excretion may be an effective 
biomarker of extreme dietary zinc intakes [57], with a dose-response effect observed 
for zinc supplementation between 15 and 50 mg/d. Urinary zinc excretion responds 
well during severe zinc depletion (< 2 mg/d) [61,62] or excess intakes [45], however 
this marker lacks the sensitivity to differentiate dietary zinc intakes within the range 
of Recommended Dietary Intakes (RDI) for zinc (8-14 mg/d) [27]. Similar to urinary 
zinc excretion, hair zinc appears to respond to zinc supplementation with limited data 
supporting its validity in zinc depletion.  
Functional biochemical tests, specifically enzymatic activities of zinc-dependent 
metalloenzymes, also have been explored as biomarkers of zinc status. Commonly 
analysed enzymes include plasma ALP and RBC Cu-Zn SOD. Meta-analysis of zinc 
supplementation and depletion trials revealed plasma ALP activity to be a poor zinc 
biomarker [57]. Zinc supplementation generally decreases Cu-Zn SOD activity in RBC, 
primarily due to an antagonistic relationship between dietary zinc intake and copper 




enzymatic activities, which complicates the delineation of relationship between zinc 
status and activities of enzymes. 
 
Other promising biomarkers of zinc status include the activity of zinc finger protein 
enzymes and signal transduction proteins. In murine models, a zinc-finger signal 
transduction protein, T lymphocyte p56lck, was elevated under zinc deficiency 
conditions, independent of protein deficiency [64]. Follow up animal studies suggest 
that T-cell dysfunction may be a sign of dietary zinc deficiency, however confirmations 
in humans, in addition to the specificy of zinc deficiency per se on immune functions 
are required to determine the usefulness of immune functions and proteins as 
biomarkers of zinc status in humans [65].  
 
Whole body zinc homeostasis is influenced by dietary factors, such as zinc 
bioavailability in the gut lumen, and intrinsic determinants, such as inflammation and 
zinc status. As alluded to above, the assessment of zinc status in humans is 
complicated by the tight regulatory control of zinc homeostasis and the influence of 
other factors that affect commonly used zinc biomarkers. The study of the mediators 
of cellular zinc homeostasis may shed light on the regulatory mechanism of zinc 





Given the limitations of the current zinc biomarkers, recent attention in this field has 
focused on the assessment of novel biomarkers, in both global genomic [66] and 
proteomic [67] studies. Recent investigations into the responses of serum microRNAs 
in zinc depletion and subsequent repletion have revealed possible novel biomarkers of 
zinc status [68]. The expression of zinc transporter and MT genes have been used in 
zinc supplementation and depletion studies to determine the relationships between 
mediators of cellular zinc homeostasis and whole body zinc status. In vitro studies 
have shown changes in cellular zinc transporter and MT expressions in response to 
different concentrations of zinc incubated in the media [69,70]. However, in vitro 
regulatory responses of zinc transporter and MT expressions does not appear to 
correspond with the effects observed in humans after zinc supplementation [70]. 
Hence, further studies are required to determine the usefulness of zinc transporter 





The use of the peripheral blood mononuclear cells (PBMC) transcriptome as a marker 
of interest in nutrigenomic studies has gained momentum recently, due to the ease of 
sampling and analyses in humans. To date, two distinct approaches have been used to 
explore the changes in PBMC gene expression in nutritional intervention studies. In 
the first approach, the analysis of PBMC provides an insight into the role of 
inflammation that forms part of the pathology of numerous chronic diseases. 
Examples of studies that are pertinent include supplementation trials of 
immunomodulating nutrients, such as zinc and polyphenols, and studies that explore 
acute immune responses to nutritional challenges [71].   
 
The alternative approach uses PBMC as a surrogate model for other biological tissues 
that are difficult to obtain in humans, such as those of the liver and pancreas. The 
underlying assumption of the latter approach is that the transcriptomic responses of 
PBMC and the target tissue are similar. For example, a recent study on the effects of 
aerobic exercise training reported modulations in the PBMC gene expression of 
adiponectin receptor with concomitant improvements in insulin sensitivity and 
glucose homeostasis [72], suggesting relationships between the transcriptomes of 
PBMC and insulin sensitive peripheral tissues capable of eliciting clinical outcomes 
observed. While this relationship is reasonably established in genes regulating lipid 
metabolism [73,74], the similarities between expressions of mediators of zinc 
homeostasis in PBMC and other tissues are less clear. Given that zinc mostly resides 
intracellularly within the liver and musculoskeletal system, the search for a novel zinc 
biomarker will benefit from future studies that aim to understand the intricacies of 




The regulation of cellular zinc content is under tight homeostatic control. While the 
circulating zinc concentration in zinc-sufficient conditions is maintained within the 
micromolar range (10-18 µmol/L) [41], intracellular free zinc concentrations have 
been suggested to be multiples of magnitude lower, i.e. in picomolar concentrations. 
Fluorescence spectroscopy of free zinc ions within the cell has identified 
compartmentalisation of zinc in subcellular locations, such as the golgi apparatus and 
mitochondria [75]. The accumulation of zinc within different subcellular organelles is 
important in eliciting rapid changes in cytoplasmic zinc concentration. Given the 
extensive role of zinc in modulating the activities of proteins within many cellular 




in the propagation of cellular signals, among other functions of zinc [76]. Additionally, 
recent studies have identified novel zinc sensors on the surface of cells, which can 
detect changes in extracellular zinc concentrations and initiate intracellular signalling. 
Within the cell, zinc homeostasis is regulated primarily by two families of zinc 
transporters and MT. Furthermore, recent evidence suggests that a minor route of 




MT represents a group of metal-binding proteins which have been shown to buffer 
cytoplasmic zinc concentration. In humans, multiple isoforms of MT have been found, 
of which only those in the MT-1 and MT-2 subtypes are central to mediating cellular 
zinc homeostasis [77]. Structurally, MT is defined by the unique amino acid sequence 
of cysteine residues that provide binding sites for metals, such as zinc. The seven 
metal binding sites of MT have discretely different affinities for zinc, with dissociation 
constants (Kd) ranging over four orders of magnitude [75]. This chemical property of 
MT complements its function as a chaperone and cellular storage protein for zinc, 
mediating the movement and availability of zinc to other proteins [78]. In addition to 
the maintenance of cellular zinc homeostasis and related activities, the release of zinc 
from thiol groups in MT confers the indirect antioxidant effects of zinc [79].  
 
While MT is found ubiquitously at basal levels in all tissues, the expression of MT 
genes can be induced by metal ions, oxidative stress, hormones (e.g. glucocorticoids) 
and cytokines (e.g. IL-6). The multiple promoter regions upstream of the MT 
structural gene are reflective of the various stimuli that can regulate MT expression. 
Zinc excess and depletion within humans and in vitro studies have shown MT 
expression to be highly inducible and reflective of zinc availability [68,80]. The 
regulation of intracellular zinc by MT has been attributed to the modulation of zinc 
inducible signalling pathways and novel transcription factors, such as 




To date, a total of 24 zinc transporters have been identified and categorised into two 
families of solute carriers (SLC) according to their proposed function and structure. 
Zinc is transported through plasma and subcellular membranes via secondary active 




adenosine triphosphate (ATP), suggesting that the zinc transport process is energy 
independent [48]. Both hydrogen (H+) and bicarbonate (HCO3-) ions are proposed to 
co-transport with zinc via the action of zinc transporters [82]; hence acid-base balance 
is possibly intrinsically linked to cellular zinc homeostasis.   
 
Members from the Zinc Transporter (ZnT; SLC30) family are responsible largely for 
decreasing cytoplasmic zinc concentration by zinc efflux into extracellular space or 
subcellular compartments, such as the golgi apparatus and endoplasmic reticulum 
(ER) (Table 1.1). Thus far, most of the 10 identified ZnT reside primarily on 
subcellular membranes. Members from the ZnT family initially were predicted to form 
homodimers, with the exception of ZnT5 and ZnT6, which form heterodimers. 
However, a recent in situ study using bimolecular fluorescence complementation and 
visualisation of intracellular free zinc demonstrated the ability of various ZnT, 
specifically ZnT1-4, to form heterodimers [83].  
 
Although the crystal structure is yet to be resolved, the structure for ZnT proteins can 
be estimated from YiiP, a cation-diffusion facilitator of zinc arising from Escherichia 
coli [84]. ZnT proteins are typically depicted with six transmembrane domains and  
both the N- and C-termini located intracellularly (Figure 1.7). Multiple sites of zinc 
binding have been suggested, one of which is located on the cytosolic domain and can 
trigger conformational change, facilitating zinc transport through the protein [85]. 
While ZnT9 has been identified to possess similar sequence homology to a cation 
efflux domain and hence classified as a member of the ZnT family, there is currently 
doubt over the existence of zinc transport function in ZnT9, due to the lack of a 
histidine complex that is essential for a zinc-binding site [48]. To date, only ZnT10 out 
of the ZnT family appears to have the ability to transport divalent metals other than 
zinc, specifically manganese. 
 
While dietary zinc intake can modulate the expression and activity of some ZnT [56], 
other factors also have been shown to modulate specific ZnT proteins, in a tissue 
specific manner. The function of secretory pathways in specialised cells, such as 
prostate, mammary and pancreatic cells, are reliant on the expression and activity of 
ZnT members [86]. Hormones have been shown to influence cellular zinc transport, 
for instance the regulation of ZnT2 expression by prolactin in mammary cells during 
lactation [87]. Furthermore, post-translational regulation initiates subcellular 
relocalisation of ZnT2 which enhances zinc secretion into breast milk in mammary 






Figure 1.7 Schematic showing the proposed molecular structure of Zinc Transporter 
(ZnT), in a dimer formation. ZnT functions to decrease cytosolic zinc concentration by 
transporting zinc ions to extracellular or luminal space, in exchange for hydrogen 
ions. Reproduced from [48].  
 
In contrast to the role of ZnT proteins, the 14 members of the Zrt-, Irt-like Protein 
(ZIP; SLC39) family of transporters function to increase cytoplasmic zinc 
concentration by transporting zinc from subcellular organelles or extracellular space 
(Table 1.2). The three dimensional structure of ZIP transporters has not been 
resolved. Most ZIP transporters are predicted to have eight transmembrane domains, 
with the N- and C- termini located away from the cytoplasm (Figure 1.8). The exact 
process of zinc transport through ZIP proteins remains unclear. Current evidence 
suggests that the transport of zinc by ZIP1 and ZIP2 is independent of energy [89]. 
With the exception of ZIP7, ZIP11 and ZIP13, homodimers formed by ZIP appear to 
function at the plasma membrane, either primarily or inducible by other biological 






Figure 1.8 Predicted molecular structure of Zrt, Irt-like Protein (ZIP) transporter in a 
dimer formation (shown as two separate blue structures that forms a dimer at 
complex I). ZIP increases cytoplasmic zinc concentration by importing zinc ions from 
extracellular or luminal space. Reproduced from [48].  
 
External HCO3- can induce zinc transport through ZIP2, ZIP8 and ZIP14 [90,91]. 
Other divalent metals, such as iron, cadmium and manganese, can also influence the 
activity of ZIP by direct competition for binding sites. In particular, ZIP8 and ZIP14 
have been shown to transport iron, cadmium and manganese under physiological 
conditions, in addition to zinc [92]. While tissue zinc concentration and zinc status 
play a role in determining the activities of ZIP, other factors, such as inflammation 
and hormonal changes, may have a greater influence on specific ZIP transporters [89]. 
For example, inflammation can induce ZIP14 upregulation in the liver through the 
cytokine, interleukin (IL)-6 [93]. Furthermore, current evidence suggests that zinc 
transporters can localise in different subcellular components, subject to tissue 
specificity and external stimuli [94].  
 
The importance of zinc transporters in relation to health is highlighted in the 
physiological dysfunctions arising from genetic variations in zinc transporter genes. 
Mutations and single nucleotide polymorphisms (SNP) in a number of zinc 
transporters have been associated with different pathology and diseases in humans. 
Tables 1.1 and 1.2 summarise the localisation, transcriptional regulation, and 
association with pathology of zinc transporters in humans. The regulatory mechanism 
of zinc transporters can be categorised into those that occur at the transcriptional or 




confirmed to regulate the transcription of ZnT1, ZnT2, ZIP10 and ZIP11 in murine 
models and MT in humans [95]. ‘Zinc fingers’ and the acidic activation domains 
within MTF-1 are proposed to mediate zinc sensing in the cytoplasm, which promotes 
the localisation of the activated transcription factor to the nucleus. Once within the 
nucleus, MTF-1 can bind to the metal-responsive element (MRE) of regulated genes, 
thereby modulating their expression. Another example of transcriptional control of 
zinc transporters is the activation of a novel zinc finger protein, ZNF658, which is 
suggested to repress the transcription of ZnT5 and ZnT10 when challenged with 
excess zinc [96]. The interaction between zinc transporters and chronic diseases, 
































































































































































































































The multiple levels of regulation on zinc transporter activities reflect the differences in 
intracellular zinc signalling compared to other functions of zinc. While transcriptional 
regulation of zinc transporters represents a viable system to modulate the cytoplasmic 
zinc concentration in time frames of hours or days, post-translational modifications 
that modulate the activity of zinc transporters can initiate rapid zinc flux within 
minutes [124]. Hence, most post-translational regulation of zinc transporters 
observed to date has been related to the propagation of cellular signals. For example 
external stimuli, such as extracellular zinc, can result in ZIP7 phosphorylation on the 
ER, initiating a rapid increase in cytoplasmic zinc [125]. The transient increase in free 
zinc concentration phosphorylates Akt and extracellular regulating kinase (ERK)-1/2, 
thereby activating downstream cellular signalling pathways. Multiple potential sites 
for glycosylation, a type of post-translational modification, have been identified in 
ZIP8 and ZIP14, however they do not appear to affect the movement of metals 
through these transporters [126]. It is unclear whether other post-translational 




Thus far, four families of calcium-conducting channels have been shown to transport 
zinc into the cell, specifically voltage-gated calcium channels (VGCC), glutamate 
receptors, acetylcholine receptors and transient receptor potential (TRP) channels. 
The uptake of zinc by VGCC was identified in murine muscle cells initially and 
confirmed subsequently in in vitro studies of the heart, brain and pancreatic β-cells 
[127]. The transport of zinc in the brain appears to be reliant on both VGCC and 
glutamate receptors under depolarised conditions [128]. To date, the largest family of 
calcium-conducting channels capable of zinc transport is the TRP channels, of which 
seven members have been reported to transport zinc under physiological conditions 
[129]. The activation and depolarisation of TRPM3 channels to transport zinc into 
pancreatic β-cells can activate other VGCC, which potentiates the influx of zinc [130]. 
The biological significance and relative contribution of zinc transport through 




Fluctuations in extracellular zinc also have been shown to modulate cellular function 
and processes. The mechanism of action is proposed to be mediated through an 




receptor that can trigger changes in intracellular calcium in response to extracellular 
zinc via the IP3 pathway [131]. Increases in intracellular calcium have a flow-on effect 
in mediating cellular signals, such as those involved in secretion, cell proliferation and 
growth [132], through the modulation of ERK-1/2 and Akt pathways. The significance 
of GPR39 in cellular function is established in the pancreas, intestinal tract and the 
brain. GPR39 knockout (KO) mice display reduced ability to secrete insulin and 
deregulation of normal gastrointestinal function [133]. In the GPR39 KO model, 
insulin levels were decreased under high sucrose diet; the decrease in circulatory 
insulin has been attributed to lower expression of various transcription factors in the 
signalling pathways within pancreatic islets and β-cells [134,135]. A lack of human 
studies limits the translation of GPR39 functions to whole body zinc homeostasis.  
 
Numerous transport routes and proteins play a role in maintaining cellular zinc 
homeostasis, as summarised in Figure 1.9. Coordination among various zinc 
transporters and MT has been documented in humans previously [136]. However, the 
mechanisms and organisation by which the novel mediators of cellular zinc 
homeostasis and zinc-binding proteins coordinate cellular responses to biological 
challenges, such as exercise, inflammation and chronic diseases, remain to be 
elucidated. In particular, information on the contribution of different zinc 
transporters and MT, under conditions of health and diseases, will shed light on the 






Figure 1.9 Schematic showing the mediators of cellular zinc homeostasis, their proposed sites of action and their influence on cellular function. 
The primary mediators of cellular zinc homeostasis include the two families of zinc transporters (ZnT and ZIP) and metallothionein (MT). 
Recent evidence suggests calcium-conducting channels provides a minor route of cellular zinc import. Changes in zinc content in subcellular 
locations have been linked to cellular processes, such as the production of secretory proteins. In a similar vein, the action of extracellular zinc 
sensor (GPR39) can mediate cellular signalling pathways through fluctuations in extracellular zinc. Abbreviations: GPR39, G protein-coupled 





There is increasing evidence that zinc is implicated in the pathogenesis and 
management of chronic diseases, such as Type 2 DM and CVD. Patients with Type 2 
DM and CVD often present with perturbed zinc status as a result of disease state 
and/or suboptimal dietary zinc intake. Recent studies investigating the 
interrelationship of zinc and chronic diseases have identified novel interactions 




The discovery of zinc’s role in the biosynthesis, storage and secretion of insulin 
initiated interest in zinc metabolism within the context of Type 2 DM. Marginal zinc 
status can affect glycaemic control by compromising the production and secretion of 
insulin in the pancreas [137] and impacting insulin sensitivity in peripheral tissues  
[28]. Cross-sectional studies have suggested that Type 2 DM pathology coexists with a 
state of perturbed zinc homeostasis [28]. In particular, individuals with Type 2 DM 
have reduced zinc content in plasma and RBC with a concomitant increase in urinary 
zinc loss [138]. An example of Type 2 DM pathology impacting zinc metabolism is 
increased urinary zinc secretion observed as a result of polyuria [139], particularly in 
individuals with uncontrolled Type 2 DM. Dietary zinc intake in individuals with Type 
2 DM also appears to be poor compared to the RDI [140], further contributing to 
suboptimal zinc status in Type 2 DM.  
 
Evolving evidence supports the increase of dietary zinc intake through diet or 
supplementation as an adjunct therapy in Type 2 DM [11]. While limited studies have 
explored the mechanistic effects of zinc on insulin sensitivity by the gold standard 
method of the euglycaemic hyperinsulinemic clamp procedure, some studies have 
reported the effects of zinc on fasting insulin and related measures. Table 1.3 shows 
selected studies that report on the effects of zinc supplementation on fasting insulin 
concentration and/or Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) 
in either obese individuals or those with Type 2 DM. Although the zinc 
supplementation studies with measures of insulin sensitivity/resistance showed 
inconsistent findings in Type 2 DM, other biological markers, namely fasting blood 
glucose and lipidemia, of Type 2 DM showed marked improvements following zinc 
treatment. Recent meta-analyses have consistently revealed beneficial effects of zinc 




[143,144] in Type 2 DM. Zinc supplementation has been shown to produce statistically 
significant improvements in fasting glucose levels, haemoglobin A1c (HbA1c) and 
serum lipids. In a prospective cohort study of patients with Type 2 DM, Soinio et al. 
identified low serum zinc levels (≤ 14.1 µmol/L) as an independent risk factor for 
coronary heart disease events and mortality [145]. However, the clinical significance 
of improvements in these biomarkers is not yet clear, especially in terms of disease 
progression and minimising the risk of complications arising from Type 2 DM. A 
synthesis of the epidemiological evidence will allow elucidation of the relationship 
between zinc intake and risk of complications from Type 2 DM, such as CVD.   
 
 
Table 1.3 Effects of zinc supplementation on insulin sensitivity in humans from a 






















































































In contrast to the link between zinc and glycaemia in patients with existing Type 2 
DM, there is limited evidence in the relationship between zinc status and its potential 




controlled trials (RCT) concluded that zinc supplementation in adults with insulin 
resistance appears to have no effect for measures of insulin resistance and serum lipid 
levels [152]. The authors concluded that further studies are required to ascertain the 
effect of zinc supplementation in the prevention of Type 2 DM for at-risk populations. 
Moreover, the epidemiological evidence for the relationship between dietary zinc 
intake and the risk of developing Type 2 DM was not assessed in the Cochrane review, 
and hence a synthesis of epidemiological studies is required to further examine 
potential effects of zinc intake on Type 2 DM risk.  
 
The biological plausibility of zinc exerting beneficial effects on Type 2 DM risk is 
demonstrated in numerous in vitro studies. Recent studies have elucidated the role of 
zinc in regulating blood glucose fluctuations when released as part of the insulin-zinc 
complex in pancreatic cells. Within the pancreatic β-cells, insulin is produced and 
packaged with zinc ions within secretory vesicles. Upon stimulation of glucose, 
secretory packages of insulin and zinc ions are released from β-cells. While insulin 
enters the systemic circulation, released zinc ions have been shown to produce 
autocrine effects on the pancreas. In the initial phase of glucose stimulation, zinc ions 
trigger the inhibition of glucagon release from α-cells [153], enhancing the 
physiological response to glucose stimulation. Furthermore, recent in vitro studies 
have shown that endogenous zinc secreted from β-cells inhibits the release of insulin, 
thereby providing a feedback loop of insulin secretion in response to elevated glucose 
levels [154].  
 
At the mechanistic level, the beneficial effects of improved zinc status in Type 2 DM 
appears to be related to modulations in the expression and function of zinc 
transporters. Genome-wide association studies (GWAS) have identified SNP variants 
in the ZnT8 gene to be associated with risk of developing Type 2 DM in numerous 
ethnic groups [155]. ZnT8 protein is highly expressed in pancreatic β-cells and 
functions to provide zinc to the secretory vesicles, assisting the storage and secretion 
of insulin. Variants in the ZnT8 gene are proposed to disrupt the protein structure and 
thereby its function in zinc transport [156]. A recent study in ZnT8 KO mice revealed 
that increased insulin secretion from the pancreas corresponded with lower systemic 
insulin concentration. This paradoxical relationship between insulin secretion and 
systemic concentration was explained by the role of ZnT8 in regulating hepatic insulin 
clearance [157]. A recent trial found that, while individuals with the risk allele of ZnT8 
gene had lower hepatic insulin clearance relative to those in the non-risk allele group 




supplementation [158]. Larger studies have shown that the adverse effects of ZnT8 
SNP on glycaemic control can be moderated by improvement in zinc status through 
increases in dietary zinc intake [103] and plasma zinc concentration [159].  
 
The attenuation of insulin signalling pathway, at least in part, contributes to the 
pathogenesis and pathology of Type 2 DM [160]. Zinc can interact with the insulin 
signalling pathway at multiple levels. In vitro studies have shown that zinc ions can 
inhibit PTP activity at the proximal end of the pathway, thereby propagating the 
insulin signal [161]. Increased glucose uptake was observed in 3T3-L1 adipocytes cell 
line upon incubation with zinc, in both the presence and absence of insulin. The 
insulinomimetic effect of zinc appears to be dose responsive at concentrations of 0, 
20, 50, 100 and 200 µmol/L of zinc chloride (ZnCl2) in the media [162]. Taken 
together, the evidence suggests that zinc is capable of increasing glucose uptake in the 
absence of, and synergistically with, insulin. Molecular analysis from in vitro studies 
revealed that improvements in cellular glucose uptake were mediated through 
improved tyrosine phosphorylation of the insulin receptor and insulin receptor 
substrate (IRS)-1 [163]. Figure 1.10 shows the proposed sites of zinc action on the 
insulin signalling pathway.  
 
The expressions of specific zinc transporters have been implicated in the insulin 
signalling pathway. ZnT7 is responsible for the translocation of cytoplasmic zinc into 
the golgi apparatus and intracellular vesicles; ZnT7 KO mice were found to be more 
susceptible to high fat diet-induced postprandial hyperglycaemia and insulin 
resistance than their wild-type counterparts [164]. This may be due to the crucial roles 
that ZnT7 play in insulin secretion and activation of the insulin signalling pathway. 
ZnT7 KO mice display down-regulation of Irs2 gene expression, reduced Akt 
activation and subsequent lowered efficiency of the insulin signalling pathway. The 
expression of another zinc transporter, ZIP7, also appears to be important for cellular 
energy metabolism; ZIP7 is restricted to the golgi apparatus or ER of the cell and has 
the potential to initiate the ‘zinc wave’ [125], providing a rapid influx of cytosolic zinc 
ions that are involved in cellular signalling pathway. In muscle cells, the lack of ZIP7 
expression resulted in reductions in the expression of glucose transporter-4 (GLUT4), 
insulin receptor and downstream signalling molecules [114]. Thus, ZIP7 is proposed to 
be implicated in glycolysis and glycogen synthesis within muscle cells. The interaction 
between zinc transporters and Type 2 DM pathology is further demonstrated in the 
relationships amongst the expression of zinc transporter genes and measures of 




and insulin concentrations were related to fold changes of ZIP10 and ZnT6 gene 
expression, respectively. Further studies are required to ascertain the intricacies and 
altered function of the cellular zinc transport system in Type 2 DM. 
 
Figure 1.10 Potential sites of zinc action on the key targets of the insulin signalling 
pathway (green, increase zinc; red, zinc deficiency). Zinc activates the formation of 
insulin receptor complex, phosphoinositide 3-kinase (PI3-K) pathway, and also Akt 
indirectly. Zinc can also inhibit the activity of some inhibitors within the insulin 
signalling pathway, protein tyrosine phosphatase 1B (PTP1B) and glycogen synthase 
kinase-3 (GSK-3), thereby producing an overall net effect of propagating the insulin 
signalling pathway and promoting glucose metabolism. Reproduced from [28]. 
 
 
The interaction between zinc transporters and exercise prescription in Type 2 DM has 
been investigated recently in a study exploring the influence of SNP variants of ZnT8 
and exercise training outcomes.  In two cohorts of healthy adults, the authors found 
that differences in muscle morphology and function were observed in individuals with 
the risk allele for Type 2 DM, however the differences were resolved with resistance 
exercise training [166]. This preliminary study presents a rationale for further 
investigations into the influence of zinc status on exercise-related functions and 







CVD comprise of a group of disorders that affect the heart and blood vessels, for 
instance coronary heart disease, cerebrovascular disease and peripheral artery 
disease. The primary goals in the prevention of CVD include reduction in low density 
lipoprotein-cholesterol (LDL-C), blood pressure [167] and optimal glycaemic control 
in patients with DM [168]. However, it is now established that residual CVD risk exists 
and contributes to morbidity and mortality in high-risk patients despite achievement 
of treatment goals for LDL-C, blood pressure and glycaemia [169]. The presence of 
residual CVD risk highlights the numerous complex factors contributing to the 
pathogenesis of CVD.  
 
One of the principal underlying causes of CVD is atherosclerosis, which involves the 
formation of lipid-laden plaque on the walls of blood vessels. The development and 
ultimate rupture of atherosclerotic plaques manifest in adverse clinical outcomes, 
such as myocardial infarction, stroke or peripheral artery disease. The Residual Risk 
Reduction Initiative identified atherogenic dyslipidaemia, defined as the imbalance of 
pro-atherogenic cholesterol-rich lipoprotein (primarily LDL-C) and anti-atherogenic 
lipoprotein, i.e. high density lipoprotein-cholesterol (HDL-C), to be the primary target 
for reducing residual CVD risk [169]. While the proportion of different serum 
lipoproteins contributes to the atherosclerotic process, oxidative stress also can 
promote atherosclerosis by lipid peroxidation [170]. Oxidised LDL-C can promote the 
adhesion of circulating monocytes and macrophages to endothelial cells, initiating the 
first steps of atherosclerosis development. 
 
Zinc has been proposed to play a role in attenuating the atherosclerotic process and 
optimising redox balance through moderation of apoptotic, nitric oxide and nuclear 
factor-kappa B (NF-κB)-related signalling mechanisms [26]. One of the initial key 
steps in the pathogenesis of atherosclerosis is the loss of endothelial function. Termed 
as endothelial dysfunction, the characteristics of this phenomenon include the 
presence of inflammation and the subsequent upregulated expression of inducible 
nitric oxide synthase (iNOS). In endothelial cells, the presence of nitric oxide 
increases intracellular zinc ions by releasing zinc from proteins with sulphur clusters, 
thereby propagating the production of glutathione peroxidase that protects against 
hydrogen peroxide-induced toxicity [171]. Furthermore, influx in intracellular zinc has 
been suggested to provide a feedback mechanism to attenuate iNOS expression 





While zinc does not confer antioxidative activity per se, in vitro and animal studies 
have shown that the provision of zinc can inhibit lipid peroxidation [173] and 
oxidation of LDL-C [174]. Furthermore, zinc supplementation in rabbits fed a high 
cholesterol diet reduced the accumulation of total cholesterol in the aorta and size of 
aortic lesions, compared to no zinc treatment [173]. Invasive outcomes, such as size of 
aortic plaques and lipoprotein accumulation in the aorta, rarely can be assessed in 
human investigations. Instead, risk factors such as plasma lipoprotein concentrations 
are used as surrogate measures for CVD outcomes. In a meta-analysis of RCT, zinc 
supplementation produced no significant changes in plasma lipoprotein 
concentrations in healthy participants. However, a statistically significant increase of 
0.36 mmol/L in HDL-C was observed following zinc supplementation in those with 
Type 2 DM (Figure 1.11) [143,175]. Conversely, the pathology of atherosclerosis 
contributes to perturbation in zinc metabolism. Alteration in the distribution of zinc 
among its plasma carriers has been observed in patients with atherosclerosis [176], 
possibly as a result of the interaction between circulating fatty acids and binding 
affinity of zinc and albumin [50]. Taken together, these results highlight the 
interaction of zinc and lipoprotein metabolism, in particular under conditions where 




Figure 1.11 Effect of zinc supplementation on plasma high density lipoprotein 
cholesterol (HDL-C) concentrations, stratified by health status, as determined by 
meta-analysis of randomised controlled trials. Reproduced from [175]. Abbreviations: 






Hypertension is another key contributor to the risk of CVD. The pathogenesis of 
arterial hypertension has been associated with changes in the distribution of zinc 
between extracellular and intracellular spaces [177]. In addition, a lower level of 
plasma zinc concentration combined with higher RBC zinc content in hypertensive 
patients suggests perturbed whole body zinc homeostasis. Untreated arterial 
hypertension appears to increase gastrointestinal uptake of zinc, which is attenuated 
upon anti-hypertensive treatment [178]. It is unclear which mechanisms of cellular 
transport mediate the changes in zinc homeostasis as a result of arterial hypertension. 
In a recent GWAS, a SNP variant in the ZIP8 gene has been associated with blood 
pressure [116], HDL-C level and coronary heart disease risk [115], suggesting that zinc 
transporters may play a role in perturbed zinc homeostasis that co-exists with the 
pathogenesis of CVD.  
 
The in vitro work in the development of CVD provides insights into mechanisms of 
zinc metabolism in the cell culture context, however human investigations have been 
lacking in this field. While favourable effects of zinc supplementation on HDL-C have 
been observed for patients with Type 2 DM [143], the overall effect of zinc on CVD 
risk, as related to lipid profile and atherosclerosis, is currently unclear. In particular, a 
synthesis of epidemiological studies is required to further the understanding of the 




Traditionally, inflammation has been described as the programmed immune response 
to stimuli that are potentially harmful [179]. As part of the innate immune system, 
acute inflammatory response is characterised by the transmittance of cellular signals 
within the immune cell network that, in part, requires changes in cellular zinc 
concentration [180]. The intricate management of zinc concentration in the cytoplasm 
of immune cells serves functional purposes, i.e. cellular signal propagation and 
activation of zinc-dependent proteins [180], while simultaneously minimising the 
supply of zinc to intracellular microbes [181]. At the systemic level, the acute phase 
response of inflammation includes a transiently rapid decline in plasma zinc 
concentration as a result of the redistribution of zinc to other tissues [182]. This is 
facilitated primarily by altered zinc transporter and MT expressions that are instigated 
by systemic pro-inflammatory molecules, such as C-reactive protein (CRP) and 
cytokines [98,183]. For example, the redistribution of zinc from plasma to the liver 




transcriptional regulatory control of zinc transporters by specific inflammatory signals 
are summarised in Tables 1.1 and 1.2.  
 
Extracellular stimuli, such as lipopolysaccharide (LPS), activate toll-like receptors 
(TLR) that initiate acute immune responses through the activation of cellular 
signalling pathways. The classic transcription factor, NF-κB, represents the master 
regulatory protein that facilitates immune function in cells. In addition to modulating 
the expression of cytokines, such as tumour necrosis factor (TNF)-α and IL-1β, in 
vitro studies have confirmed that NF-κB has direct transcriptional regulation of ZIP8 
[184]. NF-κB activation induces ZIP8 expression, which contributes to cellular zinc 
uptake in immune cells. In turn, the increase in cytoplasmic zinc inhibits the 
activation of NF-κB, thereby providing a potent negative feedback loop of NF-κB 
signalling pathways in acute immune response. The role of zinc in immune function is 
further supported by the recent observation of higher expression and secretion of IL-
1β in zinc-depleted macrophages through the activation of NACHT, LRR and PYD 
domains-containing protein 3 (NLRP3) [185]. 
 
It is now recognised that despite acute localised inflammation being a crucial part of 
the immune defence system, chronic activation of the inflammatory processes forms 
an underlying feature of many chronic diseases. The classic presentation of elevated 
CRP and pro-inflammatory cytokines in the systemic circulation have physiological 
implications for the pathogenesis of chronic diseases. For example, chronic low grade 
inflammation is a key factor for both the development of insulin resistance in Type 2 
DM and atherosclerosis in CVD [186]. In particular, there is good evidence in 
observational and in vitro studies to suggest that IL-1β and associated pathways are 
responsible for the development of Type 2 DM and its vascular complications [187]. 
The implication of zinc status on low-grade inflammation under condition of chronic 
diseases, in particular Type 2 DM, remains unclear.  
 
Furthermore, ageing of the immune system, also known as immunosenescence, is 
associated with aberrant physiological changes in both adaptive and innate immunity. 
The disruptions in immune function lead to the development of ageing-related low-
grade chronic inflammation, or “inflamm-ageing” [188]. The attenuation of age-
related inflammation has been suggested to be a potential strategy in delaying or 
deterring the development of chronic diseases, such as CVD and Type 2 DM. Recent 
literature suggests that the elements of aging-related changes, in particular 




vicious cycle [189]. Specifically, zinc deficiency, which is often observed in the elderly 
population, can contribute to the decline in immune function. In turn, perturbations 
in the immune system have been shown to cause significant changes in biomarkers of 
zinc status [60].  Given the crucial role zinc plays in immune functions, zinc 
supplementation has been suggested to improve age-related inflammation and 
immune deficiency in the elderly population [190].  
 
While zinc deficiency has been associated with impairments in immune function, the 
specific role of zinc in immunity and associated mechanisms within the context of 
low-grade inflammation, Type 2 DM and CVD remains to be determined. The 
emerging observation of zinc signalling, mediated by zinc transporters and MT, is 
postulated to be involved in the regulation of immune function, through modulations 
of signalling pathways [191]. In vitro studies have shown zinc can transiently bind to 
specific proteins, such as PTP [192], thereby promoting or dampening cellular signals.  
Whether the observations in cell and animal models are reflected in human 




Established first-line strategies for the prevention and treatment of chronic diseases, 
such as Type 2 DM and CVD, include dietary manipulation and exercise prescription 
[9]. For instance, a program of aerobic exercise performed at moderate intensity for at 
least 3 days/week (totalling around 150 min/week) is recommended for exercise-
induced benefits on glycaemic control in individuals with Type 2 DM. Exercise 
training has been used to induce beneficial effects on the low-grade inflammatory 
state [193] that coexists with many chronic diseases. While exercise has proved to be 
an effective means of modifying and managing chronic disease risk, it also poses 
alteration in zinc homeostasis by modulating inflammation, promoting zinc loss and 
redistributing zinc in the body.  
 
Zinc loss during exercise, in particular through sweat, is well documented [194,195]. 
In a study of recreational cyclists, sweat zinc loss from two hours of cycling at ~50% 
VO2max represented 9% and 8% of recommended dietary zinc intake for men and 
women, respectively [194]. The magnitude of zinc loss in sweat is dependent on 
training status, duration of exercise and ambient temperature. In prolonged exercise, 
conservation of sweat zinc is evident after an hour of aerobic activity and this 




urinary zinc loss as a result of exercise has been difficult to quantify due to differences 
in exercise test conditions [197,198]. The duration of exercise may be a contributing 
factor into the amount of urinary zinc excreted, with significant increase in urinary 
zinc losses after a 6-mile run [197], but no differences observed following a maximal 
exercise test [198].  
 
Reports of the change in plasma zinc concentration immediately after an aerobic 
exercise bout are mixed [197,199,200]. Table 1.4 summarises selected studies 
reporting on changes in plasma zinc concentrations immediately after exercise and 
during exercise recovery. In studies that report increases in plasma zinc immediately 
after exercise, a decrease in plasma zinc concentration is observed typically during 
exercise recovery [197,201]. Furthermore, lower levels of zinc and CA-I in RBC were 
found immediately after high intensity cycling, which returned to baseline levels after 
30 minutes of rest [202]. Taken together, the results suggest a shift of zinc from 
plasma to RBC; the redistribution of zinc between different body compartments 
highlights the rapid flux of zinc when challenged by exercise. A systematic overview of 
the literature is required to determine the exact changes in whole zinc body 
homeostasis as a result of exercise. 
 
Localised exercise-induced muscle inflammation and its sequelae have been proposed 
to explain the flux of zinc observed during exercise recovery. In a study where 70Zn 
was infused into participants after a maximal aerobic exercise bout, zinc flux shifted 
from plasma into the interstitial fluid and the liver, presumably due to the acute phase 
response and/or changes in oncotic pressure associated with exercise [206]. The acute 
stress of exercise induces the production of inflammatory cytokines, such as IL-6, 
which can sequester zinc in the liver via increases in hepatic MT and differential 
regulation of zinc transporters [93]. 
 
For inactive individuals who undergo repeated bouts of exercise, additional zinc losses 
and transfer between body compartments are hypothesised to compromise zinc 
status. In previously inactive individuals, a decline in serum zinc concentration was 
observed after several weeks of aerobic training [207]. In addition, Ohno et al. 
reported a reduction in albumin-bound plasma zinc in men after a 10-week running 
program [208]. Collectively, these observations suggest an increased requirement for 
zinc when previously inactive individuals are under chronic exercise stress. This 
population may include individuals with newly diagnosed Type 2 DM or CVD, where 




interaction between exercise prescription and zinc status in chronic disease 
populations require further investigation.  
 
Table 1.4 Effect of an acute exercise bout on plasma zinc concentration immediately 





















































































Training status of the individual is implicated in the regulation of zinc homeostasis 
during exercise, however the details of this process remain uncertain. Smaller 
fluctuations in serum zinc concentration during exercise were found in endurance-
trained individuals with higher aerobic thresholds, when compared to inactive 
individuals [198]. Longitudinal studies that followed athletes over a competitive 
season report contradictory changes to blood zinc concentrations [209,210], however 
the failure of some studies to assess dietary zinc intake during the study period limits 
the interpretation of the results. The lack of robust information regarding the 
adequacy of dietary intake in athletes was highlighted in a recent systematic review of 





In cross-sectional studies, there appears to be no significant differences in plasma zinc 
levels between athletes and the general population [212]. However, differences in zinc 
metabolism may occur as a result of different athletic activities. Athletes in aerobic 
disciplines, such as triathletes or long distance runners, are more likely to display 
signs of zinc redistribution from plasma to RBC when compared to their 
anaerobically-trained counterparts [213]. It is plausible that, over time, adaptations 
associated with exercise can modulate the redistribution of zinc within the body, 
however the mechanisms of action are unknown. Moreover, RBC-SOD appears to be 
upregulated as a result of adaptation to aerobic exercise [214].  Correlations between 
RBC zinc concentration and activity of RBC-MT and -SOD in elite athletes further 
emphasise the requirement for zinc in the development of antioxidative adaptation as 
a result of exercise [213].  
 
To date, no studies have investigated the cellular network of zinc transport under 
exercise stress in humans. However, in vitro studies suggest that the loss of ZIP7 
expression in muscle cells contributes to a reduction in the expression of principal 
mediators of glucose metabolism, specifically GLUT4, the insulin receptor and 
downstream signalling molecules [114]. Thus, ZIP7 is implicated in glycolysis and 
glycogen synthesis within the muscle cell, suggesting a link between zinc homeostasis, 
cellular metabolism in muscle and exercise performance. Similarly, variants in ZnT8 
SNP have been associated with unfavourable exercise-related functional outcomes, 
such as lower muscle size and strength [166]. The interrelationship between 
inflammation and zinc homeostasis as related to exercise and chronic diseases is 




The maintenance of zinc homeostasis at the whole body and cellular levels is critical in 
optimising the biological functions of zinc. In comparison to the investigation of 
cellular zinc transport, the mechanisms that maintain whole body zinc homeostasis 
are fairly well established. Factors, such as exercise, inflammation and chronic 
diseases, present as challenges to zinc homeostasis in humans. The management of 
chronic diseases, such as Type 2 DM and CVD, often involves the provision of exercise 
training regimes, which may impose additional requirements for dietary zinc to 
maintain optimal zinc status. Therefore, further investigations on the interaction 
among zinc status, exercise and chronic diseases are necessary to further the 





Figure 1.12 Interrelationship between inflammation and zinc homeostasis. Exercise 
and chronic diseases can influence the inflammatory state of the body, which in turn 
initiates changes in zinc homeostasis through redistribution or loss of zinc. Altered 
zinc status, as a result of zinc depletion or supplementation, can affect the immune 
system and its inflammatory processes, thereby impacting the pathogenesis of chronic 
diseases such as Type 2 diabetes mellitus and cardiovascular diseases. 
 
While earlier studies with zinc isotopes have confirmed the major sites of zinc 
homeostatic regulatory control in the gastrointestinal tract and liver, the exact cellular 
zinc transport mechanisms remain to be determined. The current knowledge of 
cellular zinc homeostasis is based on fluorescence techniques and the expression of 
mediators of cellular zinc homeostasis in cell culture studies, thereby limiting the 
translation of results to humans. A sensitive zinc biomarker to detect marginal zinc 
deficiency in humans remains to be discovered. Future research that ascertains the 
connection between whole body zinc homeostasis and the cellular zinc transport 
network under conditions of health and diseases will extend the current knowledge 













The primary objective of this thesis was to explore the interaction between zinc 
homeostasis, exercise and chronic diseases. The thesis comprises of a series of studies 
that explores the interactions among zinc status, exercise and chronic diseases, using 
a range of scientific methods, including molecular analysis and systematic reviews. 
The specific aims of each chapter are as follow:  
 
1. To evaluate the evidence of relationships between zinc status and prospective 
risk of chronic diseases, such as Type 2 DM and CVD by undertaking a 
systematic review of the literature (Chapter 2);   
2. To quantify changes in zinc biomarkers immediately after an aerobic exercise 
bout in healthy populations by undertaking a systematic review and meta-
analysis (Chapter 3);  
3. To quantify changes in zinc biomarkers during recovery phase of an aerobic 
exercise bout in healthy populations by undertaking a systematic review and 
meta-analysis (Chapter 4);  
4. To determine the effect of zinc supplementation on gene expressions of zinc 
transporters and MT in a healthy population by undertaking a RCT (Chapter 
5); 
5. To determine the effect of zinc supplementation on gene expression of 
cytokines in patients with Type 2 DM by undertaking a RCT (Chapter 6); 
6. To explore and compare the relationships among cellular zinc transporters and 






































Chronic metabolic diseases, such as CVD and Type 2 DM, represent a significant 
proportion of non-communicable disease (NCD) deaths around the world. Zinc is an 
essential trace element with proposed therapeutic effects in Type 2 DM, however the 
associations between zinc status and the prospective risks of CVD and Type 2 DM 
have not been evaluated. The current systematic review aims to determine the 
relationships between zinc intake or plasma/serum zinc levels and prospective 
incidence of CVD and Type 2 DM. Twelve papers describing prospective cohort 
studies were included, reporting either CVD (n = 91,708) and/or Type 2 DM (n = 
328,207) outcomes. Primary analyses from four out of five studies reported no 
significant association between zinc intake and CVD events, when adjusted for 
multiple variables. Higher serum zinc level was associated with lower risk of CVD in 
three of the five studies; pronounced effects were observed in vulnerable populations, 
specifically those with Type 2 DM and patients referred to coronary angiography. The 
limited evidence available suggests a trend towards protective effect of dietary zinc 
intake on Type 2 DM risk; two studies reported decrease in Type 2 DM incidences 
with increasing zinc intake, while the two other studies reported no association. 
Further investigations into the mechanisms of zinc’s action on the pathogenesis of 
chronic diseases and additional evidence from observational studies are required prior 
to the establishment of dietary zinc recommendation for the prevention of CVD and 







Chronic metabolic diseases, such as CVD and Type 2 DM, represent a significant 
proportion of NCD deaths around the world [1]. In 2012, 17.5 million and 1.5 million 
deaths were attributed to CVD and Type 2 DM, respectively. Deaths due to NCD are 
projected to increase, with the majority occurring in LMIC. The role of diet and 
physical activity in the prevention and management of chronic metabolic diseases is 
recognised by numerous health organisations [167,215]. While there is substantial 
evidence for optimal dietary patterns and macronutrient compositions for the 
prevention of diseases, the influence of micronutrient intakes, such as zinc, on the risk 
of developing chronic metabolic diseases remains to be elucidated.  
 
Zinc is an essential trace element with known functions of antioxidant activity, energy 
metabolism and growth [24]. In relation to the interactions with chronic metabolic 
diseases such as CVD and Type 2 DM, zinc can modulate levels of oxidative stress and 
inflammation, both of which are implicated in the development of CVD and Type 2 
DM. In addition, zinc has been shown to serve a regulatory role in many signalling 
pathways, including potentiation of leptin and insulin signalling [26]. Recent GWAS 
identified the potential role of Zinc Transporter-8 (ZnT8; SLC30A8), and zinc status 
in the pathogenesis and management of Type 2 DM [155]. Meta-analyses of RCT 
involving patients with Type 2 DM revealed improvements in measures of glycaemic 
control [141] and dyslipidaemia [143] following zinc supplementation. The 
mechanisms of action have been proposed to involve improvements in the stability of 
insulin within pancreatic β-cells and insulin sensitivity in peripheral tissues. While the 
therapeutic effects of zinc in Type 2 DM have been proposed [141,143], the 
associations between zinc status and the prospective risks of developing CVD and 
Type 2 DM have not been evaluated.  
 
Findings in cell and animal studies support the protective role of zinc on the risk 
factors of CVD, such as the development of atherosclerosis. The modulating effects of 
zinc on the formation of atherosclerotic plaque are primarily attributed to the role of 
zinc in supporting the structural integrity of endothelial cells and attenuating lipid 
peroxidation through zinc-regulated redox signalling pathways [26,29]. In cultured 
endothelial cells, the aberrant expression of iNOS forms the basis of endothelial 
dysfunction and pathogenesis of atherosclerosis. Zinc has been shown to regulate the 
activity of iNOS, reversing the adverse effects of inflammation on the endothelium 




formation and plasma and arterial wall lipid peroxidation in rabbits fed a high 
cholesterol diet [173]. Taken together, the growing evidence derived from 
experimental models provides biological plausibility for a potential role of zinc on 
CVD prevention.  
 
Furthermore, the association between zinc deficiency, low grade inflammation and 
immune response supports the importance of optimal zinc status in modulating the 
inflammatory events required for atherosclerosis development in humans [216,217]. 
While RCT aimed to study the effects of zinc supplementation on the development of 
CVD are limited, a number of observational studies have explored the relationship 
between zinc status and CVD outcomes [218,219]. In a Finnish nested case-control 
study, the highest tertile of serum zinc concentration was associated with 43% 
reduction in the relative risk (RR) of CVD death compared to those in the lowest 
tertile of serum zinc [218]. Similar trends were observed in an urban Indian 
population, where higher dietary zinc intakes and higher concentrations of serum zinc 
concentrations were correlated with reduced prevalence of coronary artery disease 
and Type 2 DM [219]. 
 
To date, no systematic review has explored the link between zinc status and the risk of 
developing chronic metabolic diseases, specifically Type 2 DM and CVD. Therefore, 
the current paper aims to determine the relationship between zinc intake and 
plasma/serum zinc concentrations and prospective incidence of CVD and Type 2 DM 






Search strategy  
 
A literature search was conducted of PubMed, Cochrane Central Register of 
Controlled Trials, EMBASE, MEDLINE and Web of Science from inception to the 25th 
of May, 2015. Search terms used were (zinc AND [(dietary OR supplement*) OR 
(plasma OR serum)] AND (diabetes OR cardiovascular diseases OR metabolic 
syndrome OR cerebrovascular diseases OR chronic kidney disease). Related terms and 
MeSH terms were used where appropriate. Studies were limited to humans and 
English language. Full search details for the search of “zinc and diabetes” in the 
EMBASE database are presented in Table A1 (Appendix A). Figure 2.1 shows the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
flowchart describing the electronic search outcomes and selection process [220]. 
Review questions, search strategies and inclusion criteria were prospectively specified 
and registered with PROSPERO register at http://www.crd.york.ac.uk/PROSPERO/ 
(CRD42015020589).  
 
Study eligibility criteria 
 
Prospective cohort studies that examined the association between zinc status and the 
risk of developing chronic metabolic diseases (Type 2 DM and CVD) were eligible for 
inclusion. The definitions of diseases derive from the International Classification of 
Diseases [221]; for instance, CVD encompasses coronary heart disease and 
cerebrovascular disease. Apparently healthy participants and those with existing co-
morbidities were included in this review. Studies were selected if plasma/serum zinc 
concentration or zinc intake (dietary and/or supplemental) were measured as indices 
of zinc status, in conjunction with exposure risk for developing chronic diseases 
stratified by zinc status. Plasma and serum zinc concentrations were grouped to 
represent systemic zinc concentration; the terms plasma and serum are used 
interchangeably in this report to reflect the measurement provided by the study 
authors. All other studies and review papers on the topic were excluded. Two 
independent reviewers screened the title and abstract of each citation identified in the 
literature search to determine the paper’s eligibility for full review. The full report of 







Figure 2.1 PRISMA diagram showing the systematic review process. 
 
#
Data extraction and quality assessment of included studies 
 
Data from all included studies were extracted independently by two investigators and 
any differences were resolved by discussion. The data extraction sheet included study 
description; participants’ characteristics (age, sex, disease characteristics), number of 
included participants and cases identified, zinc biomarker used and method of 
analysis, years of follow up, and characteristics of outcome measures (risk estimates 
and precisions, statistical models used, adjustments for confounding measures). 
Where available, outcome measures for CVD events were extracted as fatal, non-fatal 
and combined events. For studies where multiple models were presented with 
different statistical adjustments, outcome data of the unadjusted and fully adjusted 
models were extracted, along with the identified covariates. Only published data were 
included as no attempt was made to contact authors of included studies. Meta-
analyses for the relationships were deemed inappropriate due to the variability in 








All individual studies were assessed for their risk of biases that are specific to 
observational studies as recommended by the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) guidelines [222]. Two 
independent reviewers assessed the potential risk of biases, including failure to 
develop and apply appropriate eligibility criteria, flawed measurement of exposure 
and/or outcome, failure to adequately control for confounding variables and 
incomplete or inadequately short follow up. Data on risk of bias in individual studies 
were entered into Review Manager 5.3 [223].  
 
The adequacy of controlling for confounding variables was scored by a defined 
checklist of confounding variables relevant to the specific exposure measure. For 
statistical models using zinc intake as an exposure, eight types of variables were 
considered to be important confounding factors for consideration, giving a total score 
of 5. Where models included an aspect of family history, comorbidities, lifestyle 
factors, anthropometry, dietary factors or medications, the study was given a score of 
0.5 for each variable. Saturated fat and trans fat intakes were considered to be 
essential dietary factors for the models involving CVD, and therefore studies that 
included these variables in the fully adjusted statistical models were given a score of 1 
for each variable. For models with Type 2 DM as an outcome, saturated fat and dietary 
fibre intakes were considered to be important confounding factors and therefore 
inclusion of each factor was given a score of 1. In the statistical models considering 
serum zinc concentration as an exposure factor, the essential confounding variables 
(each representing a score of 1) were as follows: total cholesterol or LDL-C 
concentrations; HDL-C concentration; and a biomarker of inflammation, hence giving 
a total score of 3. In the evaluation of the quality of studies, for those with the highest 
potential total score of 5, scores less than 2 were considered to be at high risk of bias; 
scores between 2 and 4 were considered to be at unclear risk of bias; and scores 
greater than 4 were considered to be at low risk of bias. For those with highest 
potential total score of 3, scores less than 1.5 were considered to be at high risk of bias; 
scores between 1.5 and 2.5 were at unclear risk of bias; and scores greater than 2.5 
were considered to be at low risk of bias. The factors and associated scores are shown 









The electronic database searches identified a total of 5807 citations once duplicates 
were removed. After screening the titles and abstracts, 5742 citations were excluded as 
irrelevant to the current review, leaving 65 full texts that were retrieved for eligibility 
assessment. Of the full texts that were retrieved, 12 papers satisfied the inclusion 
criteria. Details of study selection and reasons for full text exclusion are presented in 
Figure 2.1.  
 
Zinc status and CVD outcomes 
 
Nine papers [145,224–231] describe the relationship between zinc status and fatal and 
non-fatal CVD events. Two of the identified papers [226,229] report on different 
aspects of the Iowa Women’s Health Study and therefore both were included in the 
current systematic review. All studies were conducted in high-income countries: USA, 
Britain, France, Finland and Germany. The majority of included participants were 
recruited from the general population and were apparently healthy at baseline, with 
the exception of the study conducted by Soinio and colleagues, who recruited patients 
with Type 2 DM [145]. The number of participants (n = 91708) in the included studies 
ranged from n = 344 to 39633, with a median of 3655 participants. Five studies 
[145,225,228,230,231] sampled a mixed-sex population, while two studies reported on 
males only [224,227] and another study included an exclusively female population 
[226,229]. Included participants were followed for a mean of 12.4 y (median: 13 y; 
range: 6.2-19 y).  
 
The exposure measurement, zinc status, was described as zinc intake (dietary and/or 
supplemental) [224–226,229,230] or serum zinc levels [145,225,227,228,231]. 
Dietary zinc intakes were derived from food frequency questionnaires (FFQ) for all 
studies, with the exception of the British National Diet and Nutrition Survey [225], 
which used a 4-day weighed food record. Questions regarding specific supplements of 
zinc were used for participants in two of the studies [224,229]. Zinc concentrations in 
serum or plasma were determined by atomic absorption spectroscopy (AAS) 
[145,227,228] or colorimetric assays [225,232]. To determine the relationship 
between measures of zinc status and CVD events, the majority of included papers used 
multivariate models with stratified levels of zinc intake or serum zinc concentration 





Five included papers explored the relationship between zinc intake (dietary and/or 
supplemental) and CVD events (Table 2.1). Two studies stratified zinc intake into 
quintiles [224,230], while another study presented quartiles of zinc intake with an 
additional stratification at the median of the highest quartile [226]. One study 
analysed the risk of CVD using standardised zinc intake as a continuous variable 
[225]. The only study that examined zinc supplement use and CVD risk categorised 
the study population as groups of users and non-users [229]. Primary analyses from 
four out of five studies reported no significant association between zinc intake and 
CVD events, when adjusted for multiple variables [224,226,229,230]. A significant 
decrease in vascular disease mortality of 16% was observed per standard deviation 
(SD) increase in dietary zinc intake (hazard ratio 0.84, CI 95% 0.71, 0.99; P = 0.04), 
after statistical adjustments for age and sex [225]. In secondary analyses, Otto et al. 
reported greater risk of CVD with increased dietary zinc intake derived from red meat 
(P < 0.01) [230]. However, CVD risk was not associated with total dietary zinc intake 
from other sources.  
 
The association between serum zinc concentrations and risk of CVD events was 
reported in five studies (Table 2.2). Four studies stratified serum zinc levels into 
tertiles [228] or quartiles [145,227,231]. Another study determined the risk of CVD by 
the continuous variable of standardised serum zinc levels [225]. No significant 
relationships were observed in two of the five included studies [227,228]. While 
reduced risk of vascular death was observed with higher plasma zinc concentration 
within the age and sex adjusted statistical model, the association was no longer 
significant once adjusted for other variables, such as serum cholesterol and lifestyle 
characteristics [225]. In a multivariate model, per quartile decrease of serum zinc 
concentrations was associated with 10% increased risk of CVD mortality in patients 
referred for coronary angiography (P = 0.038) [231]. A similar effect was noted in 
patients with Type 2 DM; participants in the lowest quartile of serum zinc level (< 14.1 










































































































































































































































































































































































































Zinc status and Type 2 DM  
 
Four studies investigated the relationship between zinc status and the risk of 
developing Type 2 DM (Table 2.3, Table 2.4). Three of the included studies 
stratified zinc intake of the study population into quintiles [230,232,233], while 
another study categorised the population into zinc supplement users or non-users 
[234]. The sample size of the four studies ranged from n = 4982 to 232,007, who were 
followed for 4.8 to 24 y. All included participants were recruited by population-based 
methods and were apparently healthy at baseline.  
 
At 24 y follow up of the Nurses’ Health Survey, increased total zinc intake was 
associated with lower Type 2 DM risk, after multiple statistical adjustments (P-trend = 
0.009) [233]. Participants in the highest quintile of total zinc intake (median: 18.0 
mg/d) had a reduced RR of 0.9 (95% CI 0.82, 0.99) for developing Type 2 DM 
compared to the lowest quintile (median: 4.9 mg/d). High dietary zinc intake, i.e. 
excluding supplements, was independently associated with reduction in Type 2 DM 
risk. Similar findings were reported for a cohort of Australian women where the 
highest quintile of dietary zinc intake was associated with a 50% decrease in the risk of 
developing Type 2 DM, compared to the lowest quintile (P-trend = 0.006) [232]. The 
use of zinc supplements was not associated with Type 2 DM [234]. No relationship 
was observed between dietary zinc intake and the risk of Type 2 DM or metabolic 
diseases in the Multi-Ethnic Study of Atherosclerosis [230]. In secondary analyses, 
Otto et al. reported no significant association between zinc intake from red meat and 
risk of Type 2 DM.  
 
Quality of included studies  
 
Figure 2.2 shows the risk of biases of individual studies with support for judgements 
presented in Table A3-A6 (Appendix A).  All included studies developed and 
applied appropriate eligibility criteria therefore scoring low risk of bias in the quality 
assessment. Follow up time and proportion of participant loss to follow up were 
appropriate for all except one study [234], which had a response rate of 56% at follow 
up. The included studies scored between low and unclear risk of bias for validity of 
exposure and outcome measurements. Some of the studies adjusted for confounding 
factors appropriately, scoring a low or unclear risk of bias. High risk of bias was 
present in two of the included studies [225,234], where significant confounding 
factors were not considered. All of the included studies did not provide access to study 
protocol or the study protocol did not specify the reported analyses, therefore 
presenting unclear risk of selective reporting.  
!
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Table 2.4 Summary of relationships between zinc status and prospective risks of 
cardiovascular diseases and Type 2 diabetes mellitus. 
# Study## CVD## Type#2#DM##
Zinc#intake# Al9Delaimy#et!al.#2004#[224]## No#association# N/A#
# Bates#et!al.#2011#[225]# !#risk## N/A#
# Lee#et!al.#2005#[226]# No#association# N/A#
# Leone#et!al.#2006#[227]# No#association## N/A#
# Otto#et!al.#2012#[230]# No#association# No#association#
# Sun#et!al.#2009#[234]# N/A# !#risk#
# Vashum#et!al.!2013#[232]# N/A# !#risk#
Zinc#supplement## Al9Delaimy#et!al.#2004#[224]## No#association## N/A#
# Mursu#et!al.!2011#[229]# No#association# N/A#





# Marniemi#et!al.#1998#[228]# No#association# N/A#
# Pilz#et!al.#2009#[231]# !#risk# N/A#







Figure 2.2 Summary of risk of biases from each included study. Green (+) symbols 
represent low risk of bias for the specific criteria within that study. Yellow (?) symbols 
represent unclear risk of bias and red (-) symbols denote high risk of bias. Support for 






The present synthesis of prospective cohort studies suggests a trend towards a 
protective effect of higher zinc intake on Type 2 DM risk in apparently healthy 
populations. Similarly, higher serum zinc level appears to be associated with lower 
risk of CVD, with pronounced effects observed in vulnerable populations, such as 
those with Type 2 DM [145] and patients referred to coronary angiography [231]. The 
effect of zinc on the prevention of CVD, as complications of DM, is supported by 
evidence from RCT [141,143] describing improvements in the intermediate markers of 
DM, such as HDL-C and fasting glucose levels. However currently, there is insufficient 
evidence to propose any relationship between zinc intake and CVD risk.  
 
The biological plausibility for the role of zinc in preventing the Type 2 DM 
development has been shown in experimental studies. Zinc has been shown to 
propagate insulin signal within peripheral tissues, by acting on multiple sites of the 
insulin signalling pathway [28]. The insulinomimetic effects of zinc have been shown 
in 3T3-L1 cells where a dose response relationship was observed between zinc 
concentration in incubated media and glucose uptake [162]. In contrast, there is 
strong evidence for improving zinc status in individuals with pre-existing Type 2 DM 
as an adjunct treatment strategy [11]. Optimal zinc status, achieved by 
supplementation or dietary means, has been associated with improvements in 
intermediate markers of Type 2 DM disease progression, such as glycaemic control 
[141] and lipidemia [143], in addition to reduced rates of complications secondary to 
DM [145,235]. However, the evidence provided by the prospective cohort studies in 
the present review are complicated by inherent confounding factors such that further 
investigations are required prior to the establishment of convincing clinical advice. 
 
The collation of prospective cohort studies highlights the inconsistency of statistical 
models utilised in the current literature. While the majority of the papers included 
adjustments for confounding factors, the combinations of factors used are largely 
varied, with some models lacking adjustments that are widely accepted in the 
literature. For example, while there is good evidence for dietary trans-fatty acids to be 
positively associated with CVD risk and events [236], some studies have not included 
trans-fatty acids as a covariate variable in their models [225,230]. The lack of 
adjustments for confounding factors can introduce bias in the reported results, 
especially taken together with the inherent limitations of prospective cohort studies 




adjustments added heterogeneity in determining the effects of zinc status on CVD and 
Type 2 DM, rendering meta-analysis of effect inappropriate currently.  
 
The majority of the studies reporting total zinc intake used FFQ to estimate habitual 
dietary zinc intake of the study population [224,226,229,230]. In validation studies 
that compared different methods of dietary assessment, long term zinc intake derived 
from FFQ and dietary records were well correlated [239]. In contrast, heterogeneity in 
results reported for serum zinc levels may be attributed to differences in methods of 
measurement. Three of the five included studies [145,227,228] used AAS to determine 
serum zinc concentration, as the “gold standard” method recommended by the 
IZiNCG [41]. The other studies [225,231] utilised colorimetric assays for serum zinc 
analyses, which are liable to significant systematic and fixed bias when compared to 
zinc analysis by AAS [240]. While the results for serum zinc levels will be comparable 
within studies, the intrinsic differences in zinc analysis methods were such that the 
present collation of results should be assessed in light of the heterogeneity within the 
available data.   
 
The findings within the present review suggest potential sex differences in the effect of 
zinc on Type 2 DM disease risk. While significant decrease in Type 2 DM incidences 
were found with higher dietary zinc intake in female participants [232,233], studies 
involving both sexes reported no association [230,234]. Furthermore, this hypothesis 
is supported by a recent study by Yary et al. [241] which showed increased Type 2 DM 
risk in men with higher serum zinc levels. Nevertheless, the available evidence are 
limited by the small number of studies examining the relationship between zinc status 
and Type 2 DM and hence further investigations are required to confirm the current 
results.  
 
In contrast to the general trend of no association between dietary zinc and CVD risk, 
the secondary analysis of one study revealed a significant increase in the risk of CVD 
with increasing dietary zinc intake from red meat [230]. In the primary statistical 
analyses described in the paper, the authors reported no significant effect for total zinc 
intake or dietary zinc derived from other sources. When the observations from 
secondary analyses are considered with the protective effect of serum zinc levels on 
CVD risk revealed in the present systematic review, it draws doubt into whether the 
reported adverse effect of zinc from red meat sources is attributable to zinc intake or 
red meat per se. Recent evidence suggests that increased red meat intake, in particular 




differentiation of zinc intake by the food sources and its effect on the prospective risks 
of CVD and Type 2 DM requires further investigation.  
 
The interaction between zinc and other nutrients in determining the risk of 
cardiometabolic diseases were explored in several included studies. Alcohol 
consumption has been consistently associated with CVD events in a J-shaped 
relationship, whereby low to moderate alcohol consumption are protective against 
CVD mortality when compared to non-drinkers or those with high alcohol 
consumption [243]. When categories of dietary zinc intakes and RR of CVD mortality 
were stratified by alcohol consumption, Lee et al. showed protective effect of 
increasing zinc intake for women consuming ≥ 10 g alcohol/d [226], thereby 
suggesting additive and separate mechanisms of effect of zinc and alcohol on CVD 
risk. Interactions between zinc and other mineral, such as iron and copper, have been 
explored in determining the risk of CVD and Type 2 DM. Higher dietary zinc/iron 
ratio was associated with lower risk of developing Type 2 DM in a cohort of Australian 
women [232], possibly due to the antagonist effect of dietary iron on zinc absorption 
within the intestinal lumen. While known interactions between zinc and other 
nutrients were explored as ratios or stratified statistical analyses in some included 
studies, the mechanisms of interaction remain unclear.  
 
The generalisability of the present results may be limited to high income countries, 
where all included studies were conducted. Disparities in health care and 
management of chronic diseases stratified by socioeconomic development of countries 
are highlighted by differences in life expectancy and probabilities of death from NCD 
[1]. For individuals with Type 2 DM, management of DM in LMIC may be suboptimal 
in the prevention of DM associated complications [244], such as CVD. Novel 
interventions, such as those that improve zinc status of patients with DM, may be an 
applicable, low cost strategy, in conjunction with current management therapies, for 
the prevention of DM complications. 
 
Furthermore, potential interactions should be considered in regards to the effects of 
current preventative and treatment recommendations for obesity-related chronic 
diseases, such as exercise and dietary management, on zinc status. For example, 
higher intakes of dietary fibre are often suggested to individuals with Type 2 DM [245] 
and those with increased risk for cardiometabolic diseases. The effect of phytate on 
reducing the bioavailability of zinc in the gut is well-established [246]; thereby the 




important determining factor in risk of chronic diseases. Moreover, lifestyle 
modifications, specifically physical activity, can modulate nutrient status with 
implications for beneficial effects induced by exercise [10]. Further investigations are 
required to examine the interactions between zinc status and current preventative and 
treatment recommendations, especially exercise and intakes of competing nutrients, 
in the management of obesity-related chronic diseases.  
 
To the best of our knowledge, the current report is the first systematic review of 
prospective cohort studies assessing the relationship between zinc status and risks of 
CVD and Type 2 DM. The strengths of the present study lie in the systematic collation 
of available evidence and the determination of risk of study biases in line with current 
GRADE approach adopted by the Cochrane Collaboration [222]. While the available 
data did not allow for meta-analysis of effect, the qualitative assessment of the current 
evidence suggests protective effect of zinc on the development of cardiometabolic 
diseases, specifically CVD and Type 2 DM. The effect of zinc appears to be more 
pronounced in vulnerable populations, such as those with existing Type 2 DM or 
established risk factors of diseases. Further investigations into the mechanisms of 
zinc’s action on the pathogenesis of chronic diseases and additional evidence from 
observational studies are required for the establishment of dietary zinc 


































Zinc is involved in numerous metabolic roles, including energy metabolism, immunity 
and antioxidative effects. Zinc losses during exercise, in particular through sweat, are 
well documented. However, conflicting results have been reported for changes in 
circulating and tissue zinc concentration as a result of exercise. The purpose of this 
paper is to quantify the immediate effect of aerobic exercise on plasma or serum zinc 
levels, in healthy participants. We conducted a systematic review of peer-reviewed 
papers published up to 20th of December 2014 to identify studies that investigated the 
acute effects of exercise on selected indices of zinc status. Meta-analyses were 
conducted to determine the change in serum zinc concentration immediately 
following a bout of aerobic exercise. Forty-five studies were included in the systematic 
literature review. Of the included studies, sufficient data were available from 34 
studies (providing 46 comparisons) to quantify the change in serum zinc 
concentration after exercise. Serum zinc concentration was significantly higher 
immediately after exercise (change from baseline: 0.45 ± 0.12 µmol/L, P < 0.001; 
mean ± SE). Secondary analyses showed greater increase in serum zinc for untrained 
individuals and exercise sessions that involved running or maximal intensity. 
Insufficient data were available to determine the effects of exercise on urinary, sweat 
and RBC zinc. The present systematic review and meta-analysis indicated significant 
increase in serum zinc concentration immediately after an aerobic exercise session, 
suggesting acute perturbations in zinc homeostasis. Further research is required to 
ascertain the long-term effects of exercise on zinc metabolism and potential 
consequences for dietary zinc requirement for physically active populations.  






Exercise training is an established preventative and management strategy for obesity 
and related chronic diseases, such as Type 2 DM and CVD [7]. The therapeutic effects 
of exercise have been attributed to improvements in insulin sensitivity, favourable 
changes in body composition, fat oxidation and storage in muscles [247]. In addition 
to the benefits induced by physical activity, exercise also can effect changes in 
nutritional status [8], with implications for the physiological adaptations of exercise. 
For example, the provision of dietary protein in conjunction with resistance exercise 
can substantially stimulate the rate of muscle protein synthesis in skeletal muscles 
[248].  
 
Zinc is involved in numerous metabolic roles, including energy metabolism, immunity 
and antioxidative effects. The majority of zinc within the musculoskeletal system is 
found as part of protein complexes; zinc provides structural stability and enzymatic 
activities of metalloenzymes, such as LDH, SOD and CA [24]. Under zinc-depleted 
conditions, reductions in cardiorespiratory function and muscle endurance during 
exercise were observed; lowered activities of CA in RBC and LDH within skeletal 
muscles, induced by suboptimal zinc status, are suggested to contribute to the decline 
in cardiorespiratory function during exercise [249].  
 
Current literature suggests that zinc ions can modulate cellular signalling pathways 
with effects on redox activity and insulin sensitivity; in particular, the function of 
cellular zinc transporters play a role in maintaining optimal signalling capacity [250]. 
For example, the loss in expression of a specific zinc transporter, ZIP7, in muscle cells 
induces the down-regulation of glycolysis and glycogen synthesis [114]. In Chapter 5, 
we report a relationship between ZIP7 gene expression and physical activity level in 
healthy adults, which supports the notion of interaction between mediators of zinc 
homeostasis and energy metabolism during exercise.  
 
Zinc losses during exercise, in particular through sweat, have been well documented 
[194,195]. In addition to systemic zinc losses, cellular disruption as a result of 
muscular contraction also can lead to the release of zinc ions and zinc-containing 
proteins into the circulation [251]. The initial observations of lower serum zinc 
concentrations in some group of athletes, when compared to physically inactive 
individuals, posed the possibility for suboptimal zinc status in individuals who are 




suboptimal zinc status, factors directly related to exercise also contribute to altered 
zinc metabolism. Multiple factors appear to influence the distribution of zinc in the 
body, contributing to conflicting results reported for changes in circulating and tissue 
zinc concentration as a result of exercise. Hence, the present paper aims to summarise 
the current literature on the immediate effects of aerobic exercise on zinc 
concentrations in blood, sweat and urine in healthy participants; where possible, 






Search strategy  
 
A literature search was conducted of PubMed, Web of Science, Scopus and 
SPORTDiscus electronic databases up to 20th of December, 2014 using the search 
strategies: (zinc AND exercis* OR athlet*) and (serum OR plasma zinc AND physical 
activity). Full search details are presented in Table B1 (Appendix B). Studies were 
restricted to human investigations published in English. Reference lists of retrieved 
studies were inspected for additional relevant articles. The PRISMA flowchart 
describing the studies identified from the search strategy is shown in Figure 3.1 
[220]. Inclusion criteria and methods of the analysis were specified in advance and 









Study eligibility criteria 
 
Before-after trials, baseline data from RCT and longitudinal studies published in peer-
reviewed journals were eligible provided they reported on measurements in indices of 
zinc status (zinc concentration measured in serum/plasma, RBC, urine or sweat) after 
an aerobic exercise bout. Any aerobic exercise, such as running or cycling, in 
laboratory, field or competition setting, was included in the selection criteria. Other 
modes of exercise, such as resistance training, high intensity interval bouts and 
electrically stimulated muscle actions, were excluded. Participants of any age, who 
were apparently healthy i.e. not diagnosed with any major illness or health conditions, 
were considered. Literature reviews on the topic were excluded. The title and abstract 
of each study identified in the search were screened to determine the study’s eligibility 
for full review. The full report was retrieved if the study potentially or definitely 
investigated acute changes in the measures of zinc status after an aerobic exercise 
bout. Two investigators reviewed each full report independently to determine if the 
study met the inclusion criteria.  
 
Data extraction and quality assessment of selected study 
 
Data from all selected studies were extracted by two investigators and any differences 
were resolved by discussion. The data extraction worksheet included descriptive 
information, such as the study authors, year of publication, the number and gender of 
participants. Training status of participants (untrained, moderately trained or 
athletic) was extracted according to the authors’ description of population group. The 
duration, intensity and mode of exercise were detailed in the data extraction 
worksheet. Primary outcomes extracted were measures of zinc status (plasma or 
serum, urinary, sweat and RBC zinc concentrations) immediately after exercise 
compared to baseline values. Plasma and serum concentrations were grouped to 
represent systemic zinc concentration. The term ‘serum’ will be used to refer to both 
serum and plasma in this report. Estimations from figures were used where numerical 
zinc concentrations could not be found in the included reports. P-values for paired t-
test comparing serum zinc concentration immediately after exercise with baseline 
values were also recorded. In studies where multiple exercise testings were reported 
within one population group, the results from the initial intervention were taken. In 
longitudinal or interventional studies, only baseline data reporting the acute effects of 
exercise bouts were included. Units were converted to International System of Units 




standard error (SE). The quality of the selected studies was assessed using the 
American Dietetic Association’s Quality Criteria Checklist for Primary Research [252]. 
The completion of this checklist provides one of three quality rating categories 
(positive, neutral or negative), determined by how individual studies addressed 
validity issues regarding selection bias, inclusion and exclusion of study participants, 
generalisability of results, data collection and analysis. The majority of the included 
studies were rated as neutral because they addressed some issues regarding study 
validity. A positive quality rating indicates that the paper resolved most of the study 





Meta-analyses of serum zinc concentration were carried out on selected studies using 
the Comprehensive Meta-Analysis package, version 2 (Biostat, Englewood, NJ, USA; 
www.meta8analysis.com). The primary outcome measure was analysed by the mean 
difference of serum zinc concentration between baseline (pre-exercise) and 
immediately after exercise values, and the p-value from the corresponding paired t-
test. Where p-values of the paired t-test were given within a range, the average was 
taken, i.e. P = 0.03 was taken for the range of 0.01 < P < 0.05. A funnel plot of SE by 
differences in mean was generated for the main outcome to assess publication bias. 
Secondary analyses were conducted by grouping the comparisons by the study 
population’s training status (untrained, moderately trained or athletic), mode of 
exercise (running, cycling or “other”) and exercise intensity (maximal or submaximal). 
Random-effects models were used for the meta-analyses due to the large variation in 
study design among selected studies. Sensitivity analyses were conducted to 
determine the impact of individual or groups of comparisons within the included 
studies. Mixed-effects meta-regression using method of moments was performed to 
examine the relationships between the change in serum zinc concentrations 
immediately after exercise and baseline serum zinc concentration, age of study 






Study characteristics of systematic literature review 
 
The electronic database searches provided 3698 citations, after removing duplicates. 
Following initial review of all abstracts, 3330 studies were excluded as they did not fit 
the inclusion criteria. The full texts of the remaining studies were retrieved and 
examined. Of the 368 full texts retrieved, 45 studies were relevant to the present 
systematic literature review. The detailed study selection process is shown in Figure 
3.1.  
 
The characteristics of studies included in the systematic literature review are 
described (Table 3.1). The majority of included studies were before-after studies 
reporting on the effects of a single acute exercise bout [194,197,198,201–
203,206,253–270]. Multiple exercise bouts were included in four studies [195,271–
273], which aimed to examine the effects of different exercise conditions on measures 
of zinc status. The primary outcomes for the remaining studies were the effects of an 
exercise bout longitudinally [212,274] or after specific interventions, e.g. exercise 
training or nutritional supplementation [199,200,204,205,208,275–283]. Included 
studies reported on one or more of the following zinc outcomes: serum (40 studies), 
urinary (7 studies), sweat (8 studies) and RBC (3 studies). All included studies scored 
neutral in the quality assessment, with the exceptions of one study [206] scoring a 













Anderson!et!al.!1984![197]! 9! M! 23N46! Moderately!trained! Running,!maximal! Serum,!urine!
Anderson!et!al.!1995![198]! 8! M! 40.4!±!4.3! Moderately!trained! Running,!maximal! Serum,!urine!
!
5! M! 33!±!2.1! Untrained! Running,!maximal! !




Aruoma!et!al.!1988![254]!! 12! M! 21! Moderately!trained! Cycling,!80%!VO2!max,!30N40!min! Serum,!sweat!
Bolonchuk!et!al.!1991![274]! 8! M! NP4! Athletic! Running,!maximal! Serum!
Bordin!et!al.1993![201]! 9! M! 23!±!3! Untrained! Running,!80N90%!VO2!max,!30!min! Serum!
!
10! F! 23!±!1! Untrained! Running,!80N90%!VO2!max,!30!min! !
Buchman!et!al.!1998![255]! 26! M+F! 18N55! Moderately!trained! Running,!marathon! Serum,!urine!
Cinar!et!al.!2007![276]! 10! M! 18N22! Athletic! Running,!maximal! Serum!
Cinar!et!al.!2009![275]! 10! M! 17N21! Athletic! Not!specified! Serum!
Cordova!&!Navas!1998![212]! 12! M! 25.9!±!2.6! Athletic! Cycling,!maximal! Serum,!sweat!
!
12! M! 22.3!±!1.2! Moderately!trained! Cycling,!maximal! !
DeRuisseau!et!al.!20025![194]! 9! M! 27.7!±!5.0! Moderately!trained! Cycling,!50%!VO2!peak,!4!x!30!min! Sweat!
!
9! F! 24!±!4.3! Moderately!trained! Cycling,!50%!VO2!peak,!4!x!30!min! !
Deuster!et!al.!1991![257]! 38! F! 29.9!±!0.8! Athletic! Running,!marathon! Serum,!RBC!
D’Inca!et!al.!1999![256]! 6! M! 31.3!±!4.9! Untrained! Cycling,!60%!VO2!max,!60!min! Serum!
Döker!et!al.!2014![204]! 10! M! 22!±!2! Untrained! Swimming,!400!m! Serum!
!
11! M! 25!±!4! Moderately!trained! Swimming,!800!m! !
!
14! M! 23!±!4! Athletic! Swimming,!800!m! !
Gleeson!et!al.!1995![203]! 8! M+F! 28!±!8! Untrained! Step!test,!40!mins! Serum!
GonzalezNHaro!et!al.!2011![258]! 27! M! 33.8!±!6.7! Athletic! Cycling,!maximal! Serum!
Granell!2014![259]! 22! M! 20N35! Moderately!trained! Running,!60%!VO2!max,!40!min! Serum,!urine!




Hoshi!et!al.!20025![195]! 10! M! 23.3!±!1.3! Untrained! Cycling,!60!min! Sweat!
Iri!et!al.!2007![277]! 10! M! 23.1!±!2.46! Athletic! Cycling,!maximal! Serum!
!
10! M! 20.8!±!1.16! Athletic! Cycling,!maximal! !
Iri!2011![261]! 24! M! 21.9!±!2.1! Athletic! Cycling,!70%!VO2!max,!30!min! Serum!
Kaczmarski!et!al.!1999![200]! 20! M! 29.2!±!10.8! Untrained! Running,!maximal! Serum!
Karakukcu!et!al.!2013![205]! 32! M! 12.8!±!0.7! Untrained! Boxing!training,!60!min! Serum!
Kaya!20085![262]! 10! M! 20.4!±!0.8! Athletic! Futsal!match! Serum,!urine!
Khaled!et!al.!1997![263]! 9! M! 23.6!±!3.4! Athletic! Cycling,!maximal! Serum!
!
12! M! 25.0!±!3.2! Athletic! Cycling,!maximal! !
Khaled!et!al.!1999![278]! 10! M! 26.0!±!1.3! Untrained! Cycling,!85%!VO2!max,!25!min! Serum!
Koc!et!al.!20105![264]! 30! M! 19.6!±!1.1! Athletic! Wrestling!training,!60!min! Serum!
Kondo!et!al.!1990![279]! 8! M! 44!±!12! Untrained! Cycling,!70%!VO2!max,!20!min! Serum!
Lukaski!et!al.!1984![199]! 5! M! 32.2!±!14.1! Untrained! Cycling,!maximal! Serum!
Marrella!et!al.!1993![265]! 16! M! 30.1!±!3.8! Athletic! Running,!marathon! Serum!
Ohno!et!al.!19835![202]! 5! M! 21N23! Untrained! Cycling,!30!min! RBC!
Ohno!et!al.!1985![266]! 11! M! 20.3!±!1.0! Untrained! Cycling,!75%!VO2!max,!30!min! Serum,!RBC!
Ohno!et!al.!1990![208]! 7! M! 18N19! Untrained! Cycling,!maximal! Serum!
Omokhodion!&!Howard!19945!
[267]!
15! M! 20N35! Untrained! Cycling,!4!x!10!min! Sweat!
Polat!2011![280]! 8! M! 12N14! Untrained! Kickboxing!training,!90N120!min! Serum!
!
8! M! 12N14! Untrained! Kickboxing!training,!90N120!min! !
!
8! M! 12N14! Untrained! Kickboxing!training,!90N120!min! !
Savas!et!al.!20065![281]! 12! M! 21.7!±!0.9! Untrained! Running,!maximal! Serum!
Savas!et!al.!20075![269]! 16! M! 19.4!±!1.6! Untrained! Running,!maximal! Serum!
Savas!20095![268]! 16! M! 22.7!±!1.9! Untrained! Running,!maximal! Serum!
!
16! M! 21.6!±!1.9! Untrained! Swimming,!100!m! !
Simpson!&!HoffmanNGoetz!1991!
[271]!
8! M! 21N30! Untrained! Cycling,!75%!VO2!max,!60!min! Serum!
!




! 8! M! 21N30! Athletic! Cycling,!75%!VO2!max,!60!min! !
Singh!et!al.!1992![283]! 6! M! 30.3!±!4.7! Moderately!trained! Running,!62.5%!VO2!max,!120!min! Serum,!urine!
Singh!et!al.!1994![282]! 5! M! 33!±!3! Moderately!trained! Running,!72.5%!VO2!max,!120!min! Serum,!sweat,!urine!
Tipton!et!al.!19935![272]! 9! M! 27.3!±!3.5! Moderately!trained! Cycling,!50%!VO2!max,!60!min! Sweat!
! 9! F! 28.7!±!3.3! Moderately!trained! Cycling,!50%!VO2!max,!60!min! !
van!Rij!et!al.!1986![273]! 7! M! NP4! Untrained! Running,!10!min! Serum!
! 7! M! NP
4! Moderately!trained! Running,!10!miles! !
Vlcek!et!al.!1989![270]! 13! M! 23!±!6! Moderately!trained! Cycling,!maximal! Serum,!sweat!







The number of participants (n = 727) in the included studies for the systematic 
literature review ranged from n = 5 to 38, with a median of 10 participants. The 
majority of the participants were males (n = 627), with the exceptions of four 
comparisons [194,201,257,272], which were exclusively female (n = 66) and two 
comparisons [203,255], which did not differentiate between sexes (n = 34 in total, n = 
6 females). When grouped according to their training status, the included participants 
were distributed into the categories of untrained (n = 282), moderately trained (n = 
175) or athletic (n = 270). The majority of the included studies utilised running (n = 
16) or cycling (n = 20) as their exercise mode. Participants exercised maximally, to 
exhaustion under laboratory or field test conditions in 16 of the 45 studies [197–
200,206,208,212,258,263,268–270,274,276,277,281]. In the remaining studies, 
which used submaximal testing protocols, participants performed the exercise for 10-
160 min at 50-90% of VO2 max. 
 
Serum zinc concentrations immediately after exercise – meta-analysis  
 
Sufficient data were available for meta-analysis from 34 studies [197–201,203–
206,208,212,253–259,261,263,265,266,270,271,273–280,282,283], providing 46 
comparisons of different population groups (n = 550) to explore the acute effects of 
exercise on serum zinc concentration. A number of studies 
[198,201,204,212,263,271,273,277,280] examined the effects of exercise on two or 
more population group stratified by their training status or sex, allowing for multiple 
comparisons within the meta-analysis.  
 
The overall meta-analysis of all included studies revealed an increase in serum zinc 
concentration immediately after exercise (change from baseline: 0.45 ± 0.12 µmol/L, 
P < 0.001, Figure 3.2; mean ± SE), with a high degree of statistical heterogeneity (I2 
= 82%). Two comparisons from one study [201] were significantly different from other 
comparisons and hence were identified as outliers in the present analysis. When the 
outlying comparisons were omitted from analysis, the increase in serum zinc 
concentration after exercise remained significant (change from baseline: 0.40 ± 0.12 
µmol/L, P = 0.001, Figure 3.3). No other significant impact from an individual or 
group of studies was observed. The funnel plot of SE by difference in means indicated 
some evidence of publication bias for studies with small sample size (Figure 3.4). 
The classic fail-safe N was 427, which represents the number of additional studies 





Figure 3.2 Forest plot from overall meta-analysis determining the difference of serum zinc concentration (μmol/L) between baseline (pre-





Figure 3.3 Forest plot from overall meta-analysis determining the difference of serum zinc concentration (μmol/L) between baseline (pre-





Figure 3.4 Funnel plot of overall meta-analysis on the acute effect of exercise on 
serum zinc concentration immediately following exercise. 
 
 
Secondary analyses were conducted by stratifying the comparisons by exercise 
intensity, mode and training status of study population. Serum zinc concentration was 
higher after exercising maximally (change from baseline: 0.77 ± 0.20 µmol/L, P < 
0.001, Table 3.2, Figure 3.5), however the significant effect was not observed after 
submaximal exercise (change from baseline: 0.27 ± 0.14 µmol/L, P = 0.066).  
 
 
Table 3.2 Secondary analyses of the change in serum zinc concentrations 






! ! !!!Running! 13,!16! 0.71!±!0.26! 0.0061!
!!Cycling! 15,!20! 0.43!±!0.22! 0.051!
!!Other! 6,!10! 0.22!±!0.30! 0.461!
Training!status! ! ! !
!!Untrained!! 16,!19! 0.65!±!0.19! 0.0012!
!!Moderately!trained! 12,!12! 0.35!±!0.26! 0.169!
!!Athletic! 13,!15! 0.25!±!0.25! 0.305!
Intensity! ! ! !
!!Maximal! 13,!17! 0.77!±!0.20! <!0.001!






When comparisons were separated by the mode of exercise, running significantly 
increased serum zinc concentrations (change from baseline: 0.71 ± 0.26 µmol/L, P = 
0.006, Figure 3.6). This effect remained significant when the outlying comparisons 
were omitted (change from baseline: 0.51 ± 0.24 µmol/L, P = 0.035). No significant 
changes in serum zinc concentration were observed after cycling or other exercise 
bouts. When comparisons were separated into training status of the studied 
population, there was a substantial increase in serum zinc concentration immediately 
after exercise for those classified in the untrained category (change from baseline: 
0.65 ± 0.19 µmol/L, P = 0.001, Figure 3.7), but no significant effect in the 
moderately trained or athletic groups. The effect of exercise on the untrained group 
remained significant after the removal of outliers (change from baseline: 0.53 ± 0.18 
µmol/L, P = 0.004). Meta-regression models revealed no significant relationship 
between change in serum zinc concentration and baseline serum zinc concentration, 
mean age of participants or submaximal exercise intensity immediately after exercise 








Figure 3.5 Forest plot of meta-analysis determining the difference of serum zinc concentration (μmol/L) between baseline (pre-exercise) levels 





Figure 3.6 Forest plot of meta-analysis determining the difference of serum zinc concentration (μmol/L) between baseline (pre-exercise) levels 





Figure 3.7 Forest plot of meta-analysis determining the difference of serum zinc concentration (μmol/L) between baseline (pre-exercise) levels 





Figure 3.8 Meta-regression of age on changes in serum zinc concentration (μmol/L) 
immediately after exercise (P = 0.70). Change in serum zinc concentration calculated 




Figure 3.9 Meta-regression of intensity of submaximal exercise on changes in serum 
zinc concentration (μmol/L) immediately after exercise (P = 0.10). Change in serum 
zinc concentration calculated by immediately after values minus pre-exercise values. 
!
!
Other outcomes (urinary, sweat and RBC zinc concentrations) 
 
Meta-analyses were unable to be conducted for the other measures of zinc status 
(urinary, sweat and RBC zinc) due to inability to resolve the different units of 
variables used in the identified studies within the systematic literature review. Three 
studies reported significant increases in urinary zinc excretion after exercise 
[197,259,262], while four other studies reported no significant change  
[198,255,282,283]. RBC zinc concentrations have been reported to decrease 
significantly immediately after exercise [202,257,266]. Two studies reported both 
plasma and RBC zinc [257,266]; no relationships between these two variables were 
reported. While eight studies [194,195,212,254,267,270,282,283] reported sweat zinc 
loss during exercise, no baseline values were measured and hence comparisons 






The current review and meta-analysis, which aimed to quantify changes in zinc 
homeostasis after an aerobic exercise bout, revealed an increase of 0.45 µmol/L in 
serum zinc concentration immediately after exercise. Secondary analyses showed that 
changes in serum zinc are influenced by exercise intensity, the mode of exercise and 
the participants’ training status. Higher increase in serum zinc concentration is 
observed in studies that utilised maximal exercise testing (0.77 µmol/L); conversely, 
submaximal exercise sessions failed to induce significant changes in serum zinc 
concentration. Similarly, while running causes substantial increase in serum zinc 
concentration, cycling and other aerobic exercise did not elicit similar responses, 
possibly due to the differences in the size of muscles that are recruited for the activity 
[284]. Muscular contractions and the demand for energy by exercise present as 
challenges to the multiple homeostatic systems of the body [285]. The present report 
suggests that exercise sessions that employ larger muscle groups at higher intensity 
induce the greatest disturbance to whole body zinc homeostasis.  
 
A number of mechanisms have been suggested to explain the changes in serum zinc 
after exercise, namely the release of zinc ions from ruptured myocytes and changes in 
acid-base balance during exercise. The perturbations in acid-base balance during high 
intensity exercise represent a potential factor that influences whole body zinc 
homeostasis. Active zinc transport mediated by cellular zinc transporters is proposed 
to function by the counter-transport of hydrogen (H+) and bicarbonate (HCO3-) ions 
[250]; therefore the acid-base balance within peripheral tissues and systemic 
circulation is intrinsically linked to zinc homeostasis. Zinc transporter-mediated 
movement of zinc between peripheral tissues and systemic circulation may be 
influenced by the build-up of H+ induced by exercise [286] and changes in the 
proportion of albumin-zinc complex in systemic circulation [287]. Furthermore, it is 
well established that the appearance of muscle specific proteins, such as creatine 
kinase, is the result of disruption in muscle cellular structures induced by exercise. 
The skeletal muscle system represents the majority of body zinc store [24], so the 
leakage of zinc ions from damaged muscles is likely to be a major contributor to the 
increase in serum zinc immediately after exercise. This is supported by the 
substantially larger increase in serum zinc concentration after heavy intensity 
resistance exercise, which causes greater degree of muscle damage compared to 




measure of creatine kinase, in conjunction with zinc measurements, to confirm 
whether the change in plasma zinc is due to muscle damage.  
 
While the overall analysis revealed an increase in serum zinc levels after aerobic 
exercise, there is a lack of consistency in some of the comparisons within the meta-
analysis. For instance, a statistically significant decrease in serum zinc level was 
reported immediately after a 40 min step test in a group of healthy participants [203]. 
In another study, no change in serum zinc level was noted after a marathon run [255]. 
The heterogeneity in results between some individual studies and the overall analysis 
can be attributed to the diverse nature of the exercise sessions and training status of 
the participants, which were explored as part of the secondary analyses of this meta-
analysis.  
 
A number of limitations in study designs have been identified that have implications 
for future research. While serum zinc concentration is the recommended zinc 
biomarker currently, this measure does not reflect zinc status sensitively [59]. The 
accuracy in measuring serum zinc concentration may be further confounded by 
changes in blood volume during high intensity aerobic exercise. Some of the studies 
identified for the current review failed to report serum zinc concentrations adjusted 
for hemoconcentration that occurs with exercise. Future studies should consider 
reporting and/or controlling the hydration status of participants, in addition to the 
use of van Beaumont’s quotient for changes in serum zinc concentrations [289]. In 
addition, differences in baseline body composition may influence zinc status and 
exercise-induced changes in zinc concentrations, which were not addressed in the 
current literature. Furthermore, many studies identified from the present review 
failed to report dietary zinc intake which has been shown to modulate the fluctuation 
of zinc between different compartments following exercise. During zinc depletion, the 
change in plasma zinc concentrations immediately post exercise was smaller than in 
zinc sufficient conditions [199]. The authors proposed that low dietary zinc intake, 
which has been shown to impair exercise capacity [249], contribute to the reduction in 
circulating exchangeable zinc pool that is highlighted by the stress of exercise.  
 
While the immediate effects of aerobic exercise on serum zinc levels were revealed in 
the current meta-analysis, the subsequent changes in serum zinc concentrations 
during recovery from exercise remain unclear. Conflicting results are reported for 
serum zinc changes in the hours following an aerobic exercise bout. For instance, 




significant decline in serum zinc concentration was noted at 1 hour after exercise 
cessation in participants [204]. In contrast, no changes were noted at 2 hours after the 
cessation of a maximal running test, despite significant increase in serum zinc levels 
immediately after exercise [198]. Elucidation of the changes in serum zinc levels 
during exercise recovery will further the understanding of the role of zinc in exercise 
metabolism.  
 
One of the strengths of the analysis is the inclusion of exercise sessions that are 
commonly recommended for the prevention and management of chronic diseases. 
Secondary analysis from the current report shows greater post-exercise increase in 
serum zinc for untrained individuals. Furthermore, significant reductions in resting 
serum zinc and exchangeable zinc pool were also reported after several weeks of 
aerobic training in previously inactive individuals [207,208]. Therefore, the 
prescription of exercise training as a treatment strategy may adversely impact on the 
zinc status of previously inactive patients with chronic diseases, in particular Type 2 
DM, of which suboptimal zinc status already exists as part of the disease pathology 
[290]. In clinical practice, dietary advice to increase total zinc intake may be beneficial 
for at-risk populations.  
 
Previous narrative reviews on the effect of exercise on zinc status generally reported 
conflicting changes in zinc homeostasis following exercise [291,292]. To the best of 
our knowledge, the present paper is the first systematic literature review and meta-
analysis to reveal immediate increase in serum zinc concentration as a result of 
aerobic exercise. Currently, there is limited data on how exercise affects other indices 
of zinc status in humans. Alteration of cellular zinc homeostasis at the cellular level 
has been shown to affect glucose uptake and metabolism in muscle cells [114], with 
potential implications for glycaemic control and management of Type 2 DM. Further 
research is required to ascertain the long-term effects of exercise on zinc metabolism 
and potential consequences for dietary zinc requirements, in particular for those who 
































Exercise and the subsequent recovery processes have been proposed to induce 
disturbances in zinc homeostasis. In Chapter 3, an acute increase in serum zinc 
concentration was observed immediately after aerobic exercise; the change in the 
indices of zinc status during exercise recovery was not explored. The aim of the 
current analysis is to determine the changes in zinc biomarkers during recovery from 
an aerobic exercise bout. We conducted a systematic literature search on PubMed, 
Web of Science, Scopus and SPORTDiscus electronic databases from inception to 20th 
of December 2014 to identify studies that investigated the acute effects of exercise on 
selected indices of zinc status. Meta-analyses were conducted to determine the change 
in serum zinc concentration during exercise recovery, defined as up to 4 hours 
following exercise cessation, compared to pre-exercise levels. Forty-five studies were 
included in the systematic literature review, of which 12 studies (providing 18 
comparisons) reported serum zinc levels after the cessation of exercise. During 
exercise recovery, serum zinc concentration was significantly lower than pre-exercise 
values (change from baseline: -1.31 ± 0.22 µmol/L, P < 0.001; mean ± SE). Secondary 
analyses showed significant decrease of serum zinc levels in all categories of 
participants’ training status, mode of exercise and time of blood collection. 
Insufficient data were available for meta-analysis of other zinc biomarkers. The 
present analysis showed that serum zinc levels decrease significantly during exercise 
recovery, compared to pre-exercise levels. This extends our previous report of an 
increase in serum zinc immediately after exercise. We postulate that the exercise-
induced fluctuations in zinc homeostasis is linked to the muscle repair mechanisms 
following exercise; the potential for zinc to enhance the exercise recovery process 







Zinc is an essential mineral that is found ubiquitously in the human body; a large 
portion of zinc resides in the skeletal muscle system, where it provides structural 
integrity and contributes to the enzymatic activities of metalloenzymes, such as LDH 
and CA [36]. Recent investigations have confirmed that zinc and its transporters can 
influence the transduction of intracellular signalling pathways, with downstream 
effects on cellular functions [26,76]. In particular, the role of zinc in regulating the 
activity of immune cells [180] and the insulin signalling pathway [293] are well 
documented. In an in vitro study of muscle cells, silencing of zinc transporter gene, 
ZIP7, led to impairments in glucose uptake and glycogen synthesis [114]. The 
interaction between zinc and cellular functions, such as energy metabolism and 
immune function, warrants further investigation, especially in the context of exercise.  
 
The benefits of exercise in the prevention and treatment of obesity and related 
diseases are well established [9,294]. Recent research has confirmed that 
modifications in the dietary intake of carbohydrate and protein can affect exercise-
induced adaptations of skeletal muscles, for example mitochondrial biogenesis and 
protein synthesis [248,295]. However, the availability of micronutrients, such as zinc, 
on the adaptations induced by exercise is not fully understood. For both the active 
muscles and other related physiological systems, a multitude of events occur during 
exercising and subsequent recovery, which may have an effect on the regulation of 
zinc homeostasis. For instance, high intensity exercise can induce significant 
metabolic fatigue and mechanical disruptions to the cellular structures of muscles and 
connective tissues [296]. While metabolic fatigue is typically ameliorated during the 
first hour after exercise cessation, structural repair to damaged myofibres requires a 
coordinated inflammatory response, which spans several days after exercise. The 
influence of zinc status on supporting the cellular repair events that occur during 
exercise recovery is largely unknown.  
 
Given that the musculoskeletal system contributes the highest percentage of total 
body zinc, exercise and the subsequent recovery processes have been proposed to 
induce disturbance in zinc homeostasis [291]. A significant increase in serum zinc 
concentration was reported immediately after aerobic exercise in Chapter 3, 
suggesting acute perturbations in zinc metabolism [297]. The exercise-induced 
response of serum zinc level was influenced by the characteristics of the exercise bout 




hours following cessation of aerobic exercise was not explored. Therefore, the aim of 
the current analysis is to determine the effects on zinc biomarkers during the acute 
phase of recovery from an aerobic exercise bout (defined as up to 4 hours following 
exercise cessation); specifically, meta-analysis will be conducted to quantify the 







The search strategy and inclusion criteria are similar to those reported in Chapter 3. 
In brief, a literature search was conducted on PubMed, Web of Science, Scopus and 
SPORTDiscus electronic databases from inception to 20th of December 2014. Search 
phrases used were “zinc”, “exercise”, “physical activity” and other related terms. The 
PRISMA flowchart [214] describing the search process and identification of studies for 
the present meta-analysis is shown in Figure 4.1. Two investigators independently 
reviewed each citation and full report to determine whether the study was to be 
included. Inclusion criteria and methods of the analysis were specified in advance and 










Data extraction and quality assessment of included studies 
 
Two independent investigators extracted data from included studies and any 
differences were resolved by discussion. The data extraction sheet included 
descriptions of the study, such as authors, year of publication, study population and 
training status (untrained, moderately trained or athletic) of the study population 
according to the authors’ descriptions. The data extraction sheet also included the 
duration, intensity and mode of aerobic exercise.  Primary outcomes extracted were 
measures of zinc status (plasma or serum, urinary, sweat and RBC zinc 
concentrations) at baseline and during exercise recovery, the latter was defined as 
within 4 hours from the end of the exercise bout to correspond with the initial 
inflammatory response to exercise [296]. In this report, the term ‘serum’ will be used 
to refer to both serum and plasma concentrations, which are grouped together to 
represent systemic zinc concentration. Where numerical measurements were not 
available in the included reports, estimations from figures were used. P-values for the 
paired t-test comparing serum zinc concentration during exercise recovery with pre-
exercise values were recorded. In studies where the results of multiple exercise bouts 
were reported e.g. longitudinal or interventional studies, results from the initial or 
baseline exercise bout were included.  A Quality Criteria Checklist for Primary 
Research was used to determine the quality of included studies [252]. One of three 
quality rating categories (positive, neutral or negative) was assigned to each individual 
study, depending on how the study addressed validity issues related to the risks of 
biases, generalisability of results and data collection, and analysis. A neutral rating, 
where the majority of the included studies were rated, indicates that the study 
addressed some issues regarding its validity.  
 
Statistical analysis  
 
Meta-analysis of the change in serum zinc concentration during exercise recovery was 
carried out using the Comprehensive Meta-Analysis package, version 2 (Biostat, 
Englewood, NJ, USA; www.meta-analysis.com). Where serial data were available 
during exercise recovery, the final time point was used for the meta-analysis. The 
primary outcome measure was analysed by the mean differences of serum zinc 
concentrations during exercise recovery and baseline (pre-exercise) values, and the p-
value from corresponding paired t-tests. Where P-values of the paired t-test were 
given within a range, the median was taken, i.e. for the range of 0.01 < P < 0.05, P = 




potential bias, e.g. publication bias. Secondary analysis was completed with data 
categorised by the study population’s training status (“untrained”, “moderately 
trained” or “athletic”), mode of exercise (“running”, “cycling” or “other”) and time at 
which blood sample was collected after exercise cessation (“1-30 min”, “31-60 min” 
and “> 60 min”). Times of blood collection were differentiated into three groups to 
reflect the number of comparisons available. Due to large variations in study design of 
the included studies, random-effects models were used. Sensitivity analyses were 
conducted to identify any significant impact of individual or groups of comparisons 
within the included studies. Mixed effects meta-regression models using method of 
moments was performed to examine the effect of baseline serum zinc concentration 








Details on the study selection process are shown in Figure 4.1. A total of 45 studies 
were included in the systematic review, of which 13 studies provided zinc biomarker 
data during exercise recovery (Table 4.1). Eight of the included studies reported on 
the effect of a single acute exercise bout [197,198,201,202,206,253,258,266]. Two 
studies [271,273] examined the effects of different aerobic exercise bouts on zinc 
status, while the remaining three studies [204,278,283] reported relevant data at 
baseline of interventional trials. Five studies used running as their exercise exposure 
[197,198,201,273,283], six studies utilised cycling [202,206,258,266,271,278], while 
two other studies employed other aerobic exercise [204,253], such as swimming. All 
included studies reported serum zinc as a measure of zinc status, with the exception of 
one study which reported RBC zinc content only [202]. Urinary zinc [197,198,283] 
and RBC zinc [202,266] were measured in some included studies. In the identified 
studies for meta-analysis of serum zinc data, the included participants (n = 184) 
ranged from n = 5 to 27. All sampled populations were males with the exception of one 
comparison in females (n = 10) [201]. Using the authors’ description of the study 
population, the included participants were categorised into one of three groups; 
untrained (n = 82), moderately trained (n = 42) or athletic (n = 60). In the quality 
assessment of included studies, all studies were rated as neutral with the exception of 
one study [206] scoring a positive rating. 
 
Serum zinc concentrations in exercise recovery – meta-analysis 
 
Twelve studies [197,198,201,204,206,253,258,266,271,273,278,283] (providing 18 
comparisons) reported serum zinc data during exercise recovery, with measurements 
taken between 7 to 130 min after the end of the exercise bout (Table 4.2). Most 
studies reported serum zinc concentrations at 60 and 120 min after exercise cessation. 
Overall meta-analysis showed a significant decrease in serum zinc concentrations 
(change from baseline: -1.31 ± 0.22 µmol/L, P < 0.001, Figure 4.2) during exercise 
recovery when compared to pre-exercise values; significant level of heterogeneity was 
observed (I2 = 57%). The risk of publication bias was low as indicated by a 
symmetrical funnel plot (Figure 4.3). The classic fail-safe N was computed to be 361, 
indicating the number of additional missing studies required to nullify the statistical 
significance observed.  Sensitivity analysis revealed that the overall result was not 




Table 4.1 Characteristics of included studies for systematic review. 
Study&(authors,&year)& ! n! Sex&(M/F)& Age&(y)
1& Training&status2& Exercise&session3& Source&of&zinc&biomarker&&(serum,&RBC,&urine,&sweat)&
Anderson&et!al.&[197]& & 9& M& 23K46& Moderately&trained& Running,&maximal& Serum,&urine&
Anderson&et!al.&[198]& & 8& M& 40.4&±&4.3& Moderately&trained& Running,&maximal& Serum,&urine&
&
& 5& M& 33&±&2.1& Untrained& Running,&maximal& &
Arslan&[253]& & 11& M& 20.2&±&1.23& Athletic& Conditioning&and&technical&exercise,&90&min& Serum&
Bordin&et!al.&[201]& & 9& M& 23&±&3& Untrained& Running,&80K90%&VO2&max,&30&min& Serum&
&
& 10& F& 23&±&1& Untrained& Running,&80K90%&VO2&max,&30&min& &
Doker&et!al.&[204]& & 10& M& 22&±&2& Untrained& Swimming,&400&m& Serum&
&
& 11& M& 25&±&4& Moderately&trained& Swimming,&800&m& &
&
& 14& M& 23&±&4& Athletic& Swimming,&800&m& &
GonzalezKHaro&et!al.&[258]& & 27& M& 33.8&±&6.7& Athletic& Cycling,&maximal& Serum&
Khaled&et!al.&[278]& & 10& M& 26.0&±&1.3& Untrained& Cycling,&85%&VO2&max,&25&min& Serum&
Ohno&et!al.4&[202]& & 5& M& 21K23& Untrained& Cycling,&30&min& RBC&
Ohno&et!al.&[266]& & 11& M& 20.3&±&1.0& Untrained& Cycling,&75%&VO2&max,&30&min& Serum,&RBC&
Simpson&&&HoffmanKGoetz&[271]& & 8& M& 21K30& Untrained& Cycling,&75%&VO2&max,&60&min& Serum&
&
& 8& M& 21K30& Moderately&trained& Cycling,&75%&VO2&max,&60&min& &
&
& 8& M& 21K30& Athletic& Cycling,&75%&VO2&max,&60&min& &
Singh&et!al.&[283]& & 6& M& 30.3&±&4.7& Moderately&trained& Running,&62.5%&VO2&max,&120&min& Serum,&urine&
van&Rij&et!al.&[273]& & 7& M& NP5& Untrained& Running,&10&min& Serum&











exercise&cessation&(min)&n! Baseline& Immediately&after&exercise& Exercise&recovery&
Anderson&et!al.&[197]& 9& 12.39&±&1.84&& 13&±&1.84& 11.47&±&1.84&& 120&
Anderson&et!al.&[198]& 8& 13.5&±&1.41&& 14.5&±&3.96& 12.5&±&1.41&& 120&
& 5& 13.5&±&1.79& 15.1&±&1.34& 12.9&±&0.45& 120&
Arslan&[253]& 11& 8.23&±&4.11& 8.69&±&4.13& 6.97&±&2.7& 60&
Bordin&et!al.&[201]& 9& 14.22&±&4.74& 26.15&±&8.57&& 9.94&±&2.29& 30&
& 10& 12.24&±&6.58& 22.03&±&6.27&& 9.94&±&5.2& 30&
Doker&et!al.&[204]& 10& 11.07&±&1.32& 12.82&±&1.68&& 10.05&±&0.87& 60&
& 11& 10.71&±&1.32& 11.95&±&2.26& 9.39&±&0.8& 60&
& 14& 11.21&±&1.53& 11.95&±&1.32&& 10.20&±&0.95& 60&
GonzalezKHaro&et!al.&[258]& 27& 11.17&±&1.53& 12.54&±&1.22&& 12.39&±&1.68& 7&
Khaled&et!al.&[278]& 10& 11.32&±&1.89& 11.47&±&1.4& 10.55&±&1.4&& 10&
Ohno&et!al.&[266]& 11& 12.80&±&1.52& 15.43&±&2.03&& 13.26&±&1.17&& 30&
Simpson&&&HoffmanKGoetz&[271]& 8& 14&±&1.41& 13.5&±&2.26& 11.7&±&1.98& 120&
& 8& 13.8&±&2.83& 13&±&1.98& 11.7&±&1.7&& 120&
& 8& 14&±&2.26& 14.5&±&2.26& 11.5&±&2.55&& 120&
Singh&et!al.&[283]& 6& 14.2&±&1.47&& 14.2&±&1.71&& 13.8&±&2.20& 60&
van&Rij&et!al.&[273]& 7& 16.52&±&2.43&& 19.2&±&2.83& 14.61&±&5.18&& 60&






Figure 4.2 Change in serum zinc concentration (μmol/L) during exercise recovery, compared to baseline values, as determined by meta-
analysis of trials investigating the acute effects of an aerobic exercise bout. Letters within the reference name indicate the different comparisons 







Figure 4.3 Funnel plot of overall meta-analysis on the effect of exercise on serum 
zinc concentration during exercise recovery.!
 
In secondary analyses, comparisons were stratified into groups determined by time of 
sample collection after exercise cessation (1-30 min, 31-60 min and > 60 min), 
training status of participants (untrained, moderately trained and athletic) and mode 
of exercise (running, cycling and other) (Table 4.3). When comparisons were 
stratified by time of collection after exercise cessation (Figure 4.4), subgroup 
analyses showed lower serum zinc concentrations at 1-30 min (change from baseline: 
-1.17 ± 0.75 µmol/L, P = 0.049, Figure 4.5), 31-60 min (change from baseline: -1.15 
± 0.37 µmol/L, P = 0.002) and > 60 min (change from baseline: -1.51 ± 0.35 µmol/L, 
P < 0.005). Serum zinc concentrations significantly decreased during exercise 
recovery in the untrained (change from baseline: -1.39 ± 0.75 µmol/L, P < 0.005, 
Figure 4.6), moderately trained (change from baseline: -1.17 ± 0.42 µmol/L, P = 
0.006) and athletic groups (change from baseline: -1.36 ± 0.57 µmol/L, P = 0.016). 
When comparisons were separated by the mode of exercise (Figure 4.7), serum zinc 
levels were lower in recovery from running (change from baseline: -1.45 ± 0.40 
µmol/L, P < 0.005), cycling (change from baseline: -1.31 ± 0.21 µmol/L, P = 0.001) 
and other types of aerobic exercise (change from baseline: -1.12 ± 0.47 µmol/L, P = 
0.018). Higher baseline serum zinc concentration was related to greater decrease in 
serum zinc levels during exercise recovery (Figure 4.8), however this did not reach 






Table 4.3 Secondary analyses of the changes in serum zinc concentration during 
exercise recovery when grouped by time of blood collection after exercise cessation, 





(min)! ! ! !
!!1;30! 4,!5! ;1.17!±!0.59! 0.049!
!!31;60! 4,!6! ;1.15!±!0.37! 0.002!
!!>!60! 4,!7! ;1.51!±!0.35! <!0.001!
Training!status!! ! ! !
!!Untrained! 8,!9! ;1.39!±!0.34! <!0.001!
!!Moderately!trained! 5,!5! ;1.17!±!0.42! 0.006!
!!Athletic! 4,!4! ;1.36!±!0.57! 0.016!
Exercise!mode! ! ! !
!!Running! 5,!7! ;1.45!±!0.40! <!0.001!
!!Cycling! 5,!7! ;1.31!±!0.38! 0.001!





Figure 4.4 Change in serum zinc concentration (μmol/L) during exercise recovery 
from baseline values, stratified by time of blood collection after exercise cessation. 






Figure 4.5 Change in serum zinc concentration (μmol/L) during exercise recovery, compared to the baseline values, stratified by time of blood 





















Figure 4.8 Meta-regression model showing the effect of baseline serum zinc 
concentration (μmol/L) on changes in serum zinc concentration during exercise 
recovery, compared to baseline (P = 0.059). Difference in means is calculated as 
serum zinc concentrations during exercise recovery minus pre-exercise values.  
!
!
Other outcomes (urinary, sweat and RBC zinc concentrations) 
 
Meta-analyses of other zinc outcomes were deemed inappropriate due to lack of 
conformity in the units of measurement. Two studies reported RBC zinc 
concentrations prior to exercise, immediately after exercise and 30 min after exercise 
cessation [202,266]. Both studies reported significant decrease in RBC zinc 
immediately after exercise, which returned to baseline levels 30 min post-exercise. 
Urinary zinc concentration at 2 h after running was elevated compared to pre-exercise 
levels [197], while another study observed no change [198]. When 24 h urinary zinc 
excretion was measured on the day of exercise compared to non-exercise day, one 
study found significantly higher zinc excretion on the day of exercise [197] while 







The current analysis revealed a significant mean decrease of 1.31 µmol/L in serum 
zinc concentration during aerobic exercise recovery, as compared to baseline; this 
represents an approximate mean decrease of 11% relative to the serum zinc 
concentration reference range [41]. The significant reduction in serum zinc levels 
during exercise recovery was not modulated by differences in the nature of the 
exercise session, time of blood collection or participants’ training status. Taken 
together with results from Chapter 3 that indicated an increase in serum zinc level 
immediately after aerobic exercise, the present analysis confirms the presence of 
significant acute fluctuations in serum zinc level as a result of exercise (Figure 4.9). 
 
 
Figure 4.9 Change in serum zinc concentration (μmol/L) from baseline values as 
determined by meta-analyses of trials investigating the acute effects of an aerobic 
exercise bout. Values given as mean ± SE * P < 0.05 compared to pre-exercise values. 
 
 
We postulate that the impact of aerobic exercise on serum zinc concentration 
represents the culmination of cellular events that occur during exercise and recovery. 
Immediately after aerobic exercise, increase in systemic zinc levels may be attributed 
to the release of zinc ions from damaged muscle cells and alteration in acid-base 
homeostasis, as described previously in Chapter 3. After the cessation of exercise, a 
cascade of events occur; most notable of which is the onset of inflammatory processes, 




muscles [251,296]. We hypothesise that the observed decline in serum zinc 
concentration in the hours after the cessation of exercise is a consequence of 
inflammation and related processes, initiated by exercise-induced muscle damage. 
The effects of exercise-induced inflammatory processes may extend to other organs, 
such as the liver. Inflammatory cytokines have been shown to induce significant 
changes in the expression of zinc transporters and MT, both of which represent the 
primary regulators of cellular zinc homeostasis [60]. The accumulation of 
inflammatory cytokines in the acute phase response, in addition to changes in oncotic 
pressure following aerobic exercise, have been attributed to the shift of zinc from 
plasma into interstitial fluid and the liver in a two-compartment model of zinc kinetics 
during exercise recovery [206]. The authors suggest that acute stress of exercise along 
with the concomitant appearance of inflammatory cytokines and myokines, such as 
IL-1 and IL-6, contribute to the zinc sequestration in the liver, thereby leading to a 
reduction in circulating zinc during exercise recovery [206].  
 
There is evidence that zinc redistribution occurs also within the blood compartment. 
In a study where participants cycled for 30 min at 75% VO2max, significant increase in 
plasma zinc was observed immediately after exercise, which returned to baseline after 
30 min of rest. The authors reported concomitant reductions in RBC zinc and CA-1 
concentrations immediately following exercise, which increased to baseline level at 30 
min after exercise cessation [266]. The finding of fluctuations in RBC zinc content 
after aerobic exercise was supported by the authors’ previous report of a similar 
exercise intervention [202]. CA, a zinc metalloenzyme, provides catalytic activity for 
the interconversion of carbon dioxide and bicarbonate. The activity of CA is crucial for 
gas transport and acid-base balance [298], both of which are additionally stressed 
during strenuous exercise. Taken together, these observations although preliminary, 
suggest an efflux of zinc from RBC immediately following aerobic exercise, which 
returns to baseline levels during exercise recovery. Further research is required to 
quantify the effect of zinc redistribution to changes in serum zinc concentration.  
 
In the present meta-analysis, results from the majority of the individual studies were 
in accordance with the overall outcome, which indicates a significant reduction in 
serum zinc levels during exercise recovery. Nevertheless, a significant level of 
statistical heterogeneity was observed with the overall meta-analysis. Secondary 
analyses attempted in this review offered little in differentiating the serum zinc 
decline by the characteristics of included studies. For instance, when comparisons 




discriminations among the subgroups were observed in the magnitude or direction of 
serum zinc response during exercise recovery. The findings of the current secondary 
analyses are consistent with a decline in serum zinc concentration following aerobic 
exercise that is similar across different exercise modes, training status of participants 
and time of blood collection.  
 
The universal decline in serum zinc concentration during exercise recovery is in 
contrast with results presented in Chapter 3, where changes in serum zinc levels were 
dependent on characteristics of exercise and study populations. Specifically a greater 
increase in serum zinc levels were observed immediately after exercise, compared to 
baseline, in individuals who were untrained or following exercise sessions that 
involved running or maximal exertion. The collective findings suggest that while the 
characteristics of aerobic exercise and study participants contributes to differences in 
serum zinc response immediately after exercise, the decline in serum zinc levels and 
associated homeostatic mechanisms are consistent during exercise recovery. However, 
the present analysis in exercise recovery is limited by the small number of available 
comparisons, which may have reduced the statistical power of the secondary analyses. 
In addition, the implications of changes in serum zinc on total body zinc and related 
functional outcomes remain unclear.  
 
Secondary analysis using meta-regression model revealed a trend for relationship 
between pre-exercise serum zinc concentration and changes in serum zinc during 
exercise recovery. Higher baseline serum zinc concentration was correlated with a 
greater decrease in serum zinc during recovery from aerobic exercise. Although the 
relationship did not reach statistical significance, this preliminary finding suggests 
that zinc status can affect the direction and magnitude of change in post-exercise zinc 
concentrations; this is consistent with a study where differences in zinc balance, 
manipulated by zinc depletion or supplementation, were related to changes in plasma 
zinc following exercise [199]. Taken together, the findings suggest that exercise-
induced mobilisation of zinc is dependent on whole body zinc status. Additional 
studies are required to confirm the proposed relationship between intrinsic zinc status 
and changes in zinc biomarker as a result of exercise.  
 
The interpretation of the present results should be considered in light of the 
limitations within the included studies. The changes in blood volume during and after 
strenuous exercise can confound measurements of zinc concentration within serum. 




during exercise recovery. Adjustments for hemoconcentration or hemodilution [289] 
should be considered in future reporting of serum zinc within acute exercise 
intervention studies. In one instance where adjustments for blood volume were made, 
whilst the general trend of serum zinc responses were similar following exercise [271], 
the statistically significant decrease observed previously with uncorrected serum zinc 
concentration was no longer significant after adjustments for plasma volume. The 
limitations of serum zinc as a sensitive indicator of zinc status in humans are well 
documented [59], in spite of the prominent use of serum zinc as a biomarker in the 
current literature. The included studies could be improved by the addition of dietary 
zinc intake as another baseline measure of participants’ zinc status. Furthermore, 
manipulation in the levels of dietary zinc intake has been associated with different 
responses of serum zinc levels immediately after exercise [199], and hence may be 
relevant also in the exercise recovery period.  
 
The current meta-analysis is limited by the unequal representation of both sexes in 
the available comparisons. Within the overall meta-analysis, only one comparison 
[201] provided data on serum zinc levels during exercise recovery in female 
participants; coincidentally, this comparison also presents the largest variability in the 
estimate of mean difference. While we are unable to explore the sex differences in 
serum zinc response to exercise in the current meta-analysis, it is well established that 
notable differences between sexes are observed in energy metabolism [299] and 
immune response [300] in the context of exercise. Females generally have lower 
serum zinc levels compared to males [301], which is driven by the different 
distribution of sex hormones as exemplified by the interaction between the use of oral 
contraceptive agents and serum zinc concentrations [302]. Given the sex distribution 
of the included participants, the results of the current report may be generalisable to 
males only. Additional studies are required to further the understanding of sex 
differences in serum zinc responses during aerobic exercise recovery. 
 
Recent research has shed light on the interaction of exercise and zinc transporters in 
both genomic analysis in humans and mechanistic in vitro studies. One of the most 
studied zinc transporter genes is zinc transporter-8 (ZnT8; SLC30A8), due to the SNP 
within the ZnT8 gene that has been associated with the risk of developing Type 2 DM 
[155]. In two cohorts of participants engaging in exercise interventions, the risk allele 
of the ZnT8 SNP was associated with skeletal muscle size and strength [166]. After a 
short bout of resistance exercise, significantly higher levels of muscle soreness, 




possessed the risk allele. The authors suggested that the ZnT8 gene may play a role in 
the downstream communication pathway of myokines secreted from skeletal muscles 
during exercise. In a similar vein, the significance of another zinc transporter, ZIP7, 
has been highlighted in a recent in vitro study, where the absence of this gene resulted 
in deficiencies in glucose and glycogen metabolism in muscle cells [114]. The 
integration of exercise physiology with molecular analysis of zinc transport will 
provide valuable information in understanding the determinants of zinc metabolism 
in the context of exercise.  
 
The present report extends our previous observation regarding the immediate effects 
of aerobic exercise on zinc homeostasis in Chapter 3. The overall analysis in this meta-
analysis confirmed that, compared to pre-exercise levels, serum zinc levels decreased 
significantly during exercise recovery, after an immediate increase in serum zinc 
following exercise. The response in serum zinc during aerobic exercise recovery was 
not influenced by the participants’ training status, mode of exercise and time of blood 
collection after exercise cessation. The practical implications of the acute effects of 
exercise on zinc status are currently unclear. Further studies of zinc metabolism 
during and after exercise are required to elucidate the interaction between serum zinc 
response and characteristics of specific aerobic exercise and participants; the 
inclusion of molecular analysis of zinc transporters and MT can enhance the 






































The usefulness of zinc transporter and MT gene expressions to detect changes in zinc 
intake remains unclear. This pilot study aimed to determine the effects of zinc 
supplementation on zinc transporter and MT gene expressions in humans. Healthy 
adults (n = 39) were randomised to zinc treatment (ZT), receiving 22 mg Zn/d (n = 
19), or no treatment (NT) (n = 20). Blood samples were collected on Days 0, 2, 7, 14 
and 21. Plasma zinc and serum CRP concentrations were analysed. Gene expression of 
zinc transporters and MT in PBMC were analysed using real-time polymerase chain 
reaction (PCR). Using repeated measures analysis of variance (ANOVA), MT-2A gene 
expression and fold change were higher in the ZT group (P = 0.025; P = 0.016, 
respectively) compared to the NT group, specifically at Day 2 (40 ± 18% increase from 
baseline, P = 0.011), despite no significant increase in plasma zinc concentration. In a 
multiple regression model exploring the changes in gene expressions between Days 0 
and 21, the change in MT-2A gene expression was correlated with changes in all zinc 
transporter expressions (r2 = 0.54, P = 0.029); the change in ZIP1 expression emerged 
as a univariate predictor (P = 0.003). Dietary zinc intake was predictive of zinc 
transporter and MT expressions (P = 0.030). Physical activity level was positively 
correlated with baseline ZIP7 expression (r = 0.36, P = 0.029). The present study 
shows that MT-2A expression is related to changing expression of zinc transporter 
genes, specifically ZIP1, in response to zinc supplementation. The current report adds 






Marginal zinc deficiency has been suggested to influence multiple physiological 
systems due to the extensive involvement of zinc in numerous structural and 
biochemical functions of the body [26]; a significant proportion of the world’s 
population may be at risk of marginal zinc deficiency [36], a condition that contributes 
substantially to disease burden worldwide [14]. Despite being redox-inert, zinc can act 
as a pro-antioxidant and modulate oxidative stress by maintaining cell membrane 
integrity and regulating the functions of MT, SOD, and glutathione [79,303]. Since the 
discovery of zinc deficiency in humans [304], our knowledge of the physiological roles 
of zinc has extended beyond the initially proposed functions. Recent evidence suggests 
that zinc ions participate in cellular signalling pathways as second messengers; for 
example, propagating signals in the insulin and nitric oxide signalling pathways 
within the cell [26]. The involvement of zinc in cellular signalling can be categorised 
into early or late zinc signalling, with the latter primarily dependent on transcriptional 
changes in zinc transporter expressions [76].  
 
Recent advancements in molecular techniques have enabled the use of novel 
approaches in the study of zinc metabolism and homeostasis, especially within the 
cell. The cytoplasmic zinc concentration is regulated largely by two families of zinc 
transporters; the ZnT and ZIP families [56].  Members from the ZIP family of 
transporters are responsible for increasing cytoplasmic zinc concentration by 
transporting zinc from intracellular organelles or the extracellular space, while ZnT 
proteins function to decrease cytoplasmic zinc by promoting cellular zinc efflux or 
sequestering zinc in subcellular compartments. Another key group of proteins 
involved in the regulation of cellular zinc homeostasis is MT. Within the cell, MT 
serves as a chaperone of zinc ions, mediating the movement and availability of zinc to 
other zinc binding proteins. The chemical structure of MT, which contains seven zinc-
binding sites with a range of affinities to zinc, complements the function of MT in 
buffering and shuttling zinc within the cytoplasm [75].  
 
A number of studies have explored the effect of zinc supplementation or depletion on 
the regulation of selected zinc transporters and MT in humans. The results 
predominately are consistent in showing changes at the gene expression level within 
blood cells in response to zinc depletion or supplementation; for instance, MT and 
ZnT1 expressions decreased significantly with a virtually zinc-free diet (0.3 mg/d) 




available that explores simultaneous changes in multiple zinc transporter and MT 
expressions during zinc supplementation in humans. The lack of a defined metabolic 
zinc store, in addition to the ubiquitous nature of zinc, complicates the assessment of 
zinc status in humans [305]. Multiple factors, such as oxidative stress, serum glucose 
concentration and inflammatory cytokines, have been associated with the regulation 
of zinc transporters and MT in different cell types [56,60,94], which may confound the 
delineation of the relationship between zinc status and the expression of zinc 
transporter and MT genes. The feasibility and usefulness of a range of zinc transporter 
and MT gene expressions to detect modest changes in dietary and/or supplemental 
zinc intake remain unclear.  
 
The aim of the present study is to determine the effects of zinc supplementation on the 
gene expression of zinc transporters and MT. Furthermore, this study aims to explore 
the relationships among lifestyle characteristics, such as habitual physical activity 
levels, and expression of zinc transporter and MT genes to further understand cellular 







Study design  
 
Healthy adults, aged between 18 and 65 years, were recruited to participate in the 
present study via advertising around the University of Sydney campus. Exclusion 
criteria were: diagnosis of chronic illness; use of prescription drugs (excluding oral 
contraceptive agents); use of micronutrient supplementation in the preceding six 
weeks; and women who were pregnant or breastfeeding. A screening questionnaire 
was used to determine eligibility and collect anthropometric and lifestyle data, such as 
height, weight, change in weight over the preceding 3 months, alcohol consumption 
and smoking habits. Physical activity levels of the participants were assessed using the 
self-administered International Physical Activity Questionnaire (IPAQ) short form 
[306] prior to study participation. Information gathered from the IPAQ was analysed 
according to the Guidelines for Data Processing and Analysis of the IPAQ [307].  
 
Enrolled participants (n = 39; 18 females, 21 males) were randomised to zinc 
treatment (ZT group, n = 19) or no treatment (NT group, n = 20) by a computer-
generated random-number sequence. The ZT group received an oral dose of 22 mg/d 
elemental zinc chelated with amino acid (Nature’s Own, Sanofi-Aventis Healthcare Pty 
Ltd, Australia) for 21 days. The supplemental dose of 22 mg/d elemental zinc was 
chosen to provide a substantial increase in total zinc intake whilst minimising the risk 
of exceeding the upper daily limit [27]. Participants were advised to report any 
adverse effects that they experienced during the trial. During the final week of the 
study, height (to the nearest 0.1 cm) was measured with a stadiometer and body 
weight (to the nearest 100 g) was measured on an electronic calibrated scale.  A survey 
was conducted at Day 21 to confirm that no nutritional supplements (other than the 
provided supplements) were consumed during the study period. Apparent compliance 
with the intervention was verified by counting of returned tablets at the end of the 
study. Participants were advised to maintain usual diet for the duration of the trial. All 
eligible participants provided their written informed consent to participate in the 
study. The Human Research Ethics Committee of the University of Sydney approved 









Blood collection  
 
Venous blood samples were collected from participants on Days 0 (baseline), 2, 7, 14 
and 21. At each time point, blood was collected between 0700 and 0900 after an 
overnight fast of at least 10 h. Cell Preparation Tubes (CPT) with sodium citrate 
(Becton Dickinson, Franklin Lakes, NJ) were used for the isolation of PBMC. Serum 
gel tubes (Becton Dickinson) were used for CRP analysis. EDTA tubes (Becton 
Dickinson) were used for analysis of plasma zinc. Within two hours of blood 
collection, plasma and serum were separated from whole blood after centrifugation at 





Plasma zinc concentrations were determined by flame AAS (SpectrAA220, Varian, 
Palo Alto, CA) in a single-batch run. Samples were diluted (1:4) with Milli-Q water and 
measured against a matrix-matched standard curve in triplicates, over five seconds of 
absorbance integration. Appropriate quality control samples were prepared and 
analysed throughout the run. 
 
Serum CRP concentrations were analysed using an immunoturbidimetric assay kit 
(Cardiac CRP (Latex) High Sensitive Kit, Roche Diagnostics, Basel, Switzerland), 
adapted for the Cobas C311 auto-analyser (Roche Diagnostics). Quality control serum 
(Precinorm Protein, Roche Diagnostics) were analysed throughout a single-batch run.  
 
Total RNA extraction and cDNA synthesis 
 
PBMC were isolated from CPT after centrifugation at room temperature for 30 min at 
1500 x g within 2 h of blood collection. Extracted cells were washed twice with 
Dulbecco’s phosphate buffered saline (PBS) (Sigma Aldrich, St. Louis, MO). Total 
RNA was prepared using the PARIS kit (Ambion, Life Technologies, Carlsbad, CA), 
according to the manufacturer’s instructions. The purity and yield of isolated RNA 
samples were checked using UV nanospectrophotometry, with all samples generating 
A260:A280 and A260:A230 ratios within the range of 1.7-2.1. The integrity of 
ribosomal RNA was checked by denaturing agarose gel electrophoresis (1% agarose 




using the SuperScript VILO cDNA synthesis kit (Invitrogen, Life Technologies, 
Carlsbad, CA), according to the manufacturer’s instructions. cDNA samples were 
stored at -80°C until real-time PCR analysis.  
 
Quantitative real-time PCR  
 
Relative quantification of zinc transporter and MT mRNA was conducted using 
Taqman real-time PCR (StepOnePlus Real-Time PCR System, Applied Biosystems, 
Life Technologies, Carlsbad, CA), as per the manufacturer’s instructions. Inventoried 
Taqman gene expression assays were obtained for ZnT1, ZnT5, ZnT6, ZnT7, ZIP1, 
ZIP3, ZIP7, ZIP8, ZIP10, ZIP14, MT-1A, MT-2A and 18S. The efficiency in 
amplification of the primers was determined using the standard curve method, with 
all primers generating efficiencies in the range of 85-95%. The chosen zinc transporter 
and MT transcripts represent key mediators of cellular zinc homeostasis and transport 
in PBMC. All mRNA expression levels were normalised to 18S rRNA expression as an 
endogenous reference and quantified using the ΔCP method; fold change relative to 
baseline was quantified using the ΔΔCP method. 
 
Dietary intake analysis  
 
Participants maintained a three-day estimated food record (two weekdays, one 
weekend day) during the second week of the study. Participants were instructed to 
record all food and drinks consumed during the day with portions estimated using the 
food record templates provided. A research dietitian checked each completed food 
record with the participant to clarify any missing items or unusual portions. Food 
records were analysed (FoodWorks 7 Professional Edition 2012, Xyris Software, QLD, 




Descriptive data were expressed as mean ± SD and outcome measures were described 
as mean ± SE. Differences between groups at baseline were analysed using 
independent t-tests. The primary outcomes, changes in gene expression and fold 
change (relative to baseline) between groups, were assessed by repeated measures-
ANOVA for complete sets of data. Age, BMI and physical activity were explored as 




compliance with model assumptions. Greenhouse-Geisser corrections were used when 
Mauchly’s sphericity test returned P < 0.05.  
 
Factor analysis using principal components was used to identify ‘clusters’ of zinc 
transporter gene expression at baseline. Multiple regression models were used to 
investigate whether the difference in MT-2A gene expression over the trial was 
determined by changes in the expression of zinc transporter genes, grouped either as 
‘all genes measured’ or within the identified ‘clusters’. Similarly, changes in measured 
zinc transporters and MT were used to predict the change in plasma zinc 
concentration. Multivariate ANOVA models were used to analyse whether dietary zinc 
intake and different components of physical activity levels (vigorous, moderate and 
walking physical activity) determined the expression of zinc transporter and MT genes 
at baseline. Bivariate correlations were used to explore possible relationships among 
physical activity levels, plasma zinc concentration, and zinc transporter and MT gene 
expressions at baseline. In primary analyses, i.e. comparisons between groups, P < 
0.05 was used to denote statistical significance.  In ‘secondary’ analyses, P < 0.01 was 
used to denote statistical significant with P < 0.05 being marginally significant due to 
the large number of statistical tests performed. Statistical analyses were carried out 






Of the 153 inquiries received, 66 volunteers returned screening questionnaires and 
were assessed for eligibility to participate in the study. Twelve volunteers did not meet 
the inclusion criteria, 13 declined to participate and two others withdrew their interest 
due to work commitments. Thirty-nine healthy participants (21 males, 18 females) 
were enrolled in the study and randomised into either the NT group (n = 20) or the ZT 
group (n = 19). Figure 5.1 details the trial profile.  
 
 





Thirty-four participants completed the study, with five participants lost to follow up at 
either Day 2 or 14. Two participants who completed the trial each had one missing 
time point (Day 0 and 7, respectively) due to unexpected circumstances. Given that 
the reasons for missing data and withdrawal were unrelated to the trial, only complete 
data were included for the analysis of primary outcomes. A high apparent compliance 
rate of 97% was found in the ZT group. All participants reported that no nutritional 
supplements (other than the provided supplements) were consumed during the trial. 
The age and BMI of the participants who completed the trial were 26.5 ± 11.7 y (mean 
± SD) and 22.5 ± 2.6 kg/m2, respectively. There were no significant differences in the 
baseline levels of physical activity, biochemical measurements or nutrient intakes 
between the two groups (Table 5.1).  
 
 
Table 5.1 Selected baseline characteristics and dietary intakes1 of participants who 

















Plasma Zinc and Serum CRP 
 
At baseline, the mean plasma zinc concentrations for both groups were within the 
reference range (10-18 µmol/L) [38] and were not significantly different between 
groups. Using repeated measures-ANOVA to determine the change in plasma zinc 
concentration over the course of the trial, no significant differences were found 
between the two groups (P = 0.21, Figure 5.2). In the ZT group, plasma zinc 
concentration increased by 0.98 ± 0.67 µmol/L (mean ± SE) at Day 21, however this 




observed in serum CRP between the two groups at baseline (P = 0.21) and over the 
course of the trial (P = 0.21). Serum CRP concentrations for all participants were 
below 10 mg/L, suggesting the absence of acute inflammation [303]. 
 
 
Figure 5.2 Plasma zinc concentrations in the no treatment (NT; n = 17) and zinc 
treatment (ZT; n = 14) groups. Data expressed as mean ± SE for the participants with 
complete data available.  No differences were observed between groups (P = 0.21). 
 
 
Zinc transporter and metallothionein gene expressions  
 
Gene expressions of MT-2A were higher in the ZT group compared to the NT group (P 
= 0.025), as determined by repeated measures-ANOVA. When the data were 
expressed as fold change relative to baseline, fold changes of MT-2A were higher in 
the ZT group (P = 0.016; Figure 5.3), specifically at Day 2 (P = 0.011). In the ZT 
group, the fold change of MT-2A was 1.40 ± 0.18 at Day 2, indicating an increase of 40 
± 18% in the relative copies of MT-2A mRNA from baseline. The addition of age, BMI 
and physical activity as covariates within the repeated measures-ANOVA models did 






Figure 5.3 MT-2A fold change in no treatment (NT; n = 17) and zinc treatment (ZT; 
n = 15) groups. Data expressed as estimated marginal mean ± SE from repeated 
measures-ANOVA analysis. P = 0.016 between groups, P = 0.011 at Day 2. 
 
 
Zinc supplementation did not change the gene expression (Table 5.2) or fold change 
of zinc transporters or MT-1A. Of the measured ZnT in this study, ZnT7 was the most 
highly expressed zinc transporter at baseline as judged by relative Cp values, 
expressing at more than 2-fold higher than the other cytoplasmic zinc exporters. ZIP1 
and ZIP3 had the highest expression of the measured ZIP while ZIP14 had the lowest 
expression (Figure 5.4). No significant differences were found in the gene expression 












Table 5.2 Gene expression1 of zinc transporters and metallothionein (NT group2, n = 
17; ZT group, n = 15). 
!! Day!0! Day!2! Day!7! Day!14! Day!21! POvalue3!
ZnT1!!
! ! ! ! ! !!!NT!group!! 6.27!±!0.48! 5.17!±!0.38! 5.09!±!0.53! 5.31!±!0.53! 4.92!±!0.49! 0.19!
!!ZT!group! 5.07!±!0.39! 4.18!±!0.34! 4.46!±!0.42! 4.77!±!0.46! 5.20!±!0.63!
ZnT5! ! ! ! ! !
!!!NT!group!! 1.67!±!0.10! 1.47!±!0.10! 1.53!±!0.15! 1.62!±!0.14! 1.34!±!0.09! 0.41!
!!ZT!group! 1.51!±!0.11! 1.34!±!0.08! 1.37!±!0.10! 1.33!±!0.10! 1.42!±!0.13!
ZnT6! ! ! ! ! !
!!!NT!group!! 2.69!±!0.17! 2.27!±!0.15! 2.23!±!0.16! 2.03!±!0.16! 1.93!±!0.13! 0.32!
!!ZT!group! 2.27!±!0.16! 2.13!±!0.14! 2.06!±!0.18!! 1.94!±!0.13! 1.95!±!0.16!
ZnT7! ! ! ! ! !
!!!NT!group!! 12.82!±!0.87! 11.06!±!0.77! 11.33!±!0.83! 10.82!±!0.75! 9.64!±!0.57! 0.60!
!!ZT!group! 11.79!±!1.21! 10.28!±!0.80! 9.90!±!0.77! 9.61!±!0.84! 9.64!±!0.78!
ZIP1! ! ! ! ! !
!!!NT!group!! 11.50!±!1.01! 9.19!±!0.65! 8.08!±!0.69! 10.27!±!1.18! 7.82!±!0.66! 0.47!
!!ZT!group! 9.97!±!1.00! 9.21!±!0.64! 8.22!±!0.72! 9.14!±!0.82! 8.05!±!0.73!
ZIP3!
! ! ! ! ! !!!NT!group!! 8.92!±!0.76! 8.14!±!0.50! 7.43!±!0.59! 9.00!±!0.91! 7.00!±!0.40! 0.85!
!!ZT!group! 7.60!±!0.68! 6.99!±!0.53! 6.68!±!0.80! 7.51!±!0.80! 6.19!±!0.62!
ZIP7!
! ! ! ! ! !!!NT!group!! 4.37!±!0.28! 4.14!±!0.32! 3.35!±!0.23! 3.59!±!0.25! 3.19!±!0.18! 0.63!
!!ZT!group! 3.82!±!0.34! 3.56!±!0.18! 3.35!±!0.29! 3.19!±!0.30! 2.83!±!0.17!
ZIP8!
! ! ! ! ! !!!NT!group!! 3.75!±!0.51! 3.89!±!0.51! 3.67!±!0.59! 4.11!±!0.69! 3.27!±!0.40!! 0.79!
!!ZT!group! 3.24!±!0.38! 3.08!±!0.42! 2.47!±!0.14! 3.05!±!0.58! 2.90!±!0.60!
ZIP10!
! ! ! ! ! !!!NT!group!! 5.90!±!0.44! 4.87!±!0.35! 4.54!±!0.31! 4.98!±!0.40! 4.46!±!0.35! 0.78!
!!ZT!group! 6.00!±!0.42! 5.36!±!0.36! 4.36!±!0.33! 4.90!±!0.45! 4.45!±!0.38!
ZIP14!
! ! ! ! ! !!!NT!group!! 0.92!±!0.09! 0.80!±!0.07! 0.69!±!0.05! 0.84!±!0.09! 0.68!±!0.05! 0.17!
!!ZT!group! 0.80!±!0.08! 1.06!±!0.25! 0.65!±!0.04! 0.69!±!0.06! 0.67!±!0.05!
MT01A!
! ! ! ! ! !!!NT!group!! 2.95!±!0.31! 2.73!±!0.36! 2.21!±!0.29! 2.38!±!0.24! 2.33!±!0.27! 0.70!
!!ZT!group! 3.32!±!0.61! 3.44!±!0.55! 2.82!±!0.58! 3.14!±!0.70! 2.81!±!0.45!
MT02A!
! ! ! ! ! !!!NT!group!! 9.20!±!0.86! 7.30!±!0.68! 7.15!±!0.86! 6.75!±!0.75!! 5.92!±!0.61! 0.025!








Figure 5.4 Relative gene expression of zinc transporters and metallothionein at 
baseline in the no treatment (NT; n = 19) and zinc treatment (ZT; n = 19) groups. Data 
expressed as mean ± SE. 
 
!
Relationships among zinc transporters and MT 
 
Relationships between zinc transporter and MT gene expressions at baseline are 
shown in Table 5.3. Significant relationships were observed among all transporters 
in the ZnT family (P < 0.01). ZIP7 and ZIP10 had the largest number of significant 
associations, each with five significant positive relationships with other zinc 
transporters and MT (P < 0.01). Conversely, ZIP8 gene expression was not related to 
any of the other measured zinc transporters or MT.  
 
Factor analysis using principal components revealed two ‘components’ of zinc 
transporters in which the expression of zinc transporters within each cluster were 
related to each other at baseline. The components identified were: Component 1 – 
ZIP1, ZIP3, ZIP7, ZIP10 and ZIP14; Component 2 – ZnT1, ZnT5, ZnT6, ZnT7, and 
ZIP8. When multiple regression models were used to explore the factors determining 
the change in MT-2A gene expression between Days 0 and 21, changes in all measured 
zinc transporters were predictive of the change in MT-2A expression (r2 = 0.54, P = 
0.029; Table 5.4). Similarly, changes in the gene expression of zinc transporters 
within Cluster 1 determined the change in the expression of MT-2A gene (r2 = 0.48, P 
= 0.003). In both models, ZIP1 gene expression emerged as a significant univariate 




Table 5.3 Pearson correlation coefficients (r) between zinc transporters and 
metallothionein for all participants at baseline (n = 38). 
!! ZnT5! ZnT6! ZnT7! ZIP1! ZIP3! ZIP7! ZIP8! ZIP10! ZIP14! MT01A!MT02A!
ZnT1! 0.64***!0.60***!0.46**! 0.32! 0.33*! 0.30! 0.10! 0.27! 0.25! 0.07! 0.37*!
ZnT5! ! 0.64***!0.62***!0.17! 0.33*! 0.20! 0.22! 0.36*! 0.30! 0.09! 0.11!
ZnT6! ! ! 0.65***!O0.03! 0.24! O0.03! 0.26! 0.19! 0.04! 0.09! 0.05!
ZnT7! ! ! ! 0.03! 0.33*! 0.08! 0.26! 0.27! 0.15! 0.23! 0.12!
ZIP1! ! ! ! ! 0.64***!0.76***!0.09! 0.41*! 0.64***!O0.01! 0.55***!
ZIP3! ! ! ! ! ! 0.52**! 0.22! 0.46**! 0.50**! O0.07! 0.21!
ZIP7! ! ! ! ! ! ! O0.04! 0.54***!0.52**! 0.10! 0.46**!
ZIP8! ! ! ! ! ! ! ! 0.15! 0.20! 0.20! 0.14!
ZIP10! ! ! ! ! ! ! ! ! 0.68***!0.48**! 0.44**!
ZIP14! ! ! ! ! ! ! ! ! ! 0.11! 0.47**!
MT0
1A!




Table 5.4 Multiple regression models using changes in all or ‘clusters’ of zinc 
transporters identified by principal component analysis to predict the change in MT-










Δ!MT02A! Δ!All!ZnT!and!ZIP2! 0.542! 0.029! ZIP1! 0.89!±!0.26! 0.003!
! Δ!Cluster!1
3! 0.477! 0.003! ZIP1! 0.77!±!0.22! 0.002!
! Δ!Cluster!2






Relationships among plasma zinc concentration, dietary zinc intake and gene 
expression of zinc transporters and MT  
 
In multivariate analysis, dietary zinc intake was a significant predictor of all measured 
zinc transporter and MT gene expressions at baseline (P = 0.03, Table 5.5), 
explaining 61% of variance in gene expressions; MT-1A expression emerged as a 
significant univariate factor within the multivariate ANOVA model (P = 0.002), while 
ZIP10 reached marginal statistical significance (P = 0.045). At baseline, plasma zinc 
concentration was not correlated with any of the measured zinc transporter or MT 
gene expressions.  Changes in the expression of zinc transporter and MT genes did not 





Table 5.5 Multivariate ANOVA model exploring the relationship between dietary zinc 








Dietary!zinc! 0.03! 0.61! ZnT1! NS! 0.04!
! ! ! ZnT5! NS! 0.02!
! ! ! ZnT6! NS! 0.04!
! ! ! ZnT7! NS! 0.002!
! ! ! ZIP1! NS! 0.004!
! ! ! ZIP3! NS! 0.05!
! ! ! ZIP7! NS! 0.02!
! ! ! ZIP8! NS! 0.02!
! ! ! ZIP10! 0.045! 0.12!
! ! ! ZIP14! NS! 0.01!
! ! ! MT01A! 0.002! 0.27!
! ! ! MT02A! NS! 0.11!1!Based!on!complete!data!available!for!analysis!(n!=!33).!Abbreviation:!NS,!not!significant.!
 
 
Relationships between physical activity levels and zinc transporter and MT gene 
expressions  
 
Weekday sitting time was not correlated with any of the measured zinc transporters or 
MT. When components of physical activity (vigorous, moderate or walking) were used 
to predict the gene expression of all measured zinc transporters and MT, no 
significant relationships were found (data not shown). Total physical activity level was 
correlated to ZIP7 gene expression at baseline (Figure 5.5, r = 0.36, P = 0.029). One 
participant reported a total physical activity level of 13,914 MET-minutes/weeks, 
which was > 3 SD above the group mean and therefore was considered to be an 
outlier. The positive relationship between total physical activity and ZIP7 was 







Figure 5.5 Bivariate correlation between total physical activity (MET-minutes/week) 
and ZIP7 gene expression at baseline for all participants (n = 38); inset graph shows 






The present study explored the effects of zinc supplementation on the expression of 
zinc transporter and MT genes in PBMC of healthy adults. The primary finding is a 
significant upregulation of MT-2A gene expression within two days of zinc 
supplementation, in the absence of significant change in plasma zinc concentration. 
Our previous report suggests coordination among components of cellular zinc 
homeostasis [136] [130] and the current findings extend these observations by 
demonstrating numerous relationships among the expression of zinc transporter and 
MT genes at baseline and during zinc supplementation. Specifically, the use of 
multiple regression models showed that the difference in MT-2A gene expression over 
the trial period was determined by changes in the expression of zinc transporter 
genes. In addition, to the best of our knowledge, this is the first study to report a 
relationship between habitual physical activity level and zinc transporter gene 
expression in humans.  
 
MT represents a large group of metal-binding proteins, with at least 10 functional MT 
isoforms identified in humans [77]. While MT-2A responds to many physiological 
stresses, such as hormones and thiol oxidation, the principal role of MT-2A relates to 
the maintenance of cellular zinc homeostasis. The primary observation of an increase 
in MT-2A gene expression during zinc supplementation is supported by previous 
studies of similar duration as the current report. In a study that utilised a high dose of 
zinc supplementation (50 mg/d elemental zinc), significant increase in MT mRNA was 
observed in monocytes throughout the intervention period, with a return to baseline 
level within 4 days of supplement cessation [309]. A lower dose of elemental zinc (15 
mg/d) with a shorter duration (10 days) elicited similar responses in MT gene 
expression within PBMC and subsets of leukocytes [80,310]. Moreover, MT-2A gene 
expression is responsive to suboptimal dietary zinc intake. After 10 weeks of 4.6 mg of 
dietary zinc intake/d, MT-2A mRNA in T lymphocytes decreased significantly, before 
returning to the baseline level after five weeks of zinc repletion [311]. While some of 
the earlier studies did not distinguish between the numerous isoforms of MT that are 
present in humans which present methodological differences in the present literature, 
the results are consistent in showing the responsiveness of MT transcription to 
changes in total zinc intake.  
 
The mechanisms that regulate MT transcription in cells have been explored 




induced by the binding of activated metal-regulatory transcription factor-1 (MTF-1) to 
the metal-responsive region of the MT gene [95]. Recently, a novel transcription 
factor, C/EBPα, was found to be important in the induction of MT expression, both 
independently and synergistically with MTF-1 [81]. Activation of C/EBPα by 
phosphorylation can be mediated through the phosphoinositide 3-kinase (PI3-K)/Akt 
pathway, one of the many signalling pathways in which zinc plays a regulatory role as 
a second messenger [26]. In the current study, using multiple regression models that 
explored changes over the study period, the difference in MT-2A gene expression was 
determined by changes in the expression of zinc transporter genes, both when 
measured collectively and when grouped according to the ‘clusters’ identified from 
factor analysis using principal components. In particular, the present study shows that 
the change in ZIP1 gene expression was a strong independent predictor of the change 
in MT-2A expression. ZIP1 mRNA was abundantly expressed and is a major zinc 
importer at the plasma membrane. The relationship between ZIP1 and MT-2A mRNA 
affirms the role of MT in maintaining cellular zinc homeostasis in response to changes 
in the levels of exogenous zinc; the potential cellular mechanisms that link ZIP1 with 
MT gene expression are illustrated in Figure 5.6.  
 
The lack of response in plasma zinc concentration during zinc supplementation is 
consistent with the modest effect of dietary zinc intake on systemic zinc concentration 
reported in a recent meta-analysis of RCT [59]. The duration and dose of zinc 
supplement provided in the current study may be insufficient to elicit an increase in 
plasma zinc concentration as identified in other studies, particularly with the added 
limitation of a small sample size. In contrast to plasma zinc concentrations, MT-2A 
gene expressions in PBMC are more reflective of immediate changes in dietary zinc 
intake. The transient increase in MT-2A gene expression during zinc supplementation 
is intriguing and can be explained by the rigid regulation of zinc metabolism. The 
maintenance of whole body zinc homeostasis is mediated primarily through the 
balance of endogenous zinc secretion and absorption within the gastrointestinal tract, 
which reflects immediate changes in dietary zinc intake [32]. In a study that utilised 
zinc stable isotopes, six consecutive days of 20 mg/d zinc supplementation reduced 
fractional zinc absorption in the gut by 50% [314], suggesting rapid physiological 
adaptation to increased dietary zinc intake. We propose that the MT-2A gene 
expression profile seen in the current study, comprising a rapid increase and 
subsequent return to baseline level by Day 7, is reflective of a reduction in systemic 





Figure 5.6 Schematic showing hypothesised regulation of MT-2A gene expression by 
zinc. 1.) Increased extracellular zinc is transported into the cell by the cellular zinc 
importer, ZIP1. 2.) Higher concentration of intracellular zinc can activate 
transcription factor, MTF-1. 3.) Zinc ions also can indirectly modulate the co-
activator, C/EBPα, through inhibition of PI3-K-Akt signalling pathway. 4.) Activated 
MTF-1 and C/EBPα can translocate into the nucleus, binding to the promoter region 
of MT-2A gene, upregulating gene transcription. 5.) Upregulation of gene expression 
can eventuate in increased MT-2A protein. 6.) Higher concentration of MT serves to 
sequester intracellular zinc, thereby creating a negative feedback signal within the cell. 
Abbreviations: PTP1B, protein tyrosine phosphatase 1B; PI3-K, phosphoinositide 3 
kinase; GSK-3, glycogen synthase kinase-3; C/EBPα, CCAAT/enhance binding protein 
α; MTF-1, metal-regulatory transcription factor-1; MRE, metal-responsive element. 
 
The gene expression analysis in the present study is limited to 10 of the 24 zinc 
transporters identified in humans to date. Data on the expression of other zinc 
transporters may provide further details on the fluctuations in intracellular zinc 
concentration during zinc supplementation. For instance in HEK-293 and MCF-7 cell 
lines, ZnT2 gene expression has been shown to be modulated by numerous 
suppressive and active regulators, including zinc-induced activation of MTF-1 [315]. 
In fibroblast cells, the upregulation of ZnT2 expression and its subsequent function of 
sequestering zinc within lysosomes are proposed to be one of the mechanisms in 
which cells maintain zinc homeostasis during excess zinc exposure [316]. Moreover, 
gene transcription represents one of the many points of regulation in the ultimate 




transcriptional modifications of zinc transporters and MT, impacting on the 
localisation and function of these proteins. Further investigations into the role of zinc 
transporters and MT in maintaining cellular zinc homeostasis would benefit from 
proteomic and intracellular zinc analyses.  
 
Although the inclusion of age as a covariate in the statistical models did not alter the 
overall results of the present study, age is a significant factor in maintaining immune 
and anti-oxidative functions of zinc [317]. A recent trial in an elderly population with 
low zinc status (plasma zinc < 11.77 µmol/L), reported that zinc supplementation 
upregulates the gene expressions of ZIP1 and MT-1A [318]. Discrepancies between the 
results reported by Sharif et al. [318] and those of the present study may be related to 
differences in age, zinc status and other baseline characteristics of the sampled 
populations. In addition, cellular uptake of zinc in response to zinc supplementation is 
influenced by polymorphisms in zinc transporter and MT genes. A study in an elderly 
population reported that participants with the G+ allele in the +1245 A/G MT1A gene 
polymorphism exhibited higher levels of intracellular labile zinc after zinc 
supplementation than those with the G- allele [319]. Thus the potential moderating 
effects of age, zinc status and polymorphisms on the gene expression of zinc 
transporters and MT in response to zinc supplementation and implications for 
oxidative stress warrant further research. 
 
Recent studies have shown relationships between zinc transporters and skeletal 
muscles in the context of exercise. The positive relationship between ZIP7 gene 
expression and total physical activity level found in the current study may be reflective 
of the function of this particular zinc transporter in skeletal muscles. ZIP7 transporter 
resides on the ER of the cell and is responsible for transient influx of zinc into the 
cytosol in response to cellular signals [125]. The function of ZIP7 to elicit a rapid 
increase in cytosolic zinc is related to the propagation of cellular signalling pathways, 
specifically those reliant on the phosphorylation of Akt and ERK-1/2. A recent study, 
which used siRNA to silence ZIP7 expression in a skeletal muscle cell line, found that 
both basal and insulin stimulated glucose metabolism are compromised as a result of 
reduced ZIP7 expression [114]. Due to the crucial role of ZIP7 in glycolysis, the 
authors suggest that this zinc transporter may present as a molecular target in the 
treatment of insulin resistance within skeletal muscles. This supposition is supported 
by the action of zinc ions in the insulin signalling pathway [28] and the role of 





The current study presents the influence of physical activity and zinc supplementation 
on the expression of ZIP7 and MT-2A genes, respectively. The modulations in the 
mediators of cellular zinc homeostasis by external stimuli, such as exercise and dietary 
zinc intake, may have implications for zinc-mediated intracellular signalling pathways 
and related cellular functions. MT-2A participates in “zinc-muffling” reactions [78], 
which involve the binding of excess zinc ions and delivering them to different 
subcellular compartments. Zinc-induced upregulation of MT protein may attenuate 
the spatial and temporal characteristics of transient increases in intracellular zinc 
concentration [75], which impact zinc-mediated cellular signalling pathways, such as 
those activated by insulin. The interactions among zinc homeostasis, intracellular 
signalling pathways and cellular function warrant further investigation.  
 
A number of limitations should be considered in the interpretation of this study, in 
particular the small sample size and the use of EDTA plasma tubes and CPT with 
sodium citrate for the analysis of plasma zinc and PBMC extraction, respectively. 
However, all precautions were taken to avoid zinc contamination in the collection and 
subsequent processing of the blood samples. Furthermore, the current study lacked 
the analysis of PBMC subtype populations which may influence the gene expression of 
zinc transporters and MT. PBMC represent a cohort of immune cells that can be 
modified by lifestyle factors, for example exercise [321] and zinc status [322,323]. It is 
currently unclear whether changes in the PBMC transcriptome as a result of zinc 
supplementation derive from differences in the composition of the PBMC subtypes or 
transcriptional changes in a stable cohort of PBMC. Differences in zinc status have 
been shown to account for variations in the distribution of lymphocyte subsets [324]; 
the potential confounding factor of the changing makeup of PBMC was not measured 
as part of this pilot study. In addition, the current study utilised supplementation of 
zinc chelated to an amino acid; the intestinal uptake and cellular processes in different 
forms of zinc supplements were not explored as part of this study. The current study 
included participants whose baseline plasma zinc concentration were at the higher 
end of the reference range; this participant characteristics precludes investigations 
into whether the intervention may vary with different baseline zinc status.  
 
The current study demonstrates a transient increase in MT-2A gene expression during 
zinc supplementation in healthy adults. The difference in MT-2A gene expression over 
the trial period was correlated with the change in ZIP1 expression, suggesting 
coordination in the maintenance of cellular zinc homeostasis. The positive correlation 




lifestyle and biological factors on the mediators of cellular zinc homeostasis. Given the 
complex biological functions in which zinc is involved, the understanding of multiple 
variables, including expression of zinc transporter and MT genes, may be required to 




































Chronic low grade inflammation in Type 2 DM can elicit changes in whole body zinc 
metabolism. The interaction among the expression of inflammatory cytokines, zinc 
transporter and MT genes in PBMC in Type 2 DM remains unclear. In a 12 week RCT, 
the effects of zinc (40 mg/d) supplementation on the gene expression of cytokines, 
zinc transporters and MT in women with Type 2 DM were examined. In the zinc 
supplemented group, gene expression of TNF-α tended to be upregulated by 27 ± 10% 
at week 12 compared to baseline (P = 0.053). TNF-α fold change in the zinc treated 
group was higher than those without zinc supplementation (P < 0.05). No significant 
changes were observed in the expression or fold change of IL-1β or IL-6.  Numerous 
bivariate relationships were observed between the fold changes of cytokines and zinc 
transporters, including ZnT7 with IL-1β (P < 0.01), IL-6 (P < 0.01) and TNF- α (P < 
0.01). In multiple regression analysis, IL-1β expression was predicted by the 
expression of all zinc transporters and MT measured at baseline (r2 = 0.495, P < 0.05) 
and at week 12 (r2 = 0.532, P < 0.03). The current study presents preliminary evidence 
that zinc supplementation increases cytokine gene expression in Type 2 DM. The 
relationships found among zinc transporters, MT and cytokines suggest a close 






Zinc is involved in the biosynthesis, storage and secretion of insulin within the 
pancreatic β-cells [325]. Furthermore, intracellular zinc can act directly on the insulin 
signalling pathway to improve glucose uptake and insulin sensitivity in peripheral 
tissues [26,293]. Individuals with Type 2 DM are suggested to be of poor zinc status 
due to the presentation of higher urinary zinc excretion and lower serum zinc 
concentrations [28]. Suboptimal zinc status can affect glycaemic control by 
compromising the production and secretion of insulin in the pancreas [326] and 
impacting insulin sensitivity in peripheral tissues [28,86]. Hence, the persistent 
elevation of blood glucose concentration featured in Type 2 DM may be attributed 
partly to perturbed zinc homeostasis.  
 
Cellular zinc homeostasis is regulated primarily by two families of zinc transporters 
and MT [56]. The ZIP family of transporters is responsible for increasing cytoplasmic 
zinc concentration by transporting zinc from intracellular organelles or the 
extracellular space. Conversely, the ZnT family of transporters functions to decrease 
the cytoplasmic zinc concentration by transporting zinc from the cytosol into the 
extracellular space or internal organelles, such as those involved in secretory 
pathways. MT acts as a target for zinc ion binding in the cytoplasm and is believed to 
assist in the trafficking of zinc ions through the cell [327]. The regulatory control of 
cellular zinc transporters and MT is complex and has been shown to be influenced by 
zinc status, systemic glucose and inflammatory cytokines [56,94].  
 
Cellular zinc transporters in different cell types has been shown to be both up- and 
down-regulated to meet the changing demand for zinc in inflammatory conditions 
[60]. The redistribution of zinc from the systemic circulation into cellular 
compartments is thought to be crucial for immune function. During acute infection, 
an increase in systemic IL-6 can induce hepatic accumulation of zinc, which 
contributes to the rapid decrease in the plasma zinc concentration often seen in the 
acute phase response [93]. The chronically activated innate immune system in Type 2 
DM [328] also can elicit changes to whole body zinc metabolism. Exposures to 
systemic cytokines, such as IL-1β, have been associated with down-regulation of the 
zinc transporters shown to play a role in insulin production and storage in the 





The expressions of immune markers, such as IL-1β, IL-6 and TNF-α, are often linked 
to the progression of Type 2 DM [329]. Specifically, increase in IL-1β has been shown 
to promote pancreatic β-cell destruction [330] which, in combination with TNF-α and 
IL-6, may synergistically exacerbate the extent of β-cell apoptosis and disease 
progression [331]. Furthermore, TNF-α and IL-6 can promote insulin resistance in 
peripheral tissues by modulating the expression of key regulators in the insulin 
signalling pathway [332]. Attenuation of CRP and inflammatory cytokine production 
may be achieved by dietary supplementation of anti-inflammatory nutrients, such as 
zinc and n-3 polyunsaturated fatty acids (PUFA) [60,333]. In a 6-week cross-over 
intervention study which manipulated the composition of fatty acids, a diet high in α-
linolenic acid (ALA) derived from flaxseed oil (FSO) resulted in significant reductions 
in cytokine production and vascular inflammation in hypercholesterolemic subjects 
[334,335]. The effectiveness of a modest level of ALA supplementation on 
inflammation in Type 2 DM is currently unknown.  
 
Similarly, the effect of zinc supplementation on inflammatory biomarkers in Type 2 
DM remains largely unexplored. While zinc supplementation appears to reduce the 
level of systemic CRP and IL-6 [216], conflicting findings are reported for the effect of 
zinc supplementation on ex vivo cytokine production in stimulated mononuclear cells 
[80,336]. In a recent zinc supplementation trial in individuals with Type 2 DM [337], 
we reported that systemic inflammatory markers were associated with the gene 
expression of zinc transporters and MT, suggesting an interplay between systemic 
markers of inflammation and cellular zinc transport. Consistent with our observation, 
a recent study in obese women showed levels of systemic CRP and TNF-α to be 
inversely correlated with a range of zinc transporter gene expressions [338].  
 
PBMC have been used as a candidate target tissue to detect transcriptome changes in 
response to dietary modification in humans [339]. The expression of zinc transporters 
and MT in PBMC have been described previously in a healthy population [136] and 
those with Type 2 DM [337]. However, the interactions between the gene expression 
of inflammatory cytokines, zinc transporters and MT remain unclear. To extend our 
previous report, specifically the relationships between systemic cytokines (IL-1β, IL-6 
and TNF-α) and gene expressions of zinc transporters and MT [337], the gene 
expression of IL-1β, IL-6 and TNF-α in PBMC were measured to provide further 
insight into the interactions between zinc and the immune system in Type 2 DM. The 
present study aims to investigate the effect of zinc on the gene expression of 
inflammatory cytokines in PBMC and explore possible relationships between the gene 






Study design  
 
The study design has been described previously [337,340]. The RCT was carried out 
previously and samples were made available for the present analysis. In brief, 48 
participants were enrolled in a randomised, double-blind, placebo-controlled trial. 
The primary inclusion criteria were that participants be postmenopausal (>12 months 
without menses), have normal Glomerular Filtration Rate and 
microalbumin/creatinine ratio, and were diagnosed with Type 2 DM, controlled by 
either diet and lifestyle or oral hypoglycaemic medication. Postmenopausal women 
were chosen for this trial as they have been identified as an understudied population 
group and the inclusion of women who suffer from chronic conditions such as Type 2 
DM contributes biomedical knowledge that advances patient care [341]. Enrolled 
participants were randomised into four equal groups to receive a total of 40 mg/d 
elemental zinc (‘Zn Group’), 2000 mg/d flaxseed oil (‘FSO group’), both zinc and 
flaxseed oil (‘Zn+FSO group’), or placebo for 12 weeks. Placebo capsules that were 
identical in appearance to their active counterparts were given to the placebo groups. 
Zinc placebo capsules contained cellulose, while olive oil was used as the placebo for 
FSO. All procedures followed were in accordance with the ethical standards of the 
Human Research Ethics Committee of the University of Sydney and with the Helsinki 
Declaration of 1975, as revised in 2000. Informed consent was obtained from all 
participants for being included in the study. The study protocol was registered at 
www.clinicaltrials.gov  (NCT01505803). 
 
Markers of systemic inflammation, glycaemia and zinc  
 
Venous blood samples from participants were collected at baseline, and at weeks 4, 8 
and 12 for the analysis of glucose, HbA1c, cytokines, CRP and zinc. Serum glucose was 
measured by glucose hexokinase UV method using the Gluco-quant reagent kit 
adapted for a Modular PPE auto-analyser (Roche Diganostics, Basel, Switzerland). 
Serum insulin was determined by chemiluminescent microparticle immunoassay on 
an Architect i2000SR Analyzer (Abbott Laboratories, Abbott Park, IL, USA). HbA1c 
was assayed using ion-exchange high performance liquid chromatography on a 
Variant II analyser equipped with the Variant II NU Program (Bio-Rad Laboratories, 
Hercules, CA, USA), according to the manufacturer’s protocol. Plasma zinc was 




ICPMS, Santa Clara, CA). The human cytokine/chemokine Milliplex MAP kit 
(Millipore, Billerica, MA, USA) was used for the simultaneous quantification of serum 
IL-1β, IL-6, and TNF-α concentrations, according to the manufacturer’s instructions. 
Samples were analysed on a Luminex 100 Bioanalyser (Luminex Corp., Austin, TX) 
using Fidis multiplex technology (Biomedical Diagnostics, Marne la Vallée, France). 
Serum CRP was measured using the Tina-quant CRP (gen.3) immunoturbidimetric 
method adapted for a Roche Modular PPE analyser (Roche Diagnostics, Basel, 
Switzerland) according to the manufacturer’s instructions. 
 
Zinc transporter, metallothionein and cytokine gene expressions 
 
PBMC were isolated from blood samples collected at baseline and week 12, processed 
through to cDNA and stored at -80°C until quantitative real-time PCR analysis. 
Unstimulated PBMC from individual samples were extracted and total RNA was 
prepared using the RNAqueous Small Scale Phenol-Free Total RNA Isolation Kit 
(Applied Biosystems-Life Technologies Australia Pty Ltd, Victoria, Australia) 
according to the manufacturer’s instructions. Total RNA was reverse transcribed into 
cDNA using the Superscript VILO cDNA Synthesis System (Invitrogen-Life 
Technologies Australia Pty Ltd, Victoria, Australia) following the manufacturer’s 
protocol. Forty complete samples of cDNA from study participants were recovered for 
cytokine gene expression analysis. Inventoried Taqman gene expression assays were 
obtained for IL-1β, IL-6 and TNF-α for relative quantification of cytokine mRNA using 
Taqman real-time PCR, as per the manufacturer’s instructions (StepOnePlus Real-
Time PCR System, Applied Biosystems-Life Technologies Australia Pty Ltd, Victoria, 
Australia). The selected cytokine transcripts correspond with measures of systemic 
inflammation that previously showed relationships with expression of zinc transporter 
genes [337]. Relative quantification of zinc transporter mRNA was conducted using 
Taqman real-time PCR (ABI 7500 Fast Sequence Detection System; Applied 
Biosystems-Life Technologies Australia Pty Ltd, Victoria, Australia). Inventoried 
Taqman gene expression assays, and one custom-designed assay, were obtained for 
ZnT1, ZnT5, ZnT6, ZnT7, ZnT8, ZIP1, ZIP3, ZIP7, ZIP10, MT-1A, and MT-2A mRNA 
(Applied Biosystems-Life Technologies Australia Pty Ltd, Victoria, Australia). 
Messenger RNA expression levels for all genes were normalised to 18S rRNA 
expression as an endogenous reference and quantified using the ΔCP method; fold 








Descriptive statistics were expressed as mean ± SD. Cytokine gene expressions and 
fold changes were described as mean ± SE. Differences in group means of baseline 
characteristics, cytokine expressions and fold changes were assessed by ANOVA. No 
significant changes were observed in primary outcomes measured (glycaemia, 
systemic inflammatory markers or cytokine mRNA expressions) after FSO 
supplementation, with or without zinc. Hence, post hoc investigations using 
independent t-tests were used to compare groups categorised according to whether 
participants did or did not receive zinc supplementation. Post-hoc analysis according 
to FSO supplementation was performed and confirmed no effect on cytokine gene 
expressions when FSO was consumed alone or in combination with zinc. 
 
Bivariate relationships between fold changes of cytokines, zinc transporters and MT 
were calculated using the Pearson correlation coefficient. Multiple regression models 
were used to explore the relationships among gene expression of IL-1β, IL-6, TNF-α 
and expression of all zinc transporters and MT measured, at baseline and week 12. 
The residuals from the regression models were checked to see if they satisfied the 
assumptions of normality and homoscedasticity: the initial regressions indicated that 
analyses of MT-1A and MT-2A were more appropriately conducted on a log scale. 
Statistical analyses were carried out using SPSS (PASW) version 18. With analysis of 
the primary outcomes, a value of P < 0.05 was taken to designate statistical 
significance. In univariate outcomes within multivariate analyses, a more conservative 
designation of P < 0.01 as statistically significant was used due to the large number of 








Characteristics of study participants, biomarker outcomes and zinc transporter 
expressions have been described previously in detail [337,340]. Of the 48 enrolled 
participants, complete sets of cDNA samples were available from 40 participants for 
PBMC cytokine gene expression analysis.  The age and BMI of participants were 
(mean ± SD) 65.1 ± 8.0 years and 28.3 ± 5.0 kg/m2, respectively. The average time 
since Type 2 DM diagnosis was 6.6 ± 5.4 years. The baseline fasting blood glucose 
concentration, fasting insulin and HbA1c of the participants were 6.7 ± 1.8 mmol/L, 
67.2 ± 36.8 pmol/L  and 6.7 ± 1.0%, respectively. The mean plasma zinc concentration 
was 12.8 ± 2.0 µmol/L, which is within the reference range of 10-18 µmol/L. The 
baseline serum concentrations of CRP, IL-1β, IL-6 and TNF-α were 1.7 ± 2.2 mg/L, 1.0 
±1.9 pg/mL, 1.6 ± 2.0 pg/mL and 10.3 ± 3.5 pg/mL, respectively. At baseline, there 
were no differences in zinc transporter and MT expressions between groups. 




Table 6.1 Participant baseline characteristics and biochemical measures categorised 










Age!(y)! 64.6!±!5.8! 66.2!±!8.4! 66.0!±!11.3! 63.5!±!5.4!
BMI!(kg/m2)! 29.0!±!5.3! 29.9!±!4.9! 25.2!±!4.2! 29.7!±!4.9!
Plasma!zinc!(μmol/L)! 13.3!±!1.2! 11.7!±!1.4! 13.6!±!1.9! 12.3!±!2.2!
Fasting!blood!glucose!
(mmol/L)!
7.0!±!1.5! 7.3!±!3.1! 6.9!±!0.9! 6.7!±!0.8!
HbA1c!(%)! 6.6!±!0.8! 7.0!±!1.8! 6.6!±!0.4! 6.4!±!0.5!
Serum!Insulin!(pmol/L)! 85.1!±!34.7! 64.5!±!27.2! 64.5!±!48.4! 53.8!±!29.7!
Serum!CRP!(mg/L)! 1.97!±!3.12! 2.54!±!2.27! 0.84!±!0.63! 1.60!±!1.86!
Serum!ILO1β!(pg/mL)! 1.19!±!2.38! 0.39!±!0.68! 1.12!±!2.32! 1.27!±!1.82!
Serum!ILO6!(pg/mL)! 1.39!±!1.46! 1.43!±!1.53! 1.95!±!2.99! 1.70!±!1.44!
Serum!TNFOα!(pg/mL)! 10.55!±!3.36! 10.93!±!4.11! 9.63!±!3.03! 10.23!±!4.05!
Abbreviations: FSO, flaxseed oil; HbA1c, haemoglobin A1c; CRP, C-reactive protein; 







Markers of systemic inflammation and glycaemia  
 
After 12 weeks of intervention, no significant changes were detected in the measures 
of systemic inflammation or glycaemia as a result of zinc supplementation. Plasma 
zinc concentration was significantly higher in the zinc supplemented group when 
compared to those without zinc treatment after 4 weeks of supplementation (Figure 
6.1, P < 0.05) and remained significantly higher at weeks 8 and 12. There were no 
significant changes observed in zinc transporter and MT mRNA expressions between 
treatment groups (reported previously in [337]).  
 
!
Figure 6.1 Effect of 12 week zinc supplementation on plasma zinc concentration in 
those supplemented with zinc (Zn Group, n = 20) and those without zinc 
supplementation (Control Group, n = 20). Values shown as mean ± SE. * P < 0.05 by 
repeated measures ANOVA. 
 
Cytokine mRNA expression and fold change 
 
At baseline, no differences were observed in the mRNA expression of IL-1β, IL-6 or 
TNF-α among the intervention groups. TNF-α was the most highly expressed mRNA 
transcript of the cytokines measured, expressing at almost 3-fold of IL-1β. Separated 
into the four treatment groups, no significant changes were found in cytokine gene 




Table 6.2 Relative mRNA expression1 and fold changes2 of IL-1β, IL-6 and TNF-α in 
PBMC (mean ± SE). 
! !
Placebo!(n!=!10)! FSO!(n!=!10)! Zn!(n!=!11)! Zn+FSO!(n!=!9)!
IL01β! Week!0! 0.96!±!0.11! 1.72!±!0.39! 1.04!±!0.15! 0.91!±!0.14!
!
Week!12! 0.97!±!0.02! 1.33!±!0.06! 1.46!±!0.01! 0.98!±!0.06!
!
Fold!change! 1.08!±!0.24! 0.88!±!0.43! 1.51!±!0.30! 1.21!±!0.35!
IL06! Week!0! 0.10!±!0.12! 0.13!±!0.25! 0.05!±!0.36! 0.17!±!0.13!
!
Week!12! 0.08!±!0.02! 0.14!±!0.08! 0.08!±!0.02! 0.26!±!0.10!
!
Fold!change! 0.97!±!0.30! 1.24!±!0.29! 1.46!±!0.48! 1.38!±!023!
TNF0α! Week!0! 2.86!±!0.15! 3.85!±!0.16! 2.77!±!0.26! 2.89!±!0.18!
!
Week!12! 3.01!±!0.12! 3.16!±!0.27! 3.64!±!0.25! 3.09!±!0.23!
!







Secondary analyses were conducted with the four treatment groups differentiated 
according to whether participants received zinc treatment (Zn group and Zn+FSO 
group) or no zinc treatment (FSO group and placebo). In the zinc treated group, 
mRNA expression levels at week 12 tended to be higher than baseline for TNF-α (per 
cent increase 27 ± 10%; mean ± SE; P = 0.053), IL-6 (42 ± 17%; P = 0.066), but not 
IL-1β (37 ± 16%; P = 0.19). In those without zinc treatment, no significant differences 
were found between baseline and week 12 cytokine mRNA expressions. When the data 
were expressed as fold change, TNF-α was significantly higher (P = 0.037) as a result 
of zinc supplementation (Figure 6.2). IL-1β fold change was marginally higher (P = 
0.054) in the zinc treated group while no differences were observed in the fold change 
of IL-6 (P = 0.17). 
 
When separated into those groups who did receive FSO (FSO and FSO + Zn group) or 
did not receive FSO (placebo and Zn group), IL-1β, IL-6 and TNF-α gene expressions 
were not significantly different between week 0 and week 12. Fold change of IL-1β, IL-
6 and TNF-α were not significantly different in the FSO group when compared to 






Figure 6.2 Fold change of IL-1β, IL-6 and TNF-α in PBMC separated by whether 
participants received zinc treatment (n = 20) or no zinc treatment (n = 20). Fold 
change data (mean ± SE) are calculated using the ΔΔCp method and expressed on a 
log scale.* P < 0.05 by independent t-test. 
 
 
Relationships among various cytokines and zinc transporters  
 
Bivariate correlations between fold changes of individual zinc transporters and IL-1β, 
IL-6 and TNF-α are shown in Table 6.3. Positive correlations between TNF-α fold 
change and fold changes of ZnT5, ZnT6, ZnT7, ZIP1, ZIP3, ZIP7, ZIP10, MT-1A and 
MT-2A were observed when all participants were considered (P < 0.05). Similarly, IL-
1β fold change was positively correlated to the fold change of ZnT7 (r = 0.44, P < 0.01; 
Figure 6.3a) and ZIP1 (r = 0.42, P < 0.01; Figure 6.3b). The treatment of zinc 
abolished a number of correlations between fold changes of cytokines and zinc 
transporters; in particular fold changes of IL-6 and ZnT5 (control group, r = 0.61, P < 
0.01; zinc group, r = -0.13, P > 0.05; Figure 6.4), ZnT6 (control group, r = 0.49, P < 
0.05; zinc group, r = 0.09, P > 0.05) and ZnT7 (control group, r = 0.54, P < 0.05; zinc 
group, r = 0.32, P > 0.05).  
!
143$
Table 6.3 Bivariate Pearson correlations between fold changes of cytokines, zinc transporters and metallothionein when analysed in all 
participants (n = 381) and according to whether participants received (Zinc, n = 20) or did not receive (Control, n = 18) zinc supplements 
for 12 weeks. 
$$ $$ ZnT1! ZnT5! ZnT6! ZnT7! ZnT82! ZIP1! ZIP3! ZIP7! ZIP10!! MT01A!! MT02A!
IL01β! All$ 0.28$ 0.28$ 0.33*$ 0.44**$ ,0.03$ 0.42**$ 0.38*$ 0.24$ 0.14$ 0.19$ 0.36$
! $$$Zinc$ 0.33$ 0.49*$ 0.27$ 0.57**$ ,0.23$ 0.51*$ 0.31$ 0.27$ 0.24$ 0.10$ 0.37$
! $$$Control$ 0.31$ 0.24$ 0.42$ 0.29$ 0.04$ 0.35$ 0.70**$ 0.33$ ,0.06$ 0.38$ 0.32$
IL06! All$ 0.07$ 0.21$ 0.29$ 0.43**$ 0.05$ 0.06$ 0.38*$ 0.22$ 0.42**$ 0.51**$ 0.14$
! $$$Zinc$ ,0.08$ ,0.13$ 0.09$ 0.32$ ,0.13$ 0.10$ 0.46*$ 0.31$ 0.43$ 0.59**$ 0.24$
! $$$Control$ 0.29$ 0.61**$ 0.49*$ 0.54*$ 0.32$ 0.04$ 0.41$ 0.18$ 0.39$ 0.40$ ,0.01$
TNF0α! All$ 0.31$ 0.39*$ 0.45**$ 0.56**$ 0.10$ 0.52**$ 0.34*$ 0.44**$ 0.33*$ 0.33*$ 0.60**$
$
$$$Zinc$ 0.31$ 0.44$ 0.41$ 0.60**$ 0.11$ 0.64**$ 0.49*$ 0.48*$ 0.40$ 0.28$ 0.65**$









Figure 6.3 Bivariate correlations between fold changes of IL-1β and ZnT7 (Panel a), and IL-
1β and ZIP1 (Panel b) in all participants (n = 38). Fold change data are calculated using the 













































Figure 6.4 Bivariate correlations between fold changes of IL-6 and ZnT5 in the control 
group (n = 18, Panel a) and in the zinc group (n = 20, Panel b). Fold change data are 







































Using multiple regression analysis for all participants at baseline, IL-1β expression 
was predicted by expressions of all zinc transporters and MT measured (r2 = 0.495, P 
= 0.04, Table 6.4), with marginally significant univariate correlations observed with 
ZIP1 (P = 0.02) and ZIP7 (P = 0.01). At week 12, overall significant multivariate 
relationship was maintained between expressions of IL-1β and zinc transporters and 
MT (r2 = 0.532, P = 0.02) with a single significant univariate relationship found 
between IL-1β and ZnT7 (P = 0.002); ZnT7 expression explained 36% of the 
variability in IL-1β expression. Multiple regression analyses using expression of zinc 
transporters and MT as predictors of IL-6 or TNF-α expression did not show any 
significant relationships (data not shown).  
 
 
Table 6.4 Multiple regression models using expression of zinc transporters and 
metallothionein to predict IL-1β expression at baseline (model 1) and week 12 (model 
2) for all participants. 









ZnT1! <0.02# 0.04# 0.58# # 0.02# 0.07# 0.75#
ZnT5! <0.01# 0.34# 0.97# # <0.64# 0.39# 0.12#
ZnT6! <0.19# 0.23# 0.41# # <0.09# 0.30# 0.78#
ZnT7! 0.06# 0.07# 0.38# # 0.30# 0.09# 0.002#
ZnT8! <1.38# 2.31# 0.55# # <4.81# 4.55# 0.30#
ZIP1! 0.18# 0.07# 0.02# # <0.01# 0.09# 0.89#
ZIP3! 0.11# 0.11# 0.35# # 0.12# 0.14# 0.41#
ZIP7! <0.34# 0.13# 0.01# # <0.17# 0.26# 0.53#
ZIP10! <0.01# 0.09# 0.91# # <0.11# 0.12# 0.34#
MT/1A! <0.11# 0.10# 0.28# # <0.14# 0.16# 0.40#
MT/2A! 0.05# 0.22# 0.82# # 0.32# 0.44# 0.48#








The key observation in the present study is an upregulation of cytokine gene 
expression in PBMC after zinc supplementation in post-menopausal women with Type 
2 DM. Specifically, higher fold change of TNF-α was observed, with IL-1β fold change, 
and IL-6 expression tending to increase after 12 weeks of zinc supplementation. A 
range of bivariate relationships were found among fold changes of various cytokines 
and zinc transporters. In addition, zinc transporter and MT gene expressions were 
shown to predict the expression of IL-1β. Collectively, the observations support a 
relationship between zinc and immune response in Type 2 DM. 
 
The significant upregulation observed in TNF-α expression after zinc supplementation 
in the present study is in agreement with several in vitro studies [342–344]. In 
cultured cells, changes in gene expression and secretion of cytokines as a result of zinc 
treatment have been reported. Increases in TNF-α, IL-1β and IL-6 secretion have been 
shown in otherwise unstimulated PBMC incubated with high levels of zinc (≥ 100 µM) 
in the media [342,343]. Similar effects were observed with zinc added at 
physiologically relevant levels; TNF-α and IL-1β mRNA expressions were shown to be 
upregulated with 30 µM of zinc added to the incubating media [342]. Limited data are 
available from human trials on the effects of zinc supplementation on cytokine 
production in non-activated PBMC. The gene expressions of TNF-α and IL-1β remain 
unchanged in unstimulated leukocytes extracted from healthy subjects given 15 mg/d 
of zinc for 4 days [80]. The present results are novel and to our knowledge, there are 
no previous reports of the effect of zinc supplementation on unstimulated cytokine 
expressions in postmenopausal women with Type 2 DM.  
 
Perturbation in zinc metabolism is often reported in Type 2 DM [28]. The increase in 
plasma zinc concentration seen in zinc supplemented participants in the present study 
suggests that zinc is available for intracellular zinc replenishment in previously zinc 
deficient tissues. We hypothesise that an increase in cellular zinc content in PBMC 
may explain these observations. The classic transcription factor, NF-κB, has been 
proposed to be influenced by increased zinc availability. NF-κB represents the 
converging signalling molecule in immune cells; the propagation of Toll-like, IL-1 and 
TNF receptor signalling pathways are reliant on the activation of NF-κB. Zinc has 
been proposed to enhance or inhibit NF- κB activity, dependent on the different 
health and/or zinc status of the studied population [60]. In zinc deficient subjects, 




production of immune cells [345], both of which phenomena were reversed by zinc 
supplementation.  
 
Increased plasma zinc concentration, per se, may be contributing to the upregulation 
of cytokines observed. Higher systemic zinc concentrations may initiate intracellular 
signalling through an extracellular zinc receptor, GPR39. This novel zinc sensor is 
implicated in the regulation of cell proliferation and growth [132], through 
modulation of the ERK-1/2 and Akt pathways. Although the direct effect of GPR39 on 
intracellular signalling in the immune cells is unclear, it is conceivable that the 
activation of GPR39 by increased extracellular zinc may trigger downstream signalling 
eventuating in upregulation of cytokine expression. Given that a state of zinc 
deficiency appears to co-exist with Type 2 DM, the current findings after zinc 
supplementation may be evidence of improved immune response through increased 
efficiency in signalling pathways and thereby upregulation of cytokine gene 
expressions. 
 
The multiple bivariate correlations found in the present study between fold changes of 
cytokine, zinc transporter, and MT mRNA suggest coordination between fluxes of 
cellular zinc ions and cytokine production in PBMC, an important function of immune 
cells. These findings support previous observations of a relationship between zinc 
transporter gene expression and systemic inflammatory biomarkers in humans 
[337,338]. Systemic inflammatory biomarkers, such as CRP, IL-6, and TNF-α, were 
able to predict the gene expressions of zinc transporter and MT in PBMC; in 
particular, increases in systemic IL-6 concentration were related to increases in the 
expression of a cluster of zinc transporters, ZnT5, ZnT7, ZIP1, ZIP7 and ZIP10, which 
are responsible largely for the uptake of extracellular zinc and transport of zinc into 
intracellular organelles and secretory pathways in PBMC. Considering that 
inflammatory biomarkers in the systemic circulation are the cumulative secretion of 
many peripheral tissues, the present study is unique in elucidating the relationship 
between zinc transporter, MT, and cytokine gene expression within PBMC. 
 
At both baseline and week 12, IL-1β gene expression was predicted by zinc transporter 
and MT gene expressions. Furthermore, IL-1β expression was strongly predicted by 
the gene expressions of ZIP1 and ZIP7 at baseline and ZnT7 at week 12 in univariate 
analyses. Considering their proposed localisation within the cell [82,89], these zinc 
transporters are likely to be involved in either increasing cytoplasmic zinc 




the previously observed relationships between systemic IL-6 with gene expression of 
ZnT7, ZIP1 and ZIP7 [337], we hypothesise that systemic cytokines have a regulatory 
control of zinc transporter transcription which influences the flux of zinc into the 
secretory pathway, thereby assisting in immune cell function such as IL-1β 
transcription. This hypothesis is supported by recent findings that suggest external 
stimuli such as systemic cytokines may regulate zinc transporter expression through 
the JAK-STAT pathways [346]. In particular, cytokines were found to induce the 
expression of ZIP10, thereby providing an influx of intracellular zinc. The uptake of 
zinc via this particular zinc transporter appears to be critical for the survival, function 
and signalling of B-lymphocytes [347]. In a similar vein, we have previously reported 
an association between ZIP10 gene expression and glycaemic control [164], whereby 
the change in fasting glucose was correlated with the change in ZIP10 expression. 
These observations highlight the range of external stimuli that can influence zinc flux 
and function in the cell. Figure 6.5 shows the hypothesised interaction between 
external stimuli, zinc transport and cellular function.  
 
The PBMC transcriptome has been shown to be reflective of gene expressions in 
metabolically active tissues, such as liver [73] and muscle [74], both of which play a 
role in glucose and zinc homeostasis. Furthermore, modifications in dietary 
macronutrients and antioxidants seem to effect changes in the PBMC transcriptome 
[339], hence presenting it as a promising target tissue in nutrigenomic studies. From 
the current study, it is evident that zinc supplementation impacts on the gene 
expression of cytokines and affects the relationships between cytokine and zinc 
transporter transcription in PBMC. In particular, the relationships between fold 
change of IL-6 with ZnT5, ZnT6 and ZnT7 fold changes in the control group were not 
observed in the zinc treated group. Whether zinc supplementation will elicit similar 
effects in cell types other than PBMC, such as those of the pancreas and other 





Figure 6.5 Potential zinc-mediated pathways by which external stimuli (such as systemic glucose, cytokines and zinc) may act on cellular 
function. External stimuli such as systemic IL-6, glucose and extracellular zinc bind to respective receptors on the plasma membrane (1). This 
triggers intracellular signalling events (ERK 1/2 , Akt and JAK/STAT pathways; 2), resulting in modulation of  zinc transporters and MT gene 
expressions (3). Changes in intracellular zinc concentration can influence NF-κB activation (4) and subsequent expression of cytokines, such as 
TNF-α and IL-1β (5). Eventual cytokine secretions may be related to the expression of zinc transporters implicated in the secretory pathway (6). 
Abbreviations: ER endoplasmic reticulum; ERK, extracellular regulating kinase; GPR39, G-protein receptor-39; IL-6R, interleukin 6 receptor; 
NF-κB, nuclear factor-kappa B.  
!
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The efficacy of zinc supplementation in the management of Type 2 DM has been 
investigated recently. Meta-analyses have shown that zinc supplementation in Type 2 
DM results in lower fasting glucose [141] and increased HDL-C concentrations [143]. 
In the current study, zinc supplementation upregulates gene expression of cytokines 
in PBMC despite no changes being observed in systemic levels of the corresponding 
inflammatory markers [337]. Differences in the derivation of samples may provide an 
explanation in the discrepancy of results. In PBMC, the measure of cytokine gene 
expressions is upstream of cytokine secretion. Regulatory processes at post-
transcriptional, translational and post-translational levels are required prior to 
eventual secretion of cytokines into the systemic circulation. In addition, the systemic 
cytokine concentration is reflective not only of PBMC cytokine secretion but from a 
variety of sources, such as liver, muscle and adipose tissue. Hence, the effect of 
increased cytokine gene expressions in PBMC remains uncertain in the context of the 
whole body inflammatory status in Type 2 DM. 
 
The current study presents data on the effects of zinc supplementation on the 
expression of cytokines and their relationships with zinc transporter gene expressions 
in Type 2 DM. The present observations are novel in that they provide evidence of 
interactions between zinc transport and cytokine transcription in PBMC, which add to 
our previous reports [337,340]. While we did not determined the exact makeup of 
PBMC in the samples; the isolation of PBMC were performed using commercially 
available blood tubes and should be devoid of other blood components. The study is 
limited by the lack of proteomic and intracellular zinc analyses. The ultimate function 
and activity of transcribed genes are influenced by a number of post transcriptional 
regulatory processes, and further research is needed to explore the multiple possible 
subcellular localisation sites of zinc transporter proteins which are influenced by the 
host’s zinc status [56].  
 
In summary, the current study presents preliminary evidence that zinc 
supplementation increases TNF-α gene expression in post-menopausal women with 
Type 2 DM. The multiple relationships found between gene expression and fold 
change of zinc transporters, MT and cytokines suggest a close relationship between 



































Limited studies have examined the interrelationships among the numerous zinc 
transporters and MT, under conditions of health and Type 2 DM. The current study 
aims to explore the relationships among mediators of cellular zinc homeostasis, in an 
apparently healthy (AH) population and a cohort with diagnosed Type 2 DM (T2DM). 
Cluster analysis and factor analysis by principal components were used to identify 
groupings within 10 zinc transporter and MT gene expressions measured in PBMC, 
stratified by health status. Multiple regression models were used to explore potential 
relationships between zinc transporter/MT groupings, dietary zinc intakes and plasma 
zinc concentrations. Gene expression levels of most of the analysed zinc transporters 
and MT, with the exception of ZnT6, were significantly lower in the T2DM cohort (P < 
0.01), as compared to healthy subjects. Cluster analysis showed that the groupings of 
zinc transporters and MT between the two cohorts were largely similar, with the 
exception for the placement of ZnT1 and ZIP7. In the T2DM group, ZnT1 was 
associated with ZnT6 and ZIP3, while ZIP7 was associated with the cluster of ZnT5, 
ZnT7, ZIP1 and ZIP10. When grouped by components identified by factor analysis, 
zinc transporters and MT were significant determinants of plasma zinc concentration 
(r2 = 0.48, P = 0.001) in the AH cohort, but not in the T2DM cohort. No relationship 
was observed between groupings of zinc transporters and MT with dietary zinc intake 
in either cohort. The current study suggests altered cellular zinc homeostasis in Type 2 
DM and supports the use of multiple zinc transporters and MT groupings to further 








Zinc is an essential trace element that is required for numerous functions in humans 
[36]. Biological processes that are supported by zinc include acting as a catalytic factor 
for metalloenzymes, providing structural integrity for peptides, such as insulin, and 
mediating intra- and extra-cellular signalling pathways. The involvement of zinc in 
multiple physiological processes requires tight control of cellular zinc concentration. 
Cellular zinc homeostasis is regulated primarily by zinc transporters and a group of 
zinc-binding proteins, MT [48]. Zinc transporters are categorised into two families in 
accordance to their proposed functions. ZnT proteins function to promote cytoplasmic 
zinc efflux by transporting zinc ions to extracellular space or intracellular structures, 
such as vesicles. ZIP transporters are responsible for increasing cytoplasmic zinc 
concentration by zinc influx from extracellular source or subcellular organelles, such 
as the ER. MT, a group of proteins ubiquitously expressed in humans, are involved in 
the buffering of intracellular zinc ions and thereby controlling availability of zinc to 
other proteins and cellular processes [75].  
 
The importance of the cellular zinc transport system in chronic diseases, such as Type 
2 DM, has been highlighted recently. The association between Type 2 DM risk and 
SNP in the gene encoding ZnT8 [155] initiated the interest of ZnT8 in Type 2 DM 
pathogenesis, in particular cellular processes that occur in the pancreas. Highly 
expressed in pancreatic β-cells, ZnT8 serves the functions of transporting zinc ions 
into insulin secretory granules and supporting processing pathways for the production 
of proinsulin [325]. Cellular zinc importers, in particular ZIP6 and ZIP7, also have 
been implicated in the functions of pancreatic β-cells. The knockdown of both ZIP6 
and ZIP7 genes impaired insulin secretion under glucose stimulation [348]. In the 
same study, single knockdown of ZIP6 gene resulted in significant increase in ZIP7 
gene expression, suggesting coordination between zinc transporters in maintaining 
cellular zinc homeostasis and related cellular functions.  
 
Transcriptome analysis of PBMC has become increasingly common in recent 
nutrigenomic studies. An easily obtainable tissue sample in humans, PBMC 
transcriptome has been shown to mirror characteristics of other metabolically active 
tissues that require invasive sampling techniques [339]. Furthermore, PBMC also 
possesses insulin receptors with similar binding affinities as insulin sensitive tissues, 
such as the liver and skeletal muscles [349]. These identified characteristics render 




zinc transport system and cellular processes, such as those mediated by the action of 
insulin.  
 
We have previously determined the gene expression of a range of PBMC zinc 
transporters and MT in both healthy individuals and those with Type 2 DM. In the 
initial cross-sectional study aimed to determine expression patterns of zinc 
transporters and MT in healthy adults, relationships were observed between 
individual zinc transporters measured, giving the notion of coordination amongst zinc 
transporters in healthy population [136]. We have subsequently completed two 
separate intervention trials in healthy participants (described in Chapter 5) [350] and 
those with Type 2 DM (described in Chapter 6) [337,351], where gene expression of 
zinc transporters and MT were one of the measured outcomes. To better represent the 
coordination amongst zinc transporter and MT gene expressions in previous studies 
[337,350,351], we utilised factor analyses by principal components to group correlated 
zinc transporters and MT into distinct groupings. Using the identified groupings of 
zinc transporters, we have shown significant relationships between zinc transporter 
expressions and inflammatory markers [337,351] and MT [350]. Despite significant 
relationships shown between zinc transporter groupings and other cellular markers, 
we have yet to define the coordination of zinc transporters and MT within the assigned 
groupings in healthy or Type 2 DM cohorts.  
 
Multiple reports have identified specific individual zinc transporter or MT to be 
implicated in the pathology of Type 2 DM [114,157], limited studies have attempted to 
reveal the interrelationships among the numerous zinc transporters and MT in a 
cellular model context, under conditions of health and Type 2 DM. Therefore, the 
current study aims to explore the relationships among mediators of cellular zinc 
homeostasis, specifically as measured by gene expressions of zinc transporters and 
MT, in an apparently healthy population and a cohort with diagnosed Type 2 DM. As 
Type 2 DM is often associated with suboptimal zinc status and disruptions in whole-
body zinc homeostasis [290], we hypothesise that coordination within the cellular zinc 
transport system may be altered in Type 2 DM, thereby enabling the identification of 
novel molecular targets for further investigations.  
 





The current chapter describes two different cohorts, 1.) apparently healthy (AH) 
cohort, 2.) Type 2 DM (T2DM) cohort, that were initially recruited for three 
independent cross-sectional or intervention studies. For the purpose of the present 
analysis, baseline values for all recruited participants were used. Details of the studies, 
including the selection criteria of participants, have been described in Chapters 5 and 
6 and/or have been published previously [136,337]; brief summaries for all studies are 
provided below.  
 
AH cohort study designs 
 
Study 1: Forty healthy participants were recruited for a cross-sectional study aimed at 
examining the expression patterns of zinc transporter genes in PBMC [136]. Complete 
gene expression data of 32 participants (16 males, 16 females) were available for 
statistical analysis. The Human Research Ethics Committee of the University of 
Sydney approved the study protocol.  
 
Study 2: Thirty-nine healthy adults were enrolled in a randomised, double blind, zinc 
supplementation study (see Chapter 5). Complete gene expression data of 38 
participants (21 males and 17 females) were available for statistical analysis. Baseline 
data were used for the purpose of the current analyses. The Human Research Ethics 
Committee of the University of Sydney approved the study protocol and the trial was 
registered at www.anzctr.org.au  (ACTRN12613001200774). 
 
T2DM cohort study design  
 
Study 3: Forty-eight postmenopausal women with Type 2 DM were enrolled to take 
part in a RCT of zinc and/or FSO supplementation (see Chapter 6). Complete gene 
expression data of 42 participants were available for statistical analysis. Baseline data 
were used for the purpose of the current analyses. The Human Research Ethics 
Committee of the University of Sydney approved the study protocol, and the protocol 








Collection of descriptive data  
 
Anthropometric (height and weight) data were collected for all participants. Lifestyle 
data, such as physical activity, change in weight over preceding 3 months, and alcohol 
consumption, were self-reported at baseline. Dietary intakes for all participants were 
determined by estimated food records which were analysed to determine energy, 
macro- and micronutrient compositions (FoodWorks, Xyris Software). Details on 
descriptive data collection were presented in Chapters 5 and 6.  
 
Blood collection and biochemical analyses  
 
Venous blood samples were collected from participants after an overnight fast of > 10 
h. EDTA or trace element tubes were used for analysis of plasma zinc. Plasma zinc 
concentrations were determined by inductively coupled plasma MS (Agilent 7500ce 
ICPMS) in Study 1 and 3 or flame AAS (SpectrAA220, Varian) in Study 2. In the 
T2DM cohort, serum tubes were used for glucose and insulin analyses; EDTA tubes 
for analysis of HbA1c. Methodology for biochemical analyses in the T2DM cohort has 
been described previously in Chapter 6. Insulin resistance was estimated by HOMA-
IR, calculated by fasting glucose (mmol/L) x fasting insulin (mU/L) / 22.5. Details on 
blood collection and biochemical analyses were described in Chapters 5 and 6. 
 
Gene expression of zinc transporters and metallothioneins 
 
Procedure for the determination of zinc transporter and MT gene expressions were 
similar across the three studies [136,337,350]. CPT with sodium citrate (Becton-
Dickinson) were used to isolate PBMC. All CPT were centrifuged within 2 h of blood 
collection; PBMC were then isolated, proceed through to cDNA and stored until 
quantitative real-time PCR analysis.  In brief, total RNA was extracted from PBMC 
using RNAqueous Small Scale Phenol-Free Total RNA Isolation Kit (Applied 
Biosystems-Life Technologies) or PARIS kit (Ambion, Life Technologies), according to 
the manufacturers’ instructions. Total RNA was then reverse transcribed into cDNA 
by Superscript III First-Strand Synthesis System (Invitrogen) or Superscript VILO 
cDNA Synthesis System (Invitrogen-Life Technologies).  
 
Relative quantification of zinc transporter and MT mRNA was conducted using 
Taqman real time PCR (ABI 7500 Fast Sequence Detection system or StepOnePlus 




manufacturers’ instructions. Taqman gene expression assays were obtained for ZnT1, 
ZnT5, ZnT6, ZnT7, ZIP1, ZIP3, ZIP7, ZIP10, MT-1A, MT-2A and 18S. The zinc 
transporters and MT were chosen as they are typically expressed in PBMC and 
represent some of the zinc transport routes into and within the cell; ZnT8, whilst 
important in Type 2 DM pathology, could not be reliably detected in PBMC for all 
participants and therefore is excluded from the current analysis. All mRNA gene 
expressions were normalised to 18S rRNA as an endogenous reference and quantified 
using the ΔCP method. Details on gene expressions analyses were presented in 
Chapters 5 and 6 [136,337,350]. 
 
Statistical analysis  
 
Descriptive data are expressed as mean ± SD and outcome measures are described as 
mean ± SE. To explore the relationships among zinc transporters and MT within the 
cohorts (AH and T2DM), two multivariate statistical methods were used.  
 
Firstly, cluster analysis using Ward’s method [352] was utilised to group zinc 
transporters and MT that are related to each other, but dissimilar to members of other 
clusters. Each individual zinc transporter and MT starts off in its own cluster, with 
pairs of clusters combined based on the similarities between them. To define the 
measure of similarity, the squared Euclidean distance [353] was used. By grouping 
variables according to the observations within the two cohorts, this analysis will 
identify groupings of zinc transporters and MT that are similar to each other, but 
different from those within other groups.  
 
Secondly, factor analysis using principal components [354] was utilised to reduce the 
10 zinc transporters and MT into a small number of groups which explain the most 
statistical variation within the datasets. In this process, independent linear 
combinations of the original variables (zinc transporters and MT) were progressively 
identified that accounted for as much of the variability in the data as possible. These 
combinations were then transformed by varimax rotation [355] to maximise the 
variability between groupings of zinc transporters and MT, facilitating the 
interpretation of the groupings. Three factors of zinc transporters and MT that 
explained the majority (74% and 67% for AH and T2DM cohort, respectively) of the 
statistical variance were extracted for each cohort.  Unlike cluster analysis, factor 
analysis also allows for the development of factor scores for each identified 




representative of the linear combinations of zinc transporters and MT within the 
identified groupings for each participant in the AH and T2DM cohorts.  
 
Collectively, cluster analysis and factor analysis will identify groupings of zinc 
transporters and MT according to health status, by relationships among each other 
and statistical variation explained, respectively. The two different approaches are used 
to determine the level of consistency in the identification of groupings in zinc 
transporters and MT.  
 
To further explore the relationships between sets of zinc transporters and MT with 
plasma zinc concentration or dietary zinc intake, factor scores for the components 
identified from factor analyses were generated for each participant. Factor scores 
generated were then used as independent variables to determine their relationships 
with plasma zinc concentration or dietary zinc intake within multiple regression 
models, stratified by health status. Due to the large number of statistical tests 
performed, statistical significance was taken at P < 0.01, with marginal statistical 
significance indicated at P < 0.05. All statistical analyses were carried out using SPSS 





Characteristics of cohorts  
 
Complete gene expression data were available for 112 participants (n = 70 in the AH 
cohort and n = 42 in the T2DM cohort). Participants in the T2DM cohort were 
significantly older with higher BMI than those in the AH cohort (P < 0.001, Table 
7.1). Indices of zinc status, plasma zinc concentration and dietary zinc intake, were 
both lower in the T2DM cohort compared to the AH cohort (P < 0.01). No statistical 
differences were observed in characteristics between males and females of the AH 
cohort (Table C1, Appendix C).  
 
In the T2DM cohort, the length of time since diagnosis was 5.9 ± 4.1 y (mean ± SD). 
Mean fasting glucose concentration for the T2DM cohort was 6.8 ± 1.2 mmol/L; mean 
HbA1C was 6.6 ± 0.5%; fasting insulin concentration was 68.6 ± 37.2 pmol/L and 
calculated HOMA-IR was 3.5 ± 2.1.  
 
 
Table 7.1 Characteristics of the apparently healthy (AH) cohort and Type 2 diabetes 











Gene expression of zinc transporters and metallothioineins  
 
Gene expression of measured zinc transporters and MT for the two cohorts is 
presented in Figure 7.1. Mean gene expressions for all zinc transporters and MT, 
with the exception of ZnT6, were lower in the T2DM cohort compared to the control 
group. The largest difference was observed in the gene expression of MT-1A where it 
was expressed 8.9-fold greater in the AH cohort. No differences were noted in the 




cohort, with the exception of ZIP7 where higher expression was observed in males, 




Figure 7.1 Gene expression of zinc transporters and MT, relative to 18S rRNA 
(expressed as mean ± SE), in apparently healthy (AH) cohort and Type 2 diabetes 
mellitus (T2DM) cohort. * P < 0.01 ** P < 0.001 for independent t-tests comparing 





To group zinc transporters and MT that are correlated within the identified clusters, 
separate cluster analyses were conducted in the AH and T2DM cohorts. Figure 7.2 
shows a dendrogram which depicts the relationships between the variables in the AH 
cohort. From left to right along the horizontal axis, the dendrogram shows the 
convergence of individual zinc transporter and MT into clusters, according to the 
relative relationships between the variables. For instance, ZnT1 was the first to group 
with ZIP10; then ZIP1, being the most related of the remaining variables, joined the 
grouping of ZnT1 and ZIP10. At the same level, ZnT5 and ZnT7 were grouped 
together, indicating comparable levels of relationships within the groupings of (ZnT1, 
ZIP1, ZIP10) and (ZnT5, ZnT7). An arbitrary vertical line was drawn at the Rescaled 




transporters and MT. In the AH cohort, the three clusters of zinc transporters and MT 
were: Cluster 1 (MT-1A and MT-2A); Cluster 2 (ZnT1, ZIP10, ZIP1, ZnT5, and ZnT7); 
and Cluster 3 (ZnT6, ZIP3, and ZIP7) (Figure 7.2); the numbering of clusters was 




Figure 7.2 Dendrogram showing the relative distances (and relationships) among 
individual zinc transporters and MT in the apparently healthy (AH) cohort. Shorter 
relative distance before group formation represents closer relationships between 
variables. An arbitrary rescaled distance of 15 was taken to allow for the formation of 
three distinct cohorts of zinc transporters and MT.  
 
 
Figure 7.3 shows the dendrogram, which reveals relationships amongst the gene 
expression of zinc transporters and MT in the T2DM cohort. An arbitrary vertical line 
was drawn at a Rescaled Distance axis of 15, for the formation of three distinct clusters 
of zinc transporters and MT. In the T2DM cohort, the variables most correlated with 
each other, and formed the initial group, were ZnT5, ZnT7 and ZIP1. Three final 
clusters were identified, specifically Cluster 1 (MT-1A and MT-2A); Cluster 2 (ZnT5, 
ZnT7, ZIP1, ZIP7, and ZIP10), and Cluster 3 (ZnT1, ZnT6, and ZIP3). Within the three 
clusters, similar levels of correlative relationships amongst variables were observed, as 





Figure! 7.3! Dendrogram# showing# relative# distance# (and# relationships)# among# zinc#
transporters# and# MT# in# Type# 2# diabetes# mellitus# (T2DM)# cohort.# Shorter# relative#
distance# before# group# formation# represents# closer# relationships# between# variables.# An#




Factor analyses using principal components  
 
To further explore the three groupings identified from cluster analysis, factor analyses 
using principal components were used to reduce 10 individual zinc transporters and 
MT into three components that explain the largest amount of statistical variances 
within the AH and T2DM cohorts.  
 
In the AH cohort, the extraction of three components accounted for 74% of total 
variance explained. The three components extracted and their respective variables 
were: Component 1 (ZnT1, ZnT5, ZnT7, ZIP1, and ZIP10) with 39.2% total variance 
explained; Component 2 (ZIP7, MT-1A, and MT-2A) with 20.9% total variance 
explained; and Component 3 (ZnT6 and ZIP3) with 14.1% total variance explained. 
Factor loadings of variables within their respective component in the AH cohort are 
presented in Table 7.2. Factor loadings represent the relationship between variables 




variables, i.e. Component 3 (ZnT6 and ZIP3). Similar to Pearson’s coefficient, loadings 
can range from -1 to 1. A strong relationship between variable and its component is 
indicated when factor loadings are close to -1 or 1. In the AH cohort, all zinc 
transporters and MT correlated positively to their respective component, with the 
exception of ZIP7, which had a negative coefficient within Component 2, indicating an 
inverse relationship between ZIP7 and MT. A graphical representation of all zinc 
transporters and MT with their factor loadings, in accordance to the three extracted 
factors in the AH cohort is presented in Figure C1 (Appendix C).  
 
 
Table 7.2 Factor loadings of variables within their respective component in the 
apparently healthy (AH) cohort.  
Variables# Component#1# Component#2# Component#3#
ZnT1! 0.932# # #
ZnT5! 0.784# # #
ZnT7! 0.778# # #
ZIP1! 0.836# # #
ZIP10! 0.901# # #
ZIP7! # Y0.380# #
MT,1A! # 0.841# #
MT,2A! # 0.851# #
ZnT6! # # 0.785#
ZIP3! # # 0.845#
 
 
In the T2DM cohort, the three extracted components explained 67% of total statistical 
variance within the dataset. The three components and their respective variables 
were: Component 1 (ZnT5, ZnT7, ZIP1, ZIP7, and ZIP10) with 39.2% total variance 
explained; Component 2 (ZnT1, ZnT6, and ZIP3) with 15.7% total variance explained; 
and Component 3 (MT-1A and MT-2A) with 12.1% total variance explained. Table 7.3 
shows the factor loadings of variables within their respective component in the T2DM 
cohort; all variables were positively correlated with other zinc transporters or MT 
within the assigned component. A graphical representation of all zinc transporters 
and MT with their factor loadings, in accordance to the three extracted factors in the 
T2DM cohort is presented in Figure C2 (Appendix C). The summary of both 








Table 7.3 Factor loadings of variables within their respective component in the Type 
2 diabetes mellitus (T2DM) cohort.  
Variables# Component#1# Component#2# Component#3#
ZnT5! 0.764# # #
ZnT7! 0.718# # #
ZIP1! 0.788# # #
ZIP7! 0.843# # #
ZIP10! 0.686# # #
ZnT1! # 0.848# #
ZnT6! # 0.737# #
ZIP3! # 0.540# #
MT,1A! # # 0.741#
MT,2A! # # 0.854#
 
 
Table 7.4 Summary of zinc transporters and MT groupings by cluster analysis and 
factor analysis using principal components, stratified by health status. 
## AH#cohort#(n#=#70)# T2DM#cohort#(n#=#42)#
Cluster#analysis#




# ###Component#1# ZnT1,!ZnT5,!ZnT7,!ZIP1,!ZIP10! ZnT5,!ZnT7,!ZIP1,!ZIP7,!ZIP10!!
##Component#2# ZIP7,!MT,1A,!MT,2A! ZnT1,!ZnT6,!ZIP3!!
##Component#3# ZnT6,!ZIP3! MT,1A,!MT,2A!
Abbreviations: AH, apparently healthy; T2DM, Type 2 diabetes mellitus. 
 
 
Relationships among sets of zinc transporters and metallothioneins with plasma zinc 
or dietary zinc 
 
Factor scores generated from principal component analyses were used to predict 
plasma zinc concentrations or dietary zinc intake in multiple regression models. In the 
AH cohort, when all three components were used to predict plasma zinc concentration 
an overall significant model was observed (r2 = 0.48, P = 0.001, Table 7.5). 
Components 1 and 3 emerged as significant predictors of plasma zinc concentration in 
the AH cohort. No significant relationship was observed between dietary zinc intake 
and the three groupings of zinc transporters and MT, in the AH cohort. In the T2DM 
cohort, neither plasma zinc concentration or dietary zinc intake were related to the 






Table 7.5 Multiple regression model using components identified from factor 




Plasma#zinc#concentration# Component#1# Y0.86#±#0.34# 0.015#
# Component#2# Y0.46#±#0.34# 0.18#








The present chapter describes the interactions and relationships between zinc status 
and zinc transporters and MT, under conditions of health and Type 2 DM. Gene 
expression levels of most zinc transporters and MT were significantly lower in the 
T2DM cohort, compared to the AH cohort. The groupings of zinc transporters and MT 
between the AH cohort and T2DM were largely similar, with the exception for the 
placement of ZnT1 and ZIP7. When grouped by components identified by factor 
analysis, zinc transporters and MT were predictive of plasma zinc concentrations in 
the AH cohort. No relationships were found between zinc status and zinc transporters 
and MT in the T2DM cohort. To the best of our knowledge, this is the first such 
analysis of cellular mediators of zinc homeostasis and their relations to indices of zinc 
biomarkers in health and disease. 
 
Studies comparing cellular zinc transporter and MT gene expressions between healthy 
and DM populations are scarce. Type 2 DM coexists with a state of suboptimal zinc 
status, evidenced by lower serum zinc levels and higher urinary zinc excretion in 
individuals with Type 2 DM [138,139,290]. Furthermore, in a study of individuals 
with Type 2 DM who were treated with insulin, intracellular zinc concentrations in 
lymphocytes were found to be significantly lower than healthy individuals [290]. 
Adequate levels of intracellular zinc have been shown to be important for optimal 
cellular functions, such as insulin secretion, in different cell types [156,290]. The 
lower expression of most zinc transporters and MT within the T2DM cohort in this 
study may be suggestive of disturbed zinc homeostasis associated with Type 2 DM 
[28].  
 
The differences in MT gene expression are striking when comparing between the 
cohorts in the present study. Within the present study, the lowered expression of MT 
gene, in particular MT-1A, observed in the T2DM cohort may be highlighting a 
significant defect of cellular zinc metabolism in disease pathology. While MT serves 
important roles in protection against toxic metal ions and oxidative stress, MT is also 
the primary buffering system for intracellular zinc ions, enabling the shuttling of zinc 
to different cellular locations [77]. The multifunctional capability of MT is highlighted 
in a recent paper describing the roles of MT-1A in sequestering toxic cadmium ions, 
while binding zinc ions at the terminal ends of MT for donation to other zinc proteins 
[356].  The disruption of MT-1A protein structure by SNP has been associated with 




changes in SOD and levels of oxidative stress may be one of the potential mechanisms 
in mediating Type 2 DM pathogenesis and related chronic low-grade inflammation.   
 
In the current study, the two multivariate statistical analyses attempted to unify the 
data from individual zinc transporters and MT in order to reflect the cellular zinc 
transport system in health and Type 2 DM. In the T2DM cohort, groupings of zinc 
transporters and MT found from cluster analysis were in accordance with those 
identified in factor analysis. Zinc transporters and MT grouped also similarly from 
both statistical methods in the AH cohort, with the only exception being the 
placement of ZIP7. Under healthy conditions, the grouping of ZIP7 with MT may be 
reflective of the role ZIP7 plays in zinc-mediated cellular signalling. ZIP7 has been 
identified as the zinc transporter that is responsible for rapid release of zinc from the 
ER, triggering the start of a ‘zinc signal’ for downstream cellular signalling events 
[125]. As MT is the primary buffering system for intracellular free zinc [75], it is 
conceivable that the expression of ZIP7 and MT are coordinated to effect appropriate 
spatial and temporal characteristics of zinc signals [250]. This relationship did not 
emerge in our previous analysis in Chapter 5 [350], possibly due to the small sample 
size utilised in the study.  
 
The importance of ZIP7 expression in glycaemic control was highlighted recently; the 
knockdown of ZIP7 gene in murine muscle cells manifested in defects within the 
insulin signalling pathway with implications on glucose metabolism [114]. 
Furthermore, the placement of ZIP7 among other zinc transporters and MT may be 
modulated by the independent positive correlation between physical activity level and 
ZIP7 gene expression reported previously in Chapter 5 [350]. The interaction between 
physical activity levels and cellular zinc transport system, specifically the role of ZIP7, 
warrants further investigation.  
 
In the AH cohort, the majority of zinc transporters that are localised on the plasma 
membrane were classified in the same grouping (Figure 7.4); therefore, we propose 
that zinc transporters within this grouping (ZnT1, ZnT5, ZnT7, ZIP1 and ZIP10) are 
coordinated to control cytoplasmic zinc flux through the plasma and subcellular 
membranes under healthy conditions. Zinc transporters that are localised 
intracellularly primarily and are responsible for the transport of zinc into subcellular 
organelles are similarly identified within the same component (ZnT6 and ZIP3) in the 






Figure 7.4 Schematic showing the cellular localisation of zinc transporters and MT as 
grouped by factor analysis in the apparently healthy (AH) cohort. The colour of the 
named zinc transporters or MT indicates groupings of zinc transporters and MT; 
Component 1, black (ZnT1, ZnT5, ZnT7, ZIP1, and ZIP10); Component 2, red (ZIP7, 
MT-1A, and MT-2A); Component 3, blue (ZnT6, and ZIP3). In the Type 2 diabetes 
mellitus (T2DM) cohort, ZnT1 was associated with transporters from Component 3; 
and ZIP7 was associated with transporters from Component 1 instead.  
 
 
In contrast, ZnT1, a major cellular zinc exporter, was associated with ZnT6 and ZIP3 
within the T2DM cohort. ZnT1, along with MT and ZnT4, are required for maximal 
function of the early secretory pathway that is necessary for the cellular production of 
zinc proteins and enzymes [358]. Furthermore in the T2DM cohort, ZIP7 was 
associated with the larger grouping of zinc transporters (ZnT5, ZnT7, Zip1, ZIP7, and 
ZIP10), instead of MT under healthy conditions. The disassociation of ZnT1 and ZIP7 
from their groupings, as identified in the AH cohort, highlights a potential defect in 
zinc transport system associated with Type 2 DM. The relationship between aberrant 
cellular zinc transport and pathology of Type 2 DM, such as insulin resistance, 
requires further investigation.  
 
Differences in cellular zinc homeostasis in Type 2 DM, compared to control, is further 





































plasma zinc concentration. Under healthy conditions, the expression of all zinc 
transporters and MT predicted plasma zinc concentration; in particular, Component 1 
(ZnT1, ZnT5, ZnT7, ZIP1 and ZIP10) and Component 3 (ZnT6 and ZnT3) emerged as 
significant univariate variables in the multiple regression model presented. The 
current observations extend on a previous report of coordination in zinc transporter 
expressions in healthy individuals [136]. The disconnection between cellular zinc 
transport system and systemic zinc levels in Type 2 DM may be exacerbated by the 
differences in the coordination within zinc transporters and MT. The development of 
single treatment targets for specific individual zinc transporters in Type 2 DM may be 
applicable, provided that the interrelationships within the zinc transport system 
remain.  
 
A number of limitations should be considered in the interpretation of the current 
study. The two cohorts differed in sex distribution, age, BMI and zinc status. The 
current statistical approaches were limited in their capabilities to account for potential 
confounding factors such as age, sex and BMI. Some of these factors, such as obesity 
[338] and age [359], have been associated with differences in zinc transporter gene 
expressions. Larger samples of both healthy individuals and those with Type 2 DM are 
required to investigate the potential modulating and/or confounding effects of cohort 
characteristics on the cellular zinc transport system. Furthermore, this study utilised 
PBMC as the source of transcriptome analysis; given that expression and localisation 
of zinc transporters and MT are suggested to be tissue specific [94], further 
investigations are required to assess the generalisability of the current analysis to 
other cells types, such as those in the pancreas or skeletal muscles.  
 
To the best of our knowledge, the present study is the first to define the coordination 
between individual zinc transporters and MT under conditions of health and Type 2 
DM. Differences between the gene expression levels and interrelationships between 
zinc transporters and MT observed between the two cohorts suggest Type 2 DM-
associated zinc dyshomeostasis [290] at the cellular level. A major strength of the 
current report is the uniform gene expression analysis and methodological processes 
across the sampled populations. The hypotheses generated from the present report 
warrant further studies to improve the understanding of components within the 
cellular zinc transport system and explore the influence of extrinsic stimuli, such as 
zinc supplementation and physical activity, on zinc homeostasis and pathology 






























There is growing evidence suggesting interactions between zinc homeostasis and the 
pathophysiology and clinical management of chronic diseases [11,28], including the 
role of exercise [10,114,166]. The primary objective of this thesis was to explore the 
determinants and impact of zinc status under conditions of health, exercise and 
chronic diseases, in particular Type 2 DM and CVD. To achieve the proposed aims of 
this thesis, we utilised a variety of methodologies, ranging from molecular analyses to 
systematic reviews and meta-analyses.  
 
The systematic review described in Chapter 2 aimed to determine the relationships 
between zinc status and prospective risk of CVD and Type 2 DM in cohort studies. 
While the current evidence from cohort studies is limited by heterogeneity in 
statistical models and confounding factors used, findings from the systematic review 
suggest a trend towards the protective effect of zinc intake on Type 2 DM risk in 
apparently healthy populations. Higher serum zinc levels were associated with lower 
risk of CVD, with more pronounced effects in vulnerable populations, such as those 
with Type 2 DM [145] and patients with coronary angiography [231]. The systematic 
review presented in Chapter 2 is the first to determine the relationships between zinc 
status and the prospective risks of CVD and Type 2 DM. The findings reported extend 
the current understanding and provide credible evidence in support of mechanistic 
studies that show biological plausibility for the proposed relationships.  
 
The biological plausibility for the role of zinc in preventing the development of Type 2 
DM and associated complications has been shown in numerous experimental studies 
[28,175]. Furthermore, evidence from RCT supports the improvement of zinc status, 
by zinc supplementation, for intermediate markers of DM, such as glycaemic control 
[141] and lipidemia [143]. The strengths of systemic review in Chapter 2 include the 
systematic collation of the available evidence and the determination of risk of study 
biases as per the current GRADE approach [222]. These findings provide the basis for 
further investigations into the mechanisms of zinc’s action on the pathogenesis and 
management of Type 2 DM and CVD. A combination of mechanistic studies at the 
cellular and whole body levels are required to elucidate the influence of zinc status on 
chronic diseases. Moreover, the impact of currently recommended management 
strategies, specifically exercise, on the relationship between zinc status and chronic 





To explore the influence of exercise on zinc status, systematic review and meta-
analyses were conducted in Chapters 3 and 4 with aims to quantify the changes in 
biomarkers of zinc status following a bout of aerobic exercise. Collectively, results 
from the two Chapters describe acute fluctuations in systemic zinc levels, specifically 
an increase in serum zinc concentration immediately after exercise in Chapter 3, 
subsequently followed by a decrease of serum zinc during exercise recovery in Chapter 
4. We proposed that a number of potential mechanisms may be responsible for the 
changes observed, mediated through changes in acid-base balance during high-
intensity exercise and inflammatory processes that occur following exercise [296]. 
Active cellular zinc transport is proposed to function by the counter-transport of 
hydrogen and bicarbonate ions [250]; therefore changes in acid-base balance within 
peripheral tissues and systemic circulation may be intrinsically linked to zinc 
homeostasis. Furthermore, the onset of inflammatory processes following exercise, 
including the release of cytokines and infiltration of immune cells into the working 
muscles, can mediate significant changes in the expression of zinc transporters and 
MT [60], both of which represent primary regulators of cellular zinc homeostasis. The 
contributions of different potential mechanisms to exercise-mediated changes in 
serum zinc require further investigations.  
 
One of the strengths in the systemic reviews and meta-analyses presented is the 
inclusion of exercise bouts that are commonly recommended for the prevention and 
management of chronic diseases, such as Type 2 DM. Secondary analyses revealed 
greater aberrations of post-exercise serum zinc levels for untrained participants or 
individuals with lower baseline zinc status. Given the role of zinc in the pathogenesis 
of chronic diseases proposed in Chapter 2, the results of Chapters 3 and 4 suggest that 
the maintenance of zinc status should be considered for at-risk populations. Taken 
together, the findings from the secondary analyses may be particularly relevant in 
exercise prescription for the management of chronic diseases, such as Type 2 DM, 
where suboptimal zinc status [290] may have adverse implications for exercise-
induced adaptations [10], such as insulin sensitivity, and disease progression.  
 
In the above systematic reviews and meta-analyses, while we searched for all zinc 
biomarkers, it was clear that plasma/serum zinc concentrations was the most 
commonly used marker of zinc status. However, the inherent limitations of the 
currently available zinc biomarkers to reflect zinc status are well documented [360]. 
Novel markers, such as expression of zinc transporters and MT, have been suggested 




transporters and MT gene expression to detect changes in zinc intake remains unclear. 
Therefore in Chapter 5, we undertook a time-course study aimed at identifying novel 
zinc biomarkers that included a range of zinc transporters and buffering proteins, 
such as MT. A significant upregulation of MT-2A gene was observed within 2 days of 
zinc supplementation suggests that MT-2A may be a marker for short term zinc 
status; the findings presented are supported by previous studies of similar duration 
and conditions [80,309,310]. The novel results of our trial was that changes in MT-2A 
gene expression were integrated with changes in all measured zinc transporters, in 
particular ZIP1 expression, highlighting the coordinated events between MT and zinc 
transporters that contribute to optimal cellular zinc homeostasis following increased 
total zinc intake. We proposed that increased expression of MT-2A gene was the result 
of a culmination of cellular events initiated by a change in zinc status, including the 
action of ZIP1 leading to an increase in intracellular zinc concentration and potentially 
the subsequent activation of MTF-1 and Akt pathway. Given the role of MT in 
monitoring intracellular free zinc concentration [75], the regulation of MT gene may 
have implications for zinc-mediated intracellular signalling pathways and related 
cellular functions.  
 
In the same study (Chapter 5), and as part of the collected baseline data, the influence 
of other lifestyle factors, specifically physical activity, on cellular zinc homeostasis was 
observed. A positive correlation was noted between habitual physical activity levels 
and ZIP7 gene expression. ZIP7 is responsible for eliciting a rapid increase of cytosolic 
zinc from the ER in response to cellular signals [125]. The functional significance of 
ZIP7 is highlighted in murine skeletal muscle cells where the loss of ZIP7 expression 
resulted in reductions in both basal and insulin-stimulated glucose metabolism [114]. 
The connection between physical activity and cellular zinc transporter is supported by 
a recent study where SNP variants of ZnT8 gene were associated with pre-exercise 
strength and skeletal muscle volume in men [166]. The findings of Chapter 5 
demonstrated interactions between extrinsic factors, such as zinc intake and physical 
activity, and the coordinated cellular zinc transport system in humans. The translation 
from cellular studies of glucose metabolism to the impact of zinc and its transporter 
activity to whole body metabolism is required to further investigate the role of zinc in 
exercise physiology. 
 
Coordination in cellular zinc homeostasis is required for the regulation of numerous 
biological functions of zinc [48]; this was highlighted in Chapter 6 where relationships 




individuals with Type 2 DM. Upregulation of cytokine gene expressions in PBMC, 
specifically TNF-α mRNA, were observed following 12 weeks of zinc supplementation. 
While limited data are available from human trials on the effects of zinc 
supplementation on cytokine production in PBMC, in accordance with results 
presented in Chapter 6, several in vitro studies have shown upregulated levels or 
secretion of TNF-α and IL-1β with increased concentration of zinc in the incubating 
media [342,343].  
 
The synergy between cellular zinc homeostasis and cytokine productions in PBMC was 
highlighted in Chapter 6 where the expression of IL-1β gene was predicted by zinc 
transporter and MT gene expressions, in particular ZnT7, ZIP1, and ZIP7. Considering 
their proposed localisation within the cell [82,89], these zinc transporters are 
implicated in the transport of zinc ions for the mediation of intracellular zinc 
signalling pathways and the secretion of proteins, such as cytokines. Increased 
efficiency in signalling pathways, and thereby regulation of cytokine gene expressions, 
may be an indication of improved immune response following zinc supplementation 
in Type 2 DM [290]. The redistribution of zinc within the cellular and systemic 
contexts is crucial for immune function, in particular during acute infection, where 
rapid accumulation of zinc is found in the liver, with concomitant changes in plasma 
zinc concentration [93]. As the Type 2 DM pathology is intrinsically associated with 
chronic activation of the innate immune system [328], the understanding of 
interaction between zinc availability and immune function is important in both acute 
responses to infection and the chronic low-grade inflammation observed in Type 2 
DM.  
 
To understand further the coordination between mediators of cellular zinc 
homeostasis in health [136] and type 2 DM [337], the study described in Chapter 7 
utilised statistical modelling to compare interrelationships among zinc status and the 
gene expression of zinc transporters and MT in populations drawn from different 
studies, a cohort with Type 2 DM and a healthy control group. In healthy participants, 
the groupings of zinc transporters and MT were predictive of plasma zinc 
concentrations, highlighting the coordination between systemic zinc availability and 
the regulation of cellular zinc homeostasis. Specifically, plasma zinc concentration was 
highly predicted by the gene cluster of ZnT1, ZnT5, ZnT7, ZIP1 and ZIP10 in the 
control group. Zinc transporters within this cluster have similar sites of cellular 




are coordinated to control cytoplasmic zinc flux through the plasma and subcellular 
membranes under healthy conditions.  
 
When the same approach was used to investigate the interrelationship in Type 2 DM, 
lower expression of zinc transporter and MT genes were observed, in addition to 
different coordinative relationships among zinc transporters and MT, specifically 
those related to ZnT1 and ZIP7 gene expression. While the gene expression of ZIP7 
was associated with MT in healthy participants, the relationship between ZIP7 and 
MT was no longer significant in the Type 2 DM cohort. With the functional roles of 
ZIP7 in zinc signals [125] and MT as the primary buffering system for intracellular 
free zinc [75], it is conceivable that the expression of ZIP7 and MT are coordinated to 
effect appropriate intracellular zinc signals. The disruptions in the relationship 
between ZIP7 and MT in Type 2 DM may have effects on the cellular processes 
mediated by changes in zinc signalling. Alterations in the cellular zinc transport 
system in Type 2 DM as described in Chapter 7 supports the proposed zinc 
dyshomeostasis associated with Type 2 DM [28]. Given the positive correlation 
between ZIP7 and physical activity observed in Chapter 5, the potential influence of 
exercise on the cellular zinc transport system and related functions in Type 2 DM is 
intriguing and requires further investigations.  
 
In summary, the studies described within this thesis examined interactions between 
zinc homeostasis and pathogenesis and management of CVD and Type 2 DM. In the 
evaluation of the relationships between zinc status and prospective risks of CVD and 
Type 2 DM, we observed protective effects of higher zinc status on chronic disease 
risks. Aerobic exercise, a commonly used treatment and prevention strategy for 
chronic diseases, was shown to have significant acute effects on serum zinc levels, 
suggesting changes in whole body zinc homeostasis. Similarly, changes in zinc status 
and homeostasis, by zinc supplementation, were shown to have significant impacts on 
the mediators of cellular zinc homeostasis. In Chapter 7, differences in the 
coordination of cellular zinc transport system were noted in Type 2 DM, in accordance 
with the suboptimal zinc status associated disease. The functions of zinc and its 
cellular transport system were related to inflammatory processes in Type 2 DM, as 
described in Chapter 6. Findings of this thesis generated insights regarding zinc status 





Figure 8.1 Conceptual diagram depicting the main outcomes of the present thesis. 
We have shown that zinc status is implicated in the prospective risk of chronic 
diseases. Exercise, a commonly used strategy for the prevention and management of 
chronic disease, can mediate changes in whole body zinc homeostasis. Changes in 
whole body zinc homeostasis, by increase in dietary zinc or zinc supplementation, can 
induce changes in mediators of cellular zinc homeostasis. In chronic diseases, 
specifically Type 2 diabetes mellitus, differences in cellular zinc transporters and 
metallothioneins were observed in accordance with proposed suboptimal zinc status 
associated with disease. Low-grade inflammation associated with chronic diseases has 




Limitations of studies described in Chapters 2 to 4 involved inherent constraints of 
the current literature. The limited reports available for determining the relationship 
between zinc status and prospective risks of CVD and Type 2 DM were varied in 
methods of statistical analyses and outcome measures such that quantification of 
disease risk by meta-analyses was deemed to be inappropriate. Furthermore, different 
methods of determining serum zinc levels may introduce measurement bias [240]  
between the included studies; hence, the present collation of results should be 





In the determination of changes in zinc biomarkers following aerobic exercise in 
Chapters 3 and 4, the issue of serum zinc concentration as a reliable measure of zinc 
status in humans was considered to be a limitation. In particular in the examination of 
serum zinc under exercise conditions, the changes of blood volume following high 
intensity exercise may confound measured serum zinc concentration by haemo-
concentration or -dilution. The current literature lacks consensus in the use of 
concurrent measures of serum zinc levels and blood volume or adjustments for 
changes in blood volume, such as the van Beaumont quotient [289]. Furthermore, the 
majority of included studies lacked information regarding participants’ dietary zinc 
intakes as a measure of baseline zinc status. Manipulation in the levels of dietary zinc 
intake has been associated with different responses of serum zinc immediately after 
exercise [199], and hence may provide important information regarding the 
relationship between habitual zinc intake and serum zinc response to exercise.  
  
A number of study limitations within Chapters 5 to 7 were similar. Transcriptome 
analyses of zinc transporters and MT were conducted in PBMC as a model of cellular 
zinc homeostasis; the generalisability of the presented results to other metabolically 
relevant tissues, such as the pancreas and skeletal muscles, is currently unknown 
given that localisation and expression of zinc transporters and MT are suggested to be 
tissue specific. Furthermore, PBMC represents a heterogeneous group of immune 
cells, the subtypes of which can be modified by lifestyle factors [321,323]. Specifically, 
differences in zinc status have been shown to account for variations in the distribution 
of lymphocyte subsets [324]. The studies described in Chapters 5 to 7 lacked analysis 
of PBMC subtype populations which may assist in the delineation of whether changes 
in PBMC transcriptome derive from changes in the composition of the PBMC subtypes 
or from transcriptional changes in a stable cohort of PBMC. In addition, the sample 
sizes of the studies described in Chapters 5 to 7 were too small to detect the potential 
effects of interindividual variability of PBMC subtypes on the gene expressions of zinc 
transporters and MT.  
 
The transcriptome analyses of the mediators of cellular zinc homeostasis were 
restricted to the limited number of zinc transporters and MT measured in the current 
studies. Although to the best of our knowledge, our studies present the most extensive 
number of zinc transporters and MT in healthy and Type 2 DM cohorts, within the 
current literature. Moreover, transcriptional regulation of zinc transporters and MT 
represent one of many points of regulation; analyses of protein levels with subcellular 




examination of cellular zinc homeostasis. Furthermore, the sample size of pilot studies 
described in Chapters 5 and 6 may be too small to detect other important differences; 
power calculations for the determination of Type 2 error were not conducted as 
limited previous data were available for this purpose.   
Implications(for(clinical(practice((
 
Limited robust evidence is available to provide clinical advice regarding dietary zinc 
intake in the prevention of chronic diseases, such as CVD and Type 2 DM. In contrast 
with the limited evidence for the prevention of Type 2 DM, beneficial effects of zinc 
supplementation have been shown consistently for glycaemic control [141] and 
lipidemia [143] in Type 2 DM management. Improvements in the intermediate 
markers of Type 2 DM greatly reduce risk of DM complications, especially CVD [245]. 
While the effects of zinc supplementation on the low-grade inflammatory state in Type 
2 DM are unclear from the findings of Chapter 6, the overall evidence supports the 
increase in total zinc intake as a potential coadjuvant in therapy for Type 2 DM [11].  
 
The interactions between exercise and zinc have been described throughout this 
thesis, from preliminary data indicating relationship between physical activity and 
ZIP7 within cellular studies (Chapter 5) to systemic changes in zinc biomarkers as a 
result of aerobic exercise (Chapters 3 and 4). Given that more pronounced acute effect 
of aerobic exercise on serum zinc were observed in previously untrained participants, 
the potential adverse impact on zinc status should be considered when initiating 
exercise training programs for individuals with chronic diseases, in particular Type 2 
DM, where suboptimal zinc status already exists as part of the disease pathology. 
Although the long term effects of exercise training remain unclear, dietary advice to 
increase total zinc intake, at least to meet the RDI, may be considered for at-risk 
populations in clinical practice. The level of dietary fibre intake also should be 
examined in the determination of dietary zinc requirement, in light of the reported 




To improve the quality of evidence in determining the relationships between zinc 
status and prospective risks of chronic diseases, future studies should consider more 
detailed descriptions of statistical analyses performed and rationale for the inclusion 




mechanisms of zinc’s action on the pathogenesis of chronic diseases and additional 
evidence from observational studies are required prior to the establishment of dietary 
zinc recommendation in the prevention of CVD and Type 2 DM for the general 
population. The interaction of dietary zinc with other nutrients and food sources may 
provide insights into the defined role of zinc in the prevention of chronic diseases. The 
interaction of zinc homeostasis and muscular action and recovery processes requires 
further investigation, particularly in populations who are obese or have diagnosed 
Type 2 DM. Further work is required to explore the intricacies of the cellular zinc 
transport system that were proposed in Chapters 5 to 7. To extend the coordination 
within zinc transport network reported in Chapter 7, analyses involving protein 
concentration and subcellular localisation of all cellular zinc transporters and MT, in 
addition to the determination of intracellular zinc fluxes are required. In terms of zinc 
homeostasis and cellular functions, the effect of increased cytokine gene expressions 
in PBMC (Chapter 6) remains uncertain in the context of whole body inflammatory 
state in Type 2 DM [187]. The current findings presented in PBMC require further 
confirmation in other types of cells, especially those relevant in Type 2 DM, such as 
skeletal muscles, liver and pancreas.  
 
The potential synergistic interactions of zinc and exercise on the insulin signalling 
pathway in peripheral tissues and whole body insulin sensitivity warrant future 
studies with combined cellular and metabolic outcomes. The long term effects of 
exercise training, in particular for individuals with chronic diseases, on zinc status are 
also important to determine in future investigations to extend our understanding 
regarding the interactions between exercise prescription and zinc status in the 
management of chronic diseases.  
 
While changes in serum zinc following aerobic exercise were determined in Chapters 3 
and 4, the limitations of serum zinc concentration as a robust zinc biomarker were 
highlighted, especially under the condition of exercise. In addition to addressing the 
inherent limitations of serum zinc level as a biomarker of zinc status, novel 
approaches are required in the determination of zinc status at the individual level. The 
responsiveness of MT-2A gene expression, as a potential marker described in Chapter 
5 under conditions of zinc depletion or marginal dietary zinc intake, requires 








Exploratory studies in cellular zinc homeostasis extended the current understanding 
of the coordination within cellular zinc transport system, in addition to how external 
stimuli interacts with zinc transport and cellular functions. The integration of zinc 
homeostasis from the cellular and systemic viewpoints, in addition to influences of 
external stimuli, such as exercise, is required to further enhance the knowledge 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A1. Full search strategy used in EMBASE for the search terms (zinc AND 
[(dietary OR supplement*) OR (plasma OR serum)] AND diabetes) in the systematic 
literature review of zinc and risk of CVD and types 2 DM. (Chapter 2). 
1 zinc.mp. or exp zinc/ 182532 
2 dietary.mp. or exp dietary intake/  546655 
3 exp diet supplementation/ or supplement*.mp. or exp diet/  567582 
4 plasma/ or plasma.mp.  1031803 
5 serum/ or serum.mp.  1200860 
6 2 or 3 or 4 or 5  2846464 
7 diabetes.mp. or exp diabetes mellitus/  785297 
8 1 and 6 and 7  2682 


















































































































































































































































































































































































































































































































































Table A4. Scoring criteria of confounding factors and results of each individual study with models describing zinc intake and cardiovascular 


























0.5! 0.5! 0.5! 0.5! 1! 0! 0.5! 0.5! 4!
Bates!et!al.!2011! 0! 0! 0! 0! 0! 0! 0! 0! 0!
Lee!et!al.!2005! 0.5! 0! 0.5! 0.5! 1! 1! 0.5! 0.5! 4.5!
Mursu!et!al.!
2011!
0! 0.5! 0.5! 0.5! 0! 1! 0.5! 0.5! 3.5!





Table A5. Scoring criteria of confounding factors and results of each individual study with models describing serum zinc concentration and 










Bates!et!al.!2011! 1! 1! 1! 3!
Leone!et!al.!2006! 1! 1! 0! 2!
Marniemi!et!al.!1998! 1! 1! 0! 2!
Pilz!et!al.!2009! 1! 1! 1! 3!




Table A6. Scoring criteria of confounding factors and results of each individual study with models describing zinc intake and Type 2 diabetes 
























Otto!et!al.!2012! 0! 0! 0.5! 0.5! 0! 1! 0.5! 0! 2.5!
Song!et!al.!
2011!
0! 0! 0.5! 0.5! 0! 0! 0.5! 0! 1.5!
Sun!et!al.!2009! 0.5! 0! 0.5! 0.5! 0! 0! 0.5! 0.5! 2.5!
Vashum!et!al.!
2013!








Table B1. Search strategies used in PubMed for systematic literature review of zinc 




































































Table C1. Characteristics and gene expression of zinc transporters and MT in apparently healthy (AH) cohort, stratified by sex, and the Type 2 
DM (T2DM) cohort.  
$ AH$cohort$(n$=$41$M)$ AH$cohort$(n$=$29$F)$ T2DM$cohort$(n!=$42$F)$
Age$(y)$ 31.4$±$13.1$ 34.0$±$15.2$ 65$±$8.5$
BMI$(kg/m2)$ 24.0$±$3.1$ 22.5$±$3.0$ 28.3$±$5.1$
Plasma$zinc$concentration$(μmol/L)$ 15.4$±$3.4$ 14.2$±$2.8$ 12.9$±$1.9$
Dietary$zinc$intake$(mg/d)$ 14.2$±$2.8$ 15.4$±$2.3$ 11.8$±$4.2$
Gene$expression$(copies$per$106$18S$rRNA)$$ $ $ $
!!ZnT1!! 10.4$±$1.9$ 9.9$±$1.0$$ 5.1$±$0.4$$
!!ZnT5! 4.3$±$0.6$ 4.8$±$0.7$ 1.7$±$0.1$
!!ZnT6!! 2.2$±$0.1$$ 2.2$±$0.2$ 2.1$±$0.1$
!!ZnT7!! 15.1$±$1.1$$ 16.1$±$1.3$ 7.1$±$0.3$$
!!ZIP1!! 12.0$±$1.0$$ 10.7$±$0.6$ 6.2$±$0.3$$
!!ZIP3!! 6.6$±$0.5$$ 6.7$±$0.6$ 3.3$±$0.1$$
!!ZIP7! 4.5$±$0.2$$ 3.8$±$0.2*$$ 2.4$±$0.1$$
!!ZIP10! 6.9$±$0.7$$ 7.0$±$0.4$$ 4.0$±$0.2$$
!!MT01A!! 16.3$±$3.7$ 27.6$±$9.2$$ 2.4$±$0.5$$






Figure C1 Component plot in rotated space for zinc transporters and MT in the 
apparently healthy (AH) cohort. The three axes present factor loading of each 
component. Variables of zinc transporters and MT are plotted in 3-dimension space 
according to the factor loading of the variable for each of the three components 
extracted. The three identified groupings were: Component 1 (ZnT1, ZnT5, ZnT7, ZIP1, 
and ZIP10); Component 2 (ZIP7, MT-1A, and MT-2A); and Component 3 (ZnT6 and 
ZIP3).  
$
Figure C2 Component plot in rotated space for zinc transporters and MT in the Type 
2 diabetes mellitus (T2DM) cohort. The three axes present factor loading of each 
component. Variables of zinc transporters and MT are plotted in 3-dimension space 
according to the factor loading of the variable for each of the three components 
extracted. The three identified groupings were: Component 1 (ZnT5, ZnT7, ZIP1, ZIP7, 
and ZIP10); Component 2 (ZnT1, ZnT6, and ZIP3); and Component 3 (MT-1A, and 
MT-2A).  
